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Abstract
Fatty acid amides are an emerging family of bioactive lipids that consists of
N-acylethanolamines,

N-acylarylalkylamides,

N-acylglycines,

N-monoacylpolyamides, and primary fatty acid amides.

N-acyl

amino

acids,

Short chain fatty acid amides are

products of inactivated biogenic amines such as dopamine, histamine, octopamine, and
serotonin, whereas long chain fatty acid amides have been implicated in a number of
physiological process such as the perception and inhibition of chronic pain through binding to
their specific receptors. The most famous; therefore, the most studied long chain fatty acid
amide is anandamide or also known as N-arachidonylethanolamine.

The biosynthesis of

anandamide is well defined; however, other long-chain fatty acid amides, such as the
N-acyldopamines, N-acylserotonins, N-acylglycines, N-acyl amino acids, and primary fatty acid
amides have remained elusive to date. Understanding the complete biosynthetic pathway for
these cell signaling lipids, may yield new exciting molecular targets for human health and
disease. Discovery of the long-chain fatty acid amide biosynthetic enzymes has proven to be
challenging due to the low biologic abundance of the respective metabolites found in organisms,
the interconnection of the pathways, and expense of using mammalian cells and/or organisms.
This led to the transition of studying these metabolites and their respective biosynthetic enzymes
in Drosophila melanogaster. D. melanogaster is an ideal system to study fatty acid amide
biosynthesis because the respective metabolites have been identified, the cost of maintaining the
organism is relatively low, and genetic manipulation (RNAi) is universally available.

x

This dissertation is dedicated to defining enzymes involved in D. melanogaster
N-acylarylalkyamide biosynthesis. The biologically relevant long-chain N-acylarylalkylamides
are comprised of long-chain N-acyldopamines and N-acylserotonins. Very little is known for
how these potent cell signaling lipids are biosynthesized in the cell. One possible route is the
N-acylation of the respective biogenic amine by an N-acyltransferase enzyme. An enzyme
known to catalyze this chemistry is arylalkylamine N-acetyltransferase (AANAT), which
catalyzes the formation of N-acetylarylalkylamides from acetyl-CoA and the corresponding
arylalkylamide.

The N-acetylation of biogenic amines is a critical step in Drosophila

melanogaster for the inactivation of amine neurotransmitters, sclerotization of the cuticle, and to
serve as the penultimate intermediate in the biosynthesis of melatonin.

Two AANAT(L)

enzymes has been previously evaluated in D. melanogaster and six other putative AANATL
enzymes have identified in the fly genome. One AANAT is expressed as two biologically
relevant isoforms, AANAT variant A (AANATA) and AANAT variant B (AANATB), where
AANATA differs from AANATB by the truncation of 35 amino acids on the N-terminus. The
other AANATL enzyme to be previously studied is AANATL2, which was found to catalyze the
formation of N-acetyltryptamine from acetyl-CoA and tryptamine. Herein, we expressed six
AANAT(L) enzymes (AANATA and AANATB, AANATL2, AANATL3, AANATL7, and
AANATL8) and sought to define the acyl-CoA and amine substrates for each enzyme. To
accomplish this, we developed an activity-based screening assay to define acyl-CoA and amine
substrates for AANATL2, AANATL3, AANATL7, and AANATL8. Following this work, we
defined the acyl-CoA and amine substrate specificity for AANATA, AANATL2, AANATL3,
and AANATL7.

We have identified acetyl-CoA and arylalkylamines as substrates for

AANATA, AANATL2, and AANATL3; whereas AANATL7 acetylates histamine and

xi

arylalkylamines. AANATL2 was additionally shown to catalyze the formation of long-chain
N-acyldopamines and N-acylserotonins. Following these important set of results, we solved the
kinetic mechanism for AANATA, AANATL2, and AANATL7 in which these enzymes were
shown to catalyze the formation of N-acylarylalkylamides by an ordered sequential mechanism
where the acyl-CoA substrate binds first followed by the corresponding amine substrate. Finally,
we evaluated the function of structural amino acids on regulating catalysis, structural features of
substrates that effect binding and/or catalysis, and generated data leading to a proposed chemical
mechanism by means of pH-activity profiles and site-directed mutagenesis of prospective
catalytic residues.

xii

Chapter One
Introduction

1.1 A historical perspective of cannabinoids and fatty acid amides
The origins for the field of fatty acid amide research, in particular, the N-acylserotonins
and N-acyldopamines is firmly derived from cannabis research. Cannabis has been cultivated for
> 6000 years and its origins are suggested to reside in Eastern or Central Asia. 1-4 It is commonly
referred to as hemp, hashish, marijuana, and bhang.

Cannabis has been used by people

throughout history for medicine, religious rituals, manufacturing of goods (strings, ropes,
textiles, and paper), food, and recreational purposes.3 People of the ancient world used cannabis
for medical purposes consisting of treating migraines, pain, malaria, constipation, tuberculosis,
epilepsy, impotence, etc.

3-5

In the United States, the medical use of cannabis began in the 19th

century; however, declined by the early 20th century.3 Its use subsided mainly because of the
difficulty with replicate effects from extracts and the discovery of other medical treatments,
including vaccines, aspirin, and morphine.3 Another factor in the decline of the medical use of
cannabis in the United States were the legal restrictions passed in various bills limiting its access
and sale, beginning with various state prohibition laws and with the Marihuana Tax Act of 1937
(federal law).3, 6 This act resulted in a tax placed on the sale of cannabis in the United States.
Following this law, the Controlled Substance Act was passed as part of the Comprehensive Drug
Abuse Prevention and Control Act of 1970, which created five “Schedules” or classifications for
different control substances.6-7

To date, cannabis is considered a “Schedule I” control
1

substance.7

Being classified as a “Schedule I” control substance means that: (a) that the

substance has a great risk of being abused, (b) there is not an accepted medical use for the
substance, and (c) there is a lack of safety for the administration of the substance in a medical
setting.7 Under this federal law, patients cannot obtain a prescription for the medical use of
cannabis.7 In addition, most of the world still classifies cannabis as illegal. However, recently
there has been a push to legalize cannabis and related cannabinoids for medicinal purposes. In
fact, there are 23 States, in the United States, that have legalized “medical marijuana” to date
(2014), with many more considering this type of legislation.8-9 In addition, there has been a
larger push for “medical marijuana” and related cannabinoid research.

One major issue

hindering the expansion of cannabinoids as medicinal therapeutics is the recreational use or the
abuse of cannabis by the general population. The National Institute on Drug Abuse (NIDA), as
part of the National Institute of Health (NIH) published a series of statistics from 2013, showing
that ~46% of people have used marijuana recreationally at some point in their life by the 12 th
grade.10 It is also reported that ~7% of people abuse marijuana daily for recreational use by the
12th grade, in 2013.10 Further studies and work are necessary to combat the recreational abuse of
cannabis; however, at the same time elevating its potential as a medicinal therapeutic.
Medical research in cannabis and cannabis related compounds were first published in the
1840s by an Irish physician, Sir William B. O’Shaughnessy.11-12 From O’Shaughnessy seminal
work, it took until the 1930s for Thomas Wood13 and Robert Cahn14 to isolate and elucidate most
of the structure for the first identified cannabinoid, cannabinol (Figure 1.1A).11 Subsequently, it
took until 1940 for Roger Adams15-19 and Lord Alan Todd20 to synthesize cannabinol and
complete a chemical elucidation of its structure.11 Following this work, Raphael Mechoulam and
colleagues were the first group in 1964 to isolate and elucidate the structure of the major

2

psychoactive component of cannabis, (-)-Δ9-tetrahydrocannabinol (Δ9-THC) (Figure 1.1B).21-23
In addition, the Mechoulam group continued the work started by Roger Adams and Alexander
Todd, in which they elucidated the first complete structure of the major non-psychotropic
cannabinoid in cannabis, cannabidiol (CBD) (Figure 1.1C).24

Following the structural

elucidation of Δ9-THC, it took another ~24 years (1988) before the Howlett group identified its
specific mammalian brain receptor, cannabinoid receptor 1 (CB1).25 The CB1 receptor is most
abundant in the brain; however, it is also found in different peripheral tissues, including the
gastrointestinal tract, heart, liver, kidney, eye, pancreas, prostate, testis, adipose tissue, and
uterus.26 Then a second CB receptor was identified in 1993, cannabinoid receptor 2 (CB2),27
which was initially identified in spleen and subsequently in the tissues of the immune system and
low levels were found in the brain.26 Following the identification of the CB1 receptor, it was
postulated that an endogenous ligand in mammalian brain must exist.28 At this time Bill Devane,
who published the paper on the identification of the CB1 receptor, received his Ph.D. from Allyn
Howlett’s group and joined the Mechoulam group as a post-doctoral fellow.28 As a post-doctoral
fellow in the Mechoulam group,28 he discovered anandamide (N-arachidonoylethanolamine)
(Figure 1.1D) from pig brains, as the first endogenous ligand for the CB1 receptor (Figure
1.1D).29 The seminal discovery of anandamide in 199229 marks the beginning of evaluating
endocannabinoids and fatty acid amides as potent cell signaling lipids. However, the discovery
of fatty acid amides date back to the 1820’s, with the identification of hippurate
(N-benzoylglycine) as an urine excreted metabolite that is derived from benzoic acid. 30-31 In
1957, N-palmitoylethanolamine was the first long-chain fatty acid amide discovered in egg
yolk.32-33 Historically, most of the research on endocannabinoids and fatty acid amides has been
with anandamide. Ironically, this metabolite only accounts for ~10% of all the long-chain

3

N-acylethanolamines found in the brain.30,

33-35

Anandamide functions in a series of

physiological processes including: (a) pain perception,36-41 (b) locomotion,42 (c) regulation of
body temperature,42 (d) memory,43-46 (e) appetite,47 and (f) fear and anxiety,48-49 which arise from
its binding to number of receptors including the CB1,

29

CB2,50 and the transient receptor

potential vanilloid type 1 (TRPV1) receptors.30, 33, 51 The biosynthesis of anandamide has been
extensively discussed in a series of publications and review articles.30, 33, 52-56

Figure 1.1. Structures of different cannabinoids. (A.) Cannabinol. (B.) Δ9-tetrahydrocannabinol
(THC). (C.) Cannabidiol (CBD). (D.) Anandamide (N-arachidonoylethanolamine).

The field of fatty acid amide research expanded further with the discovery of oleamide,
which was identified in mammalian cerebrospinal fluid and functions to induce sleep.57
Subsequently, a series of fatty acid amides were systematically identified from mammalian brain,
peripheral tissues, and other organisms (see reviews30,

33, 39, 58-60 61-63

).

This led to the

classification of the fatty acid amides into different families consisting of the primary fatty acid
amides, N-acylglycines, N-acyl amino acids, N-acylarylalkylamides, N-monoacylpolyamides,
and N-acyltaurines. The general structure of fatty acid amides is illustrated in Figure 1.2, where

4

the R1 group represents a varying length of an acyl group conjugated to a Y group, which is
typically derived from a biogenic amine as shown in Table 1.1.

Figure 1.2. General structure of fatty acid amides.

Table 1.1. Structures of different fatty acid amides.a, b
Fatty acid amide family

Structure

N-acylethanolamines

N-acylglycines

N-acyl amino acidsc

Primary fatty acid amides

N-acylarylalkylamidesd

N-monoacylpolyamidese

N-acyltaurines
a

R1 = acyl group of varying lengths, shown in red.
Blue represents the biogenic amine conjugated to the acyl group through an amide bond.
c
R2 group represent the various side chains of amino acids.
d
The N-acylarylalkylamide represented here is an N-acyldopamine.
e
The N-monoacylpolyamide represented here is an N-acylputrescine.
b

5

Currently, most fatty acid amides do not have a defined neurological function, their
receptors are undefined, and the biosynthetic pathways have not been completely elucidated.30, 33
There is a series of speculative proposals related to the possible function of these metabolites
consisting of an “entourage effect”,64-65 serving as a chemical step to inactivate biogenic amines,
biological intermediates to other cell signaling lipids, or possess a direct neurological function
through binding to an orphan receptor. The “entourage effect” is defined as: related fatty acid
amides are biosynthesized to function as substrates to enzymes that degrade anandamide in order
to stabilize the cellular concentration of anandamide.

64-65

For example, other N-acyldopamines

such as N-palmitoyldopamine are biosynthesized to enhance the effect N-arachidonoyldopamine
has with its endogenous receptor. One interesting observation by Dr. Mechoulam is that these
molecules must have a function, since the brain invests a considerable amount of energy in their
biosynthesis.28 He continues to speculate that the subtle chemical differences of these molecules
in the brain could be related to the differences observed in human personality, with different
levels and/or ratios of these metabolites, could lead to an infinite amount of different
personalities, which contributes to our individual differences.28 Further work is necessary to
completely elucidate the physiological function for each of the fatty acid amides and define the
receptors that disseminate these functions. In addition, a significant amount of work is still
required to discover all the possible fatty acid amides and elucidate the biosynthetic and
degradative pathways for these important cell signaling lipids.
The research highlighted in this dissertation, sets to define enzymes involved in the
biosynthesis of the N-acylarylalkylamides. Therefore, the focus for the rest of this dissertation
will be on the N-acylarylalkylamides; including characterization of possible biosynthetic

6

enzymes, defining the chemical mechanism for these enzymes, and understanding how enzyme
structure affects its function.

1.2 Function and biosynthesis of long-chain N-acylserotonins and N-acyldopamines
There have been two groups of biologically relevant long-chain N-acylarylalkylamides
identified from mammals66-67 and insects,62,

68

which are the N-acyldopamines and

N-acylserotonins. Long-chain N-acyldopamines were first synthesized in 2000 by the Di Marzo
group, to be evaluated as inhibitors to anandamide hydrolysis that is catalyzed by fatty acid
amide hydrolase (FAAH).69

In addition, they evaluated the affinity of the long-chain

N-acyldopamines for the CB1 receptor by using a radiolabeled ligand displacement assay.69
These data showed that long-chain N-acyldopamines (acyl group ≥ 18) can function to inhibit
anandamide hydrolysis competitively, with N-pinolenoyldopamine and N-arachidonoyldopamine
displaying the greatest apparent affinity (IC50 = 19.0 ± 4.5 µM and 22.0 ± 5 µM, respectively).69
In addition, displacement experiments with a radiolabeled ligand demonstrated that
N-arachidonoyldopamine has the greatest affinity (Ki = 250 ± 130 nM) for the CB1 receptors
when compared to all other N-acyldopamines evaluated in this study.69

These data, in

combination with a published hypothesis by Matysiak in 1998 that N-acyldopamines existed in
vivo; led the Di Marzo and Walker groups to identify the first endogenous long-chain
N-acyldopamine, N-arachidonoyldopamine (Table 1.2), from bovine brain.66

The highest

concentration of N-arachidonoyldopamine was identified in the striatum, hippocampus, and
cerebellum; which are at similar levels as the TRPV1 receptors.66 In addition, they showed that
N-arachidonoyldopamine is an endogenous ligand for the human and rat TRPV1 receptors, by
showing that it produced a significant increase of intracellular Ca2+ (EC50 = 40 ±6 nM and 48 ± 7

7

nM, respectively) in HEK293 cells that overexpress either receptor.66

The physiological

functions identified for N-arachidonoyldopamine are similar to that produced by anandamide,
likely mediated from having the same receptors.66, 69 These functions consist of pain perception,
regulation of body temperature, and locomotion.66, 69 It also showed a dose-dependent protection
of cultured cerebellar neurons, by functioning as an antioxidant and neuroprotectant.70 In 2003,
the Walker group identified more long-chain N-acyldopamines from bovine brains, consisting of
N-oleoyldopamine, N-palmitoyldopamine, and N-stearoyldopamine (Table 1.2).67 There is not
much information on the function or the receptors for these other long-chain N-acyldopamines;
except for some data published on N-oleoyldopamine. N-oleoyldopamine was shown to bind to
the human TRPV1 receptors (EC50 = 63.0 ± 5.5 nM) and weakly to the CB1 receptors (Ki = 16
µM), while producing a dose-dependent response to thermal hyperalgesia in rats.67 Recently,
N-oleoyldopamine was shown to bind weakly (EC50 = 4.4 µM) to human G coupled-protein
receptor 119 (GPCR119), which is important to glucose homeostasis by stimulating insulin
release and increasing the levels of cAMP and gastric inhibitory peptide in pancreatic cells. 71 In
addition, N-oleoyldopamine was shown to possess a dose-dependent stimulation of locomotor
activity,72 protect the heart against ischemia and reperfusion injury,73 decrease rat muscle rigidity
(myorelaxant),74 and function in pain perception.75-76

The plasma concentration of

N-oleoyldopamine were also shown to significantly decrease in individuals with post-traumatic
stress disorder and might be used as a robust indicator for this disease.77 Currently, there are
neither receptors nor a function defined for N-palmitoyldopamine and N-stearoyldopamine.
N-palmitoyldopamine and N-stearoyldopamine were both evaluated as potential TRPV1 ligands;
however, neither showed any increased in the intracellular concentration of Ca2+ in HEK cells
overexpressing human TRPV1.67,

78

One proposed function for N-palmitoyldopamine and

8

N-stearoyldopamine is that they function as an “entourage effect”, essentially enhancing the
effect of N-arachidonoyldopamine or anandamide on the TRPV1 receptors.78
Recently our lab identified long-chain N-acyldopamines in D. melanogaster, consisting
of N-arachidonoyldopamine, N-oleoyldopamine, and N-palmitoyldopamine.62 It is unclear what
the endogenous receptors are or the physiological function is for these N-acyldopamines in D.
melanogaster. It has been suggested that the CB receptors are not found in D. melanogaster;79-80
however, there is a report of TRVP receptors found in the fly, which might function as an
endogenous receptor for these metabolites.81

Table 1.2. Structures of endogenous N-acydopamines.
Structurea

N-acyldopamine

N-arachidonoyldopamineb, c

N-oleoyldopamineb, d

N-stearoyldopamineb

N-palmitoyldopamineb, c, d

a

References for structures include, Huang et al.,66 Chu et al.,67 and Farrell et al.82
References for in vivo identification in mammalian brain include, Huang et al.66 and Chu et al.67
c
References for in vivo identification in D. melanogaster brain include, Jeffries et al.62
d
References for in vivo identification in D. melanogaster thorax-abdomen include, Jeffries et al.62
b
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A biosynthetic pathway for the long-chain N-acyldopamines has not been completely
elucidated.

Generally, there have been four pathways proposed in the literature for the

biosynthesis of these metabolites (Scheme 1.1).30,

33, 83-84

The cognate metabolites in each of

these pathways are tyrosine and the fatty acids. Scheme 1.1A has the precursor metabolite as an
N-acyltyramine that undergoes hydroxylation of the tyramine ring to generate an
N-acyldopamine. The N-acyltyramine is likely synthesized by a conjugation reaction catalyzed
by an N-acyltransferase from tyramine and the corresponding activated fatty acid (acyl-CoA)
substrate, by direct condensation of tyramine and the corresponding fatty acid, or from
decarboxylation of an N-acyltyrosine. Evidence for this pathway consists of when L-tyrosine
and tritiated arachidonic acid is incubated with rat striatum, there is formation of tritiated
N-arachidonyldopamine.66 In addition, endogenous levels of long-chain N-acyltyrosines were
detected in mammalian brains.61
Scheme 1.1B invokes the possibility that an N-acyl-L-Dopa is the direct precursor to the
N-acyldopamines. In this reaction, an N-acyl-L-Dopa is decarboxylated by a decarboxylase
enzyme to generate an N-acyldopamine. Evidence for this pathway consists of the identification
of endogenous long-chain N-acyltyrosines,61 which could be the precursor metabolites to the
N-acyl-L-Dopas. The N-acyltyrosine would undergo hydroxylation on the aromatic ring to
generate the corresponding N-acyl-L-Dopa.

In addition, after incubation of a tyrosine

hydroxylase inhibitor (α-methyl-p-tyrosine) there was a time dependent decrease in the
formation of the N-arachidonoyldopamine.84 Tyrosine hydroylase is the rate-limiting enzyme in
the biosynthesis of dopamine, which could also function in the formation of N-acyl-L-Dopas.85-87
The decrease in the N-arachidonoyldopamine from inhibiting tyrosine hydroxylase84 suggests
that it functions in the biosynthesis of long-chain N-acyldopamines; however, does not prove that

10

it catalyzes the direct hydroxlyation of N-acyltyrosines. The decrease in the endogenous levels
of N-arachidonoyldopamine could also be attributed to the inhibition of general dopamine
biosynthesis, by inhibiting the formation of L-Dopa. In fact, the Walker group showed that
N-arachidonoyltyrosine is a poor substrate for tyrosine hydroxylase, in an experiment comparing
the hydroxylation of L-tyrosine to deuterated N-arachidonoyltyrosine.84

After a 10 min

incubation time, it was shown that 24% of the L-tyrosine was converted to L-Dopa, whereas only
0.23%

of

deuterated

N-arachidonoyl-L-Dopa.84

N-arachidonoyltyrosine

was

converted

to

deuterated

Subsequently, N-arachidonoyldopamine was not detected after

injection of deuterated N-arachidonoyl-L-Dopa into the rat striatum.84 These data suggest that
N-arachidonoyltyrosine → N-arachidonoyl-L-Dopa → N-arachidonoyldopamine is an unlikely
biosynthetic pathway.
Another proposed biosynthetic step in the chemical formation of N-acyldopamines is the
direct condensation of a fatty acid and dopamine as shown in Scheme 1.1C. The literature points
to FAAH as the biosynthetic enzyme for this condensation reaction.84 FAAH is an amidase that
has

been shown to

N-acylethanolamines.88-91

catalyze the hydrolysis

of primary fatty acid

amides

and

This proposal suggests that FAAH catalyzes the formation of

N-acyldopamines in the reverse direction when compared to its hydrolase activity. Evidence for
this pathway is derived from the incubation of rat brain homogenates with 50 µM dopamine (or
tyrosine), 50 µM tritiated arachidonic acid, and a catechol O-methyltransferase (COMT)
inhibitor (OR-486), which resulted in the formation of tritiated N-arachidonoyldopamine.66 The
COMT inhibitor was used to minimize the breakdown of N-arachidonoyldopamine, which is one
of its major degradative products.83 A conflicting set of results were published by the Bezuglov
group, which showed that N-arachidonoyldopamine is not generated in rat brain homogenates
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from the incubation of tritium-labeled arachidonic acid and dopamine.83 This published work
also analyzed numerous chemical steps for N-arachidonoyldopamine biosynthesis, by incubating
different precursors with liver, spinal cord, or brain rat homogeneates.83 In addition, they
analyzed

the

COMT

catalyzed

degradation

of

N-arachidonoyldopamine

to

3-O-methyl-N-arachidonoyldopamine for each tissue homogenate. Interestingly, there was a
considerable amount of 3-O-methyl-N-arachidonoyldopamine and arachidonic acid in the rat
brain homogenates after 30 min incubation with tritium-labeled arachidonic acid and
dopamine.83 This suggests that either the dopamine is rapidly methylated to 3-methoxytyramine
by COMT before being N-acylated or N-arachidonoyldopamine is rapidly converted to
3-O-methyl-N-arachidonoyldopamine after its initial formation.

The major experimental

difference between the two groups (Benzuglov and Di Marzo groups) is that the Di Marzo group
used a COMT inhibitor.66, 83 This likely allowed for the observation of N-arachidonoyldopamine
in rat brain homogenates by inhibiting the formation of a major degradative product.
3-O-methyl-N-arachidonoyldopamine is considered to be a major inactive degradative product of
N-arachidonoyldopamine, where it was found to be ~10-fold less potent with the TRPV1
receptors.66

In fact, after incubation of tritiated N-arachidonoyldopamine and S-adenosyl

methionine with rat brain homogenates, ~40% of the tritiated molecule was converted to
3-O-methyl-N-arachidonoyldopamine and ~11% was hydrolyzed to arachidonic acid.83 These
results and the data published by the Di Marzo group, suggests that the pathway order is the
following:

arachidonic

acid

+

dopamine

→(→)

N-arachidonoyldopamine

→

3-O-methyl-N-arachidonoyldopamine.66, 83 The second arrow, found in the parenthesis, indicates
that it is still unknown if N-arachidonoyldopamine is generated by the direct condensation of
arachidonic acid and dopamine or if arachidonic acid is activated to arachidonoyl-CoA prior to
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its conversion to N-arachidonoyldopamine. A summary for the precursor incubation conditions
that contributed to the greatest observed formation of N-arachidonoyldopamine that was
published by the Benzuglov group can be found in Table 1.3.83

This group showed that

N-arachidonoyldopamine could be synthesized in every tissue homogenate analyzed, but the set
of precursors that generated the greatest yield of N-arachidonoyldopamine varied for each
tissue.83 Incubation of arachidonic acid and tyrosine generated more N-arachidonoyldopamine in
the liver and spinal cord homogenates, whereas incubating arachidonic acid + tyrosine +
tetrahydrobiopterin + NADPH + Fe2+ + Mg2+ generated the most N-arachidonoyldopamine in the
brain homogenates.83

Three possible explanations for the differences seen in each tissue

homogenate is: (a) the pathway for the formation of N-arachidonoyldopamine is tissue
dependent, (b) there is a time-dependence in the formation and degradation of
N-arachidonoyldopamine, and/or (c) N-arachidonoyldopamine could be biosynthesized by
numerous pathways, in which the predominant pathway is tissue dependent. The data generated
by the Di Marzo,66 Walker,84 and Benzuglov83 groups suggest that a direct condensation of a
fatty acid and dopamine (or tyrosine) is possible by FAAH. The Walker group also evaluated
the in vivo and in vitro role FAAH has in N-arachidonoyldopamine biosynthesis.84 Using a
FAAH inhibitor (URB579) fed to rats or FAAH knockout rats, the level of anandamide and
N-arachidonoyldopamine were evaluated and compared to a vehicle fed to rats or wild-type rats,
respectively.84

Anandamide was chosen because it is a known FAAH substrate that is

hydrolyzed to arachidonic acid and ethanolamine.89 In both of these experiments, the levels of
anandamide increased, whereas the levels of N-arachidonoyldopamine decreased when compared
to the controls.84
related

to

These data suggest that N-arachidonoyldopamine biosynthesis is directly

FAAH

activity.

The

two

possible
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functions

FAAH

can

have

in

N-arachidonoyldopamine biosynthesis is: (a) catalyzes the direct condensation of arachidonic
acid and dopamine (tyrosine), or (b) functions to liberate arachidonic acid by hydrolysis of
anandamide (or other fatty acid amides), which can shuttle it to other pathways such as
N-arachidonoyldopamine biosynthesis.
recombinant

FAAH

as

N-arachidonoyldopamine.84

either

Subsequently, the Walker group then evaluated
a

degradative

or

biosynthetic

enzyme

for

Hydrolysis of N-arachidonoyldopamine (at 30 mins, ~50%

converted) was low compared to anandamide (at 10 mins, ~95% converted), suggesting that
N-arachidonoyldopamine is a poor substrate for FAAH.84 Then they incubated FAAH with
anandamide and deuterated dopamine, and monitored the formation of deuterated
N-arachidonoyldopamine over a 30 min period.

The hypothesis was that liberation of

arachidonic acid from anandamide hydroylysis could serve as a substrate for FAAH catalyzed
condensation with dopamine to generate N-arachidonoyldopamine.84

Under these set of

conditions used in this publication, they observed a rate of deuterated N-arachidonoyldopamine
formation that is ~150 pmoles/min/mg.84 It is unclear from these published methods, if the
substrates were held at a saturating concentration; however, with this in mind, the rate of
N-arachidonoyldopamine biosynthesis84 is 180-fold less than the published Vmax of FAAH
catalyzed hydrolysis of anandamine.88 Depending on the assay conditions, these data suggest
that arachidonic acid and dopamine are poor substrates for a FAAH catalyzed condensation
reaction.84 In addition, we are not sure why the authors did not evaluate arachidonic acid and
dopamine, directly.84 It is unlikely that this reaction is biologically significant because it is
thermodynamically unfavorable to generate an amide from a carboxylate and amine by an
amidase.

FAAHs likely function in fatty acid amide biosynthesis and degradation is the
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liberation of fatty acids, which can be shuttled to different fatty acid amide biosynthetic
pathways.

Table 1.3. A summary of data published by Akimov et al.83 showing the corresponding
precursors that generated the greatest amount of N-arachidonoyldopamine from incubation with
different rat tissue homogenates.a, b
Tissue Homogenate
Liver
Spinal Cord
Brain

Precursor combination that produced greatest
amount of N-arachidonoyldopamine
arachidonic acid + tyrosine
arachidonic acid + tyrosine
arachidonic acid + tyrosine +
tetrahydrobiopterin+ NADPH + Fe2+ + Mg2+

a

Reference - Akimov et al.83
Other precursors used in various combinations
N-arachidonyldopamine, and S-adenosyl methionine.
b

were

N-arachidonyltyrosine,

dopamine,

Finally, the last proposed pathway (Scheme 1.1D) utilizes an activated fatty acid, in the
form of an acyl-CoA in a conjugation reaction with dopamine. This pathway is chemically more
attractive than a FAAH catalyzed condensation reaction, since a thioester is thermodynamically
more favorable; therefore, more susceptible for nucleophilic attack from the neutral amine of
dopamine. One piece of evidence for this pathway is that the incubation of arachidonic acid with
either

tyrosine

or

dopamine

N-arachidonoyldopamine.66

in

mammalian

brain

homogenates

will

generate

In this case, tyrosine could be converted to dopamine through

normal dopamine biosynthesis concurrently with the rapid conversion of arachidonic acid to
arachidonoyl-CoA by an acyl-CoA synthetase.92 Then an N-acyltransferase enzyme can catalyze
the formation of N-arachidonoyldopamine from dopamine and the newly generated
arachidonoyl-CoA.

This chemistry has been well characterized for the N-acetylation of

dopamine or serotonin, which is catalyzed by arylalkylamine N-acetyltransferase (AANAT) or
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also known as serotonin N-acetyltransferase (SNAT) (further discussed in Section 1.3; Chapters
2, 4, and 5).93-101 Therefore, it has been hypothesized that either AANAT or another AANATL
enzyme with specificity for long-chain acyl-CoA substrates, could be the biosynthetic enzyme
for the formation of long-chain N-acyldopamines. Similar chemistry was recently observed from
the Hunt group, which identified an N-acyltransferase enzyme, glycine N-acyltransferase like 2,
could catalyze the formation of long-chain N-acylglycines, another class of fatty acid amides.102
Evidence against this pathway, is after the rat striatal, midbrain, or hippocampal homogenates
were incubated with 50 µM radiolabeled arachidonoyl-CoA and 50 µM dopamine, there was no
detectable radiolabeled N-arachidonoyldopamine.84

This data could suggest that an

N-acyltransferase enzyme is not involved in N-acyldopamine biosynthesis.

However, it is

possible that N-arachidonoyldopamine was generated but rapidly degraded as shown by Akimov
et al.83 In combination to degradation of N-arachidonoyldopamine, it is possible that the tritiated
dopamine is rapidly degraded to either its methylated (3-methoxytyramine) or oxidized product
(3,4-dihydroxyphenylacetic

acid),

yielding

undetectable

levels

of

tritiated

N-arachidonyldopamine.84 It is also possible that the brain homogenates does not include the
biosynthetic N-acyltransferase enzyme or could be inactivated under the published set of
conditions. These set of data are inconclusive and further work needs to be addressed to confirm
or exclude this chemical step in the biosynthesis of long-chain N-acyldopamines.
The long-chain N-acylserotonins (Figure 1.3) are another group of endogenously found
fatty acid amides. N-arachidonoylserotonin was first synthesized as an inhibitor for FAAH,
resulting in an IC50 = 12 µM.103 Following this work, N-arachidonoylserotonin was shown to
have analgesic bioactivity, likely through duel mechanisms consisting of FAAH inhibition 103 and
serving as a TRPV1 antagonist.104-105 Subsequently, it was shown that N-arachidonoylserotonin
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can function in regulating gastric emptying,106 inhibiting anxiety,107 and possess anti-allergic
activity.108

N-arachidonoylserotonin,

N-palmitoylserotonin,

N-stearoylserotonin,

and

N-oleoylserotonin were the first long-chain N-acylserotonin identified in different regions of the
porcine gastrointestinal tract.109 Subsequently, N-arachidonoylserotonin was identified in human
and bovine brain samples.110 In addition to these fatty acid amides, N-eicosapentaenoylserotonin
and N-docosahexaenoylserotonin were identified in the jejunum of mice after the feeding of fish
oil over a six week period.109

Scheme 1.1. Proposed biosynthetic enzymes in the formation of long-chain N-acyldopamines.
(A.) Hydroxylase. (B.) Decarboxylase. (C.) Fatty acid amide hydroylase. (D.) N-acyltransferase.
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Figure 1.3. General structure of N-acylserotonins. R1 = varying acyl chain lengths.
Very little data has been generated for the biosynthesis of long-chain N-acylsertonins
since their seminal discovery in 2011.109 What is known, (a) is that the N-acylserotonins are
located in the mammalian gastrointestinal tract and brain,110 which is the region of the body that
has the highest level of serotonin,111 (b) incubating porcine ileum segments with serotonin
produced a concentration dependent increase in the N-acylserotonins, and (c) a dietary dependent
increase in N-eicosapentaenoylserotonin and N-docosahexaenoylserotonin in the mouse jejunum
after feeding high concentrations of the corresponding fatty acid in the form of fish oil over a six
week period.109 A summary of these data suggest that a fatty acid and serotonin is a set of
precursors to the long-chain N-acylserotonins. Two pathways consistent with this chemistry are
a FAAH catalyzed condensation reaction from the corresponding fatty acid and serotonin or a
prerequisite formation of the activated fatty acyl-CoA, followed by a N-acyltransferase catalyzed
conjugation reaction to generate the final N-acylserotonin product. It is unlikely that FAAH is
the biosynthetic enzyme in this pathway since a portion of the long-chain N-acylserotonins
function as inhibitors to its enzyme catalyzed hydrolysis reaction.109 This leaves an unknown
N-acyltransferase enzyme that could be the biosynthetic enzyme. Further work defined in this
dissertation will help answer this fundamental question (Appendix B).
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1.3 Possible chemical mechanisms for N-acyltransferases
N-acetylation is an important chemical reaction for the inactivation of biogenic amines,
biosynthesis of melatonin, and cuticle sclerotization.112-115

In insects, the known biogenic

amines are octopamine, serotonin, tyramine, dopamine, and histamine, which functions primarily
as neurotransmitters.116 One major chemical step for the inactivation of these bioactive amines
in D. melanogaster is the N-acetylation of the primary amine. N-acetylation of serotonin is also
the penultimate chemical step in the biosynthesis of melatonin.117-121 Melatonin is a metabolite
of serotonin biosynthesis (Scheme 1.2), catalyzed by the N-acetylation of serotonin (AANAT or
SNAT)

followed

by

the

methylation

of

the

hydroxyl

group

(hydroxyindole

O-methyltransferase).117-121 Melatonin is primarily found in the pineal gland of mammals and
functions to regulate the sleep wake cycle.122-124 Concentration of melatonin in the pineal gland
fluctuates during a 24 hour period, where high levels are synthesized at night and low levels
during the day.122-124 AANAT is the rate-limiting enzyme in the formation of melatonin, which
controls the day/night fluctuations of melatonin in mammals.122, 125 Very little work has been
published for melatonin in D. melanogaster; however, it has been shown that its biosynthesis is
similar to mammals (Scheme 1.2).126-127

Melatonin also regulates the life span of D.

melanogaster, likely because of its antioxidant properties.126

Scheme 1.2. Biosynthesis of melatonin. AANAT – arylalkylamine N-acetyltransferase, SNAT –
serotonin N-acetyltransferase, HIOMT – hydroxyindole O-methyltransferase, SAM –
S-adenosylmethionine, SAH – S-adenosylhomocysteine.
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The N-acylation of biogenic amines is catalyzed from the corresponding acyl-CoA and
amino donor substrates by an N-acyltransferase enzyme (NAT).

NATs can catalyze the

formation of N-acylamides by one of the three proposed chemical mechanisms found in Scheme
1.3. In Scheme 1.3A, the thioester carbonyl of acyl-CoA undergoes nucleophilic attack by the
amine substrate to generate a zwitterionic tetrahedral intermediate.

The newly formed

intermediate is then deprotonated by an amino acid residue functioning as a general base. Then
the tetrahedral intermediate collapses by the protonation of coenzyme A by an amino acid
residue functioning as a general acid, to generate the N-acylamide and CoA-SH products. This
chemical mechanism as been attributed to a number of NATs, such as aminoglycoside
N-acetyltransferase,128-129

spermidine/spermine

N1-acetyltransferase,130

and

perosamine

N-acetyltransferase.131
The mechanism in Scheme 1.3B shows a base catalyzed initial deprotonation of the
positively charged amino group of the amine substrate, followed by nucleophilic attack of the
thioester carbonyl of acyl-CoA to generate a zwitterionic tetrahedral intermediate. Then a
collapse of the tetrahedral intermediate occurs with the protonation of CoA. This chemical
mechanism as been attributed to a number of NATs, such as histone N-acetyltransferases,132
N-myristoyltransferase,133-134 QdtC N-acetyltransferase,135 and WlbB N-acetyltransferase.136

Scheme 1.3C highlights a nucleophilic attack of the acyl-CoA thioester carbonyl by a
nucleoplic residue (Cys) of the NAT enzyme. Then the tetrahedral intermediate collapses by an
acid catalyzed protonation of coenzyme A, yielding a stable covalently modified acyl*NAT
intermediate. Next, the amine substrate attacks the carbonyl of the acyl*enzyme intermediate to
generate a zwitteriontic tetrahedral intermediate. Finally, collapse of the intermediate occurs
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with an acid catalyzed protonation of the nucleophilic amino acid residue and a base catalyzed
deprotonation of the amine intermediate. Arylamine N-acetyltransferase is an example of an
NAT that utilizes this type of chemical mechanism.137

Scheme 1.3. Possible chemical mechanisms for N-acyltransferases. (A.) Acid/base catalyzed
breakdown of a zwitterionic tetrahedral intermediate. (B). Base catalyzed deprotonation of
positively charged amino group, with protonation of coenzyme A during breakdown of the
zwitterionic tetrahedral intermediate. (C.) NAT catalyzed formation of N-acylamides through a
stable covalently modified acyl-enzyme intermediate.

N-acetylarylalkylamides

is

one

set

of

acetylated

metabolites

catalyzed

by

N-acyltransferase enzymes in both mammals and insects. This reaction is catalyzed by AANAT,
which is an enzyme that is part of the Gcn5-related N-acetyltransferase family of enzymes
(GNAT).100,

138

Currently, very little work has been done to characterize insect AANAT or

AANATL enzyme(s). The first identification of N-acetyltransferase activity in D. melanogaster
was in 1972 by Dewhurst et al., which measured radiolabeled formation of N-acetyltyramine,
N-acetylserotonin, and N-acetyldopamine from fly homogenates.139 Following this work, in
1977 Maranda and Hodgetts characterized the first AANAT enzyme from D. melanogaster.112
Subsequently, Brodbeck et al. identified two biologically relevant AANAT variants, AANAT
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variant A (AANATA) and variant B (AANATB) in 1998.140 They discovered that the two
AANAT variants differed by only 35 amino acids on the N-terminus, which AANATB is the
larger variant.140 AANATA was identified in the adult fly and during late stage embryogenesis,
and localized to the brain, midgut, and ventral nerve cord.140 AANATB was identified in the
adult fly and during the late pupal stage, which its localization was in the brain.140 A second
AANATL enzyme, AANATL2, was discovered in 2000 by Amherd et al. and was shown to
catalyze the formation of N-acetyltryptamine from acetyl-CoA and tryptamine.141 No further
work has been done to characterize this enzyme since its initial discovery. In addition, Amherd
et al. and our group have identified eight possible AANATL enzymes in the D. melanogaster
genome.141-142 None of these other AANATL enzymes have been characterized to date. Very
little work has been done mechanistically on the fly enzymes until Cheng et al. published the
AANATA crystal structure in 2012.143 Their work concluded that two serines, Ser-182 and
Ser-186, function as the general base and acid in catalysis, respectively. 143 In addition, they
suggested that Glu-47 initiates catalyses by deprotonating Ser-182 to generate an alkoxide prior
to it (Ser-182) functioning as a general base.143 We found this unlikely, because of it being
thermodynamically unfavorable for a serine to function as a general acid to protonate a thiolate
(see Chapter 2).
Herein, the following chapters detail the characterization of four D. melanogaster
AANAT(L) enzymes.

We compare the chemistry for AANATA and AANATB, two

biologically relevant variants. In addition, we describe a developed screening strategy (Chapter
3) that utilizes the pooling of amines to define the substrates for D. melanogaster AANATL
enzymes. Finally, we define the kinetic mechanism, functional analysis of structurally different
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substrates, functional analysis of different amino acid residues, and proposed a chemical
mechanism for AANATA (Chapter 2),142 AANATL2 (Chapter 5),68 and AANATL7 (Chapter 4).

1.4 Future perspective in the fatty acid amide field
During our investigation of the fatty acid amide biosynthetic pathways, in addition to the
Bradshaw group,63 we identified a significant amount of fatty acid amides in D. melanogaster,
including long-chain N-acyldopamines and N-acylserotonins.62,

68

Since some of these

metabolites have been suggested to be ligands to the cannabinoid receptors and their biosynthesis
or degradation is catalyzed by FAAH, we find it amazing that these molecules are found in this
organism. It has been published that neither FAAH nor the CB receptors are found in D.
melangaster, based off primary sequence identity.79-80

The lack of CB receptors in D.

melanogaster is also derived from radioligand binding assays, in which binding of CB specific
ligands was not observed in fly head tissue homogenates.79 One intriguing result from this
published work is D. melanogaster sequence CG8839, which only has 25% sequence identity
from 85% of human FAAH.80,

144

Albeit the low sequence similarity, the catalytic core of

Lys-142, Ser-217 (or Ser-218), and Ser-241 is conserved with CG8839.90-91,

145

However, a

proline rich SH3 binding domain shown to be important for rat FAAH activity is missing in
CG8839, leading McPartland et al. to conclude that this enzyme and likely any enzyme in D.
melanogaster will function with FAAH activity.80,

146

We also identified another FAAH like

enzyme, CG5112, which the catalytic core is conserved, but the proline rich SH 3 binding domain
is missing.146 Both of these D. melanogaster enzymes have not been characterized to date and
the only data published that corresponds to them is that both are found in lipid droplets, based off
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proteomic profiling.147

It will be interesting to evaluate D. melanogaster CG8839 and/or

CG5112 to determine if it has a similar function to FAAH.
Next, some enzymes involved in biosynthesis and degradation of different fatty acid
amides have been identified in either mammals or D. melanogaster. One major question is if the
biosynthetic (and degradative) pathways for the fatty acid amides are conserved between these
two organisms? Some examples of questions related to the metabolism of fatty acid amides are:
(a) is there an AANAT(L) enzyme that will catalyze the formation of long-chain
N-acylserotonins and N-acyldopamines in mammals, (b) is there secondary pathways for the
biosynthesis of long-chain N-acylserotonins and N-acyldopamines, or (c) if there is a secondary
pathway, what is the predominate chemical step in their biosynthesis? Further evaluation of
enzymes involved in fatty acid amide metabolism is necessary to determine if D. melanogaster is
truly a model system.
Finally, we have a large panel of fatty acid amides identified in both mammals and D.
melanogaster; however, not many of these metabolites have a defined physiological function. In
addition, the receptors that potentiate their physiological function have not been completely
defined. Further work is necessary to identify the endogenous receptors for each of these lipids
and to understand their physiological role. There is still a substantial amount of work to be
completed to fully understand the biological impact these molecules have on human health.
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Chapter Two
Mechanistic and Structural Analysis of Drosophila melanogaster Arylalkylamine
N-acetyltransferases

2.1 Note to reader
This chapter has been previously published in Biochemistry, 2014, 53: 7777-7793 and has
been reproduced with permission from ACS Publications. This work can be viewed in Appendix
A.
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Chapter Three
AANATL Screening Method

3.1 Introduction
The N-acylation of a biogenic amine is an important chemical step in Drosophila
melanogaster for the inactivation of neurotransmitters, cuticle sclerotization, melatonin
biosynthesis, and biosynthesis of important cell signaling lipids.1-4 One set of enzymes, the
arylalkylamine N-acetyltransferases (AANAT), are known to catalyze the formation of
N-acetylarylalkylamides from acetyl-CoA and the corresponding arylalkylamide.

Recently,

eight putative arylalkylamine N-acetyltransferase like enzymes (AANATL) were indentified in
D. melanogaster based off their primary sequence identity.5-6 Only two (AANATA3-4,

6-8

and

AANATL25) of these enzymes have been previously characterized. AANATA was shown to
catalyze

the

formation

of

N-acetylarylalkylamides,

consisting

of

N-acetyltyramine,

N-acetyltryptamine, N-acetyldopamine, N-acetylserotonin, and N-acetyloctopamine.3-4,

6-8

Previous work also showed that acetyl-CoA and tryptamine are substrates for AANATL2.5 Prior
to our work, none of the other AANATL enzymes (AANATL3; CG10659, AANATL4;
CG18607, AANATL5; CG10476, AANATL6; CG18606, AANATL7; CG13759, and
AANATL8; CG15766) have been evaluted to define substrates each utlizes in their N-acylation
reaction.

All eight AANATL enzymes belong to the Gcn5-related N-acetyltransferase

superfamily (GNAT),9-10 which is a large family of enzymes (~10,000 members) that use
acyl-CoA and amine substrates to generate an N-acylamide (Scheme 3.1). One difficultly in
45

defining the chemistry for GNAT enzymes is that the primary sequence identity when compared
to other N-acyltransferases is very low.10 This makes it challenging to define substrates for this
family of enzymes solely from bioinformatics, whereas a developed screening method would be
advantageous in classifying the chemistry each respective enzyme catalyzes.
Herein, we report the successful development of an activity-based screening method for
GNAT enzymes. Our method employs a combination of two activity-based screening steps and
a product identification step by liquid chromatography quadruple time-of-flight mass
spectrometry (LC/QTOF-MS).

This high-throughput screening method was extremely

successful at defining different substrates for four D. melanogaster AANATL enzymes
(AANATL2, AANATL3, AANATL7, and AANATL8). Additionally, this method was able to
discover unconventional acyl-CoAs and/or amines that serve as AANATL substrates, giving new
insight to the cellular functions for this family of enzymes from the fly.

Scheme 3.1. General GNAT reaction. R – fatty acyl group. Y – amine substrate.

3.2 Materials and methods
3.2.1 Materials
Ambion RETROscript® Kit, ProBond™ nickel-chelating resin, MicroPoly(A) PuristTM
was purchased from Invitrogen. Oligonucleotides were purchased from Eurofins MWG Operon.
PfuUltra High-Fidelity DNA polymerase was purchased from Aglient. BL21 (DE3) E.coli cells
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and pET-28a(+) vector were purchased from Novagen. NdeI, XhoI, Antarctic Phosphatase, and
T4 DNA ligase were purchased from New England Biolabs. Kanamycin monosulfate and IPTG
were purchased from Gold Biotechnology. Acetyl-CoA and oleoyl-CoA were purchased from
Sigma-Aldrich. N-oleoylserotonin was purchased from Caymen Biochemical. N-acetylagmatine
and N1-acetylspermidine were custom synthesized from Cayman Biochemical. AANATL2 and
AANATL8 were codon optimized and purchased from Genscript.

All other reagents were

purchased in high quality from either Sigma-Aldrich or Fisher Scientific.

3.2.2 Cloning of recombinant D. melanogaster AANATL enzymes
AANATL2 (CG9486) was cloned, over-expressed, and purified as previously reported
(Appendix B).11 The AANATL8 (CG15766 – Accession No. NM_132040.2) gene was codon
optimized and synthesized by Genscript. The AANATL3 (CG10659 - NCBI reference sequence
NM_136174.2) and AANATL7 (CG13759) genes were amplified by PCR using PfuUltra
High-Fidelity DNA polymerase from a cDNA library generated from Drosophila heads, using
the

following

primers:

AANATL3

TACGCATATGATGGCCTCAAGCATTAAAGAC

forward

3’

and

reverse

5’
5’

TACGCTCGAGTCACAGTTTGATGAACATAATTCG 3’ or AANATL7 - forward 5’
TCAGCATATGATGGAGTACAAGATGATTGCACCC
TCAGCTCGAGTTAAAGCGACTGCTTCTTCTCAT 3’.

3’

and

reverse

The production of the

5’
D.

melanogaster head cDNA library is described in Dempsey et al or also found in Appendix B.11
The PCR conditions for the separate amplification of AANATL3 or AANATL7 were: initial
denaturing step of 95°C for 2 min, then 30 cycles (95°C for 30 s; 60°C for 30 s; 72°C for 1 min),
then a final extension step of 72°C for 10 min. The following set of cloning procedures was
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performed for each enzyme, separately. The AANATL3 and AANATL7 PCR products, in addition
to the codon optimized AANATL8 gene were then inserted into a pET-28a (+) vector using NdeI
and

XhoI

restriction

sites

to

generate

AANATL3-pet-28a,

AANATL7-pet-28a,

and

AANATL8-pet-28a expression vectors. After the formation of the expression vectors, each one
was transformed into E. coli XL-10 cells, spread onto a Luria Broth (LB) agar plate, and
incubated overnight at 37°C.

A single colony from the LB agar plates containing the

AANATL3-pet-28a, AANATL7-pet-28a, or AANATL8-pet-28a expression vector was then
cultured overnight in LB media supplemented with 40 µg/mL kanamycin at 37°C.

The

AANATL3-pet-28a, AANATL7-pet-28a, and AANATL8-pet-28a plasmids were purified from the
final cultures using the Promega Wizard® Plus SV Minipreps DNA purification kit. Each pure
plasmid was sequenced by Eurofins MWG operon and then transformed into E.coli BL21 (DE3)
cells for protein expression.

3.2.3 Expression and purification of AANATL enzymes
The BL21(DE3) E. coli cells containing the AANATL3-pet28a, AANATL7-pet-28a, or
AANATL8-pet28a vectors were cultured separately in LB media supplemented with 40 µg/mL
kanamycin at 37°C. All three cultures were induced at an OD600 of 0.6 with 1 mM isopropyl
thio-β-D-galactoside.

The cells were then culture for another 4 hrs at 37°C before being

harvested separately by centrifugation at 5,000 g for 10 min at 4°C. The following set of
purification procedures was performed for each enzyme, separately. The supernatant from the
centrifugations were discarded and the pellets were resuspended in nickel affinity purification
binding buffer (20 mM Tris pH 7.9, 500 mM NaCl, 5 mM imidazole), lysed by sonication, and
then centrifuged at 10,000 g for 15 min at 4°C. The supernatant was collected, whereas the
pellet was discarded. The supernatant was then loaded on a ProBond™ nickel-chelating column
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containing 6 mL of resin, washed with 60 mL of binding buffer, and then washed with 60 mL of
20 mM Tris, pH 7.9, 500 mM NaCl, 60 mM imidazole to remove any non-specifically bound
proteins. Then each protein was eluted in 1 mL fractions using 20 mM Tris, pH 7.9, 500 mM
NaCl, 500 mM imidazole. The purified fractions of AANATL3 and AANATL8 were dialyzed
into 20 mM Tris pH 7.4, 200 mM NaCl for 16 hr at 4°C, separately. Purified AANATL7 was
dialyzed into 50 mM HEPES pH 8.2, 500 mM NaCl, 1 mM EDTA for 16 hr at 4°C. The purity
of each protein was assayed by a 10% SDS-PAGE gel and their respective concentrations were
determined by the Bradford binding assay.

3.2.4 Enzyme screening assay
The activity-based screening for each AANATL enzyme for acyl-CoA and amine
substrates were evaluated in two separate steps. The first step was to evaluate each enzyme
using either acetyl-CoA or oleoyl-CoA separately, with seven different groups of pooled amines.
The corresponding amines in each group are found in Table 3.1. The assay conditions were 300
mM Tris pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and pooled amines at 22°C. The final
concentrations of the amine substrates for the screening assay were the following: Groups 1, 2, 3,
4, and 6, were 60 mM, whereas groups 4, 5, and 7 were 20 mM. The initial velocities were
determined using Ellmans reagent (molar extintion coefficent = 13,600 M-1cm-1), by measuring
the rate of coenzyme A release at 412 nm.12 The reported initial velocities are represented as the
background hydrolysis rate subtracted from the observed velocity.
The second step was to individually evaluate each amine from groups that had significant
velocities above the background hydrolysis rate, with the corresponding acyl-CoA substrate.
“Significant velocity” is defined herein as any rate (µmoles/min/mg) that was ≥ 0.1
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µmoles/min/mg above the background rate. The assay conditions were the same as the pooled
amine screening step, including the concentration of each amine substrate evaluated. After all
the amine and the corresponding acyl-CoA(s) substrate(s) were indentified, then the final
reaction products were analyzed by LC/QTOF-MS.

Table 3.1. Pooled amines for initial substrate screening.
Group
1
2
3
4
5
6
7

Amino Donors
Lysine, threonine, glycine, histamine
Alanine, arginine, histidine, tyramine
Serine, proline, methionine, serotonin
Glutamate, asparagine, valine, ethanolamine
Aspartate, isoleucine, tryptophan, glutamine
Leucine, phenylalanine, γ-aminobutyric acid, taurine
Spermidine, agmatine, cadaverine, putrescine, β-alanine

3.2.5 Identification of N-acylamide product by LC/QTOF-MS
Following the activity-based screening method, we confirmed the presence of the
predicted N-acylamide product by LC/QTOF-MS.

The products for each reaction were

generated by incubating the specific enzyme (AANATL2; 36 µg, AANATL3; 69 µg,
AANATL7; 9.3 µg, or AANATL8; 36 µg) for one hour in 300 mM Tris pH 8.0, 500 µM
acyl-CoA substrate, and 60 mM or 20 mM amine substrates. The amine concentration was the
same as that evaluated in the activity-based screening section. The resulting reaction mixture
was passed through a 10 kDa ultrafilter (Millipore) to remove the AANATL enzyme and the
protein-free solution was then injected on an Agilent 6540 LC/QTOF-MS. The LC/QTOF-MS
method used and the data analysis is described in the Dempsey et al. publication or also found in
Appendix B.11
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3.2.6 Enzyme assay for defining the AANATL3 steady-state kinetic constants
AANATL3 activity was analyzed using Ellman’s reagent12 by measuring the release of
coenzyme A at 412 nm under the following assay conditions: 300 mM Tris, pH 8.0, 150 µM
DTNB, while holding one substrate at a constant saturating concentration and varying the
concentration of the other substrate at 22°C. Initial velocities of CoA-SH release were measured
using a Cary 300 Bio UV-Visible spectrophotometer. The resulting initial velocity kinetic data
were fit to equation 3.1 using Sigma Plot 12.0, where vo is the initial velocity, [S] is the substrate
concentration, Vmax is the maximal velocity, and Km is the Michaelis constant. Assays were
performed in triplicate and reported as ± the standard error. The uncertainty for the kcat,app,
(kcat/Km)app, and the relative (kcat/Km)app values were calculated by using equation 3.2, which σ is
the standard error.

Equation 3.1

Equation 3.2
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3.3 Results and discussion
3.3.1 Expression and purification of AANATL enzymes
AANATL2,17 AANATL3, AANATL7 and AANATL8 from D. melanogaster were
overexpressed and purified successfully to yield 7.5 mg/L, 11 mg/L, 27 mg/L and 7.5 mg/L of
purified protein per liter culture, respectively. Purity was analyzed and shown to be ≥ 90% by a
10% SDS-PAGE gel (Figure 3.1 or Appendix B).11 Successful expression and purification of
each protein allowed for the further evaluation of potential substrates by a pooling strategy
discussed in subsequent sections.

Figure 3.1. SDS-Page analysis. (A) AANATL3, (B) AANATL7, (C) AANATL8.

3.3.2 Pooling strategy for identification of AANATL enzymes
We developed a three step substrate screening method which includes two activity-based
screening methods and one product identification step.

Specifically, our GNAT screening

strategy is composed of (a) a amine pooling strategy that is screened with either a short-chain
(acetyl-CoA) or long-chain (oleoyl-CoA) acyl-CoA by measuring the rate of CoA-SH release
using Ellmans reagent,12 (b) followed by individual screening of each amine in the group(s) with
the corresponding acyl-CoA that produced a velocity above the background hydrolysis rate, and
finally (c) confirming the presence of the N-acylamide product in the final reaction mixture by
LC/QTOF-MS. The first step in the identification of novel AANATL substrates is the initial
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screening of amine substrates that are pooled into specific groups. A general approach for how
the first six groups of pooled amines (Group 1 – 6) were assembled consists of: (a) if there is in
vivo evidence for the predicted N-acylamide product, (b) combining amines that are structurally
diverse, and (c) the solubility13 of the amine in water. Amines were chosen for the first six pools
based off previous reports of endogenous levels of N-acyl amino acids,14-15 N-acetylhistamine,16
N-acetyltyramine,17 N-acylethanolamines,14-15 N-acylserotonins,17-18 and N-acyl GABAs.14
Therefore, we evaluated AANATL2, AANATL3, AANATL7, and AANATL8 to determine if
these enzymes could function to catalyze the formation of these endogenous fatty acid amides.
In addition, we made an effort to pool structurally diverse amines into different groups in order
to minimize any inhibition effects from other amines that may occur in the enzymatic assay. The
concentration of amines in the pooled enzymatic screening assay were held at high
concentrations since some GNAT enzymes are known to have high Km,app values for the amine
substrate. For example, mouse glycine N-acyltransferase (GLYAT) has a Km,app value of 6 mM
for glycine.19 The amine concentrations for the pooled screening method were either 60 mM (10
× the Km,app value for GLYAT; Groups 1, 2, 3, and 6) or 20 mM (3 × the Km,app value for
GLYAT; Groups 4 and 5), yielding assay conditions that are saturating for most GNAT
enzymes. Groups 4 and 5 were analyzed at 20 mM, because of the solubility of glutamate (~65
mM),13, 20 tryptophan (~60 mM),13, 21-22 and aspartate (~38 mM)13,

20

in water. Following the

evaluation of the first six pooled amine groups (Table 3.2), we decided to add Group 7 because
of the low velocities observed for AANATL3 and AANATL8. Group 7 is predominantly
composed of polyamines and was evaluated at a concentration of 20 mM for each amine (Table
3.1). Some polyamines have been identified to serve as substrates for N-acetylation by different
GNAT enzymes. The Km value for polyamine N-acetyltransferase enzymes range from the
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micromolar (human spermidine/spermine N1-acetyltransferase: spermidine – 22 µM)23 to low
millimolar concentrations (rat acetyl-CoA 1,4-diaminobutane N-acetyltransferase: putrescine – 3
mM).24 Therefore, the assay conditions for the amine concentration would produce a worst case
scenario of 7-fold higher than the Km,app value for rat acetyl-CoA 1,4-diaminobutane
N-acetyltransferase,24 suggesting we are likely close to saturating conditions for most GNAT
enzymes. Tyrosine and cystine were not evaluated in this study. Tyrosine has a low solubility in
water (~2.5 mM)13, 20 when compared to the other amino acids, while cystine will interfere with
Ellman’s reagent by inducing an absorbance increase at 412 nm. Ellman’s assay measures the
free release of thiol groups, in our case, the free release of the coenzyme A product from the
AANATL-catalyzed reaction.12 Since, cystine has a free thiol as its side chain, it will induce a
color change that is non-specific to the enzyme-catalyzed reaction. We did not use a pooling
strategy for the acyl-CoA substrates because of numerous reports that long-chain acyl-CoAs
serve as inhibitors to GNAT enzymes;6,

19, 25-26

therefore, we screened each acyl-CoA

individually. Our screening method wanted to encompass a broad range of acyl-CoA substrates,
with an emphasis on the length of the acyl-chain. Acyl-CoAs will serve as substrates for GNAT
enzymes, with most using acetyl-CoA. There are reports of GNAT enzymes using oleoyl-CoA
as a substrate;27 therefore, we used acetyl-CoA and oleoyl-CoA to represent the short- and
long-chain acyl-CoAs in the screening method, respectively.
The first step of the screening method was the amine pooling strategy for D.
melanogaster AANATL2, AANATL3, AANATL7, and AANATL8 (Table 3.2). These set of
experiments identified significant hits for each enzyme, wherein we define significance as any
velocity shown in Table 3.2 that is at least 0.1 µmoles/min/mg greater that the observed
background hydrolysis activity. We decided to incorporate velocities that are small compared to
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the background rate because long-chain fatty acid amides are found in low abundances in
biological samples, in particular the fly and they function as potent cell signaling lipids.2, 28 This
indicates that their biosynthesis could be catalyzed by enzymes that function with small
velocities as observed for D. melanogaster AANATL2 (Appendix B)11 and human glycine
N-acyltransferase like 2.27

From our data (Table 3.2), we identified significant hits for

AANATL2 (acetyl-CoA: Group 1, 2, 3, 4, and 7; oleoyl-CoA: Group 3), AANATL3
(acetyl-CoA: Group 2 and 3), AANATL7 (acetyl-CoA: Group 1, 2, 3, 4, and 7), and AANATL8
(acetyl-CoA: Group 1, 2, and 7). These data directed us to further screen each amine from the
respective group that was assigned as a “hit” individually, with the corresponding acyl-CoA.

Table 3.2. Pooled screening method for the AANATL-catalyzed reaction.
Velocity
(µmoles/min/mg)
Acyl-CoA
Group
1a
2a
3a
4b
5b
6a
7b
AANATL2 – CG9486
3.8c
2.5c
1.5c
0.05
0.0
0.18c
Acetyl-CoA
2.5c
c
0.05
0.20
0.05
0.02
0.0
0.0
Oleoyl-CoA
0.02
AANATL3 – CG10659
0.38c
0.40c
0.0
0.02
0.05
0.03
Acetyl-CoA
0.03
0.0
0.0
0.0
0.0
0.01
0.0
Oleoyl-CoA
0.01
AANATL7 – CG13759
13c
11c
13c
0.04
0.0
4.2c
Acetyl-CoA
28c
0.05
0.0
0.01
0.0
0.01
0.0
Oleoyl-CoA
0.0
AANATL8 – CG15766
0.24c
0.03
0.05
0.0
0.0
29c
Acetyl-CoA
0.57c
0.0
0.0
0.0
0.01
0.0
0.0
Oleoyl-CoA
0.0
a
Enzyme reaction conditions – 20 mM Tris, pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and 60 mM
Group X (pooled amines).
b
Enzyme reaction conditions – 20 mM Tris, pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and 20 mM
Group X (pooled amines).
c
Classified as a “hit” (≥ 0.1 µmoles/min/mg when compared to background hydrolysis rate)
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3.3.3 Indiviual screening of amine and acyl-CoA substrates that yielded a “hit” from pooling
method
A summary of the data from the individual screening of every amine from pools that
were classified as “hits” can be found in Table 3.3. Amine substrates in decreasing order of
velocity identified for AANATL2 were tyramine > serotonin > histamine > ethanolamine >>
putrescine > agmatine > cadaverine > spermidine, with acetyl-CoA as the corresponding
acyl-CoA substrate.

AANATL2 was also identified to catalyze the formation of

N-oleoylserotonin from serotonin and oleoyl-CoA. These data highlight an enzyme, for the first
time that will catalyze the formation of long-chain N-acylserotonins. Serotonin and tyramine, in
combination with acetyl-CoA, were found to be substrates for AANATL3 with similar velocities.
Individual amine screening for AANATL7 identified in decreasing order of velocity:
histamine > tyramine > serotonin > putrescine > agmatine > ethanolamine > cadaverine with
acetyl-CoA as the corresponding acyl-CoA substrate. These data feature an enzyme that can
catalyze the formation of N-acetylhistamine, N-acetylagmatine, and N-acetylethanolamine,
which are unknown or understudied metabolites,16, 29 with very few reports of an enzyme that
can catalyze their direct biosynthesis.30-33
Finally, the individual screening of amine substrates for AANATL8 showed a decreasing
order in velocity: agmatine >> putrescine > spermidine > cadaverine > histamine > tyramine
with acetyl-CoA as the corresponding acyl-CoA substrate. These data indicate that AANATL8
will catalyze the formation of polyamines; therefore, functioning as a polyamine
N-acetyltransferase (PNAT). Agmatine generated the highest velocity, which is an understudied
amine substrate for GNAT enzymes.33
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Table 3.3. Summary of data from the individual screening method for AANATL enzymes.a
Retention
[M + H]+
Time
(m/z)
(min)
b
1
Histamine
2.2
0.317
154.0982
2b
Tyramine
4.0
0.687
180.1030
3b
Serotonin
3.1
0.715
219.1140
4c
Ethanolamine
0.85
0.220
104.0710
Acetyl-CoA
AANATL2
Spermidine
0.1
0.230
188.1753
Agmatine
0.13
0.323
173.1389
c
7
Cadaverine
0.11
0.318
145.1335
Putrescine
0.16
0.345
131.1183
3b
Serotonin
Oleoyl-CoA
0.21
6.126
441.3463
2b
Tyramine
0.45
0.694
180.1030
AANATL3
Acetyl-CoA
b
3
Serotonin
0.47
0.713
219.1142
1b
Histamine
23
0.320
154.0975
2b
Tyramine
7.7
0.687
180.1019
3b
Serotonin
5.8
0.719
219.1133
c
AANATL7
4
Ethanolamine Acetyl-CoA
1.7
0.345
104.0695
Agmatine
3.3
0.318
173.1393
7c
Cadaverine
1.0
0.317
145.1335
Putrescine
3.9
0.345
131.1179
1b
Histamine
0.51
0.318
154.0972
2b
Tyramine
0.24
0.694
180.1031
Spermidine
0.67
0.232
188.1758
AANATL8
Acetyl-CoA
Agmatine
32
0.322
173.1395
7c
Cadaverine
0.59
0.324
145.1329
Putrescine
5.1
0.329
131.1182
a
Data in table represents each the acyl-CoA and amine that produced a positive “hit” in velocity above
the background hydrolysis rate (≥ 0.1 µmoles/min/mg). All other amines from the respective pools did
not produce a velocity above the background hydrolysis rate.
b
Enzyme reaction conditions – 20 mM Tris, pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and 60 mM
amine substrates.
c
Enzyme reaction conditions – 20 mM Tris, pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and 20 mM
amine substrates.
Enzyme

Group

Amine
Substrate

Acyl-CoA
Substrate

Velocity
(µmoles/min/mg)

3.3.4 High resolution LC/QTOF-MS identification of the N-acylamide product generated from
individual screening method
The screening data was extremely successful at identifying substrates for each AANATL
enzyme evaluated. We wanted to further evaluate each enzyme by identifying if the predicted
N-acylamide product is present in the final reaction mixture.

We compared commercial

N-acylamide standards to the AANATL final reaction mixture using high resolution
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LC/QTOF-MS. The N-acylamide product from the AANATL final reaction mixture (Table 3.3)
and commercially available standards (Table 3.4) were compared by the retention time and the
m/z value of the [M + H]+ peak using high resolution LC/QTOF-MS. The data in Tables 3.3 and
3.4 confirms the presence of the predicted N-acylamide product in the AANATL-catalyzed
reaction sample for each enzyme evaluated in this study.

All data represented herein is

consistent for retention time (± 0.1 reported error for LC/QTOF-MS) and the [M + H]+ peak
when compared to commercially available standard.

Table 3.4. N-acylamide LC/QTOF-MS standards.
Standard
N-acetylhistamine
N-acetylserotonin
N-acetylethanolamine
N-acetylputrescine
N-acetylagmatine
N1-acetylspermidine
N-oleoylserotonin

Retention Time
(min)
0.256
0.726
0.299
0.345
0.316
0.233
6.145

[M +H]+
(m/z)
154.0976
219.1131
104.0710
131.1172
173.1424
188.1758
441.3509

3.3.5 Steady-state kinetic analysis of AANATL3
AANATL3 was further evaluated to determine the substrate specificity for biologically
relevant arylalkylamines found in the fly (Table 3.5). The order for the specificity of the
biogenic arylalkylamines is as follows: serotonin > tyramine > octopamine. Dopamine was also
evaluated at a concentration of 10 mM, but did not yield a velocity above the background
hydrolysis of acetyl-CoA, suggesting that it is either not a substrate or has a significantly higher
Michaelis constant (Km,app > 10 mM;) for AANATL3 when compared to the other
arylalkylamines in Table 3.5.
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Table 3.5. AANATL3 kinetic constants.a
Km, app
kcat, app
(kcat/Km)app
Relative (kcat/Km)app
(µM)
(s-1)
(M-1s-1)
b
3
Acetyl-CoA
46 ± 3
0.202 ± 0.003
(4.4 ± 0.3) × 10
N/Ad
Tyraminec
760 ± 80
0.23 ± 0.01
310 ± 40
1.7 ± 0.4e
c
Serotonin
550 ± 30
0.229 ± 0.004
410 ± 20
2.3 ± 0.4e
c
Octopamine
1300 ± 200
0.23 ± 0.01
180 ± 30
1.0 ± 0.2e
a
Kinetic constants are reported with the standard error (n = 3).
b
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 7.5 mM tyramine, and varying concentration
of acetyl-CoA.
c
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 500 µM acetyl-CoA, and varying
concentration of arylalkylamine.
d
N/A – not applicable. The second order rate constant for acetyl-CoA was not indexed to any other
substrate.
e
Relative (kcat/Km)app was normalized to octopamine [(kcat/Km)app = 180 ± 30].
Substrate

3.3.6 Discussion
There are over 10,000 GNAT superfamily enzymes identified in all kingdoms of life, 10
which makes this one of the largest known superfamilies. Methods used to define a cellular
function for previously uncharacterized enzymes consist of genome sequencing and
bioinformatics,34-35 identifying the sub-cellular localization of the protein,36 substrate docking
methods,37-38 and activity-based individual screening of substrates.39-41 Using bioinformatics to
define the chemistry of a GNAT enzyme is challenging because of the very low primary
sequence identity for this family of enzymes.10 For example, D. melongaster AANATA was
reported to have ≤ 12% sequence identity with its mammalian ortholog.7 In addition, using
bioinformatics to solve the function of uncharacterized proteins can be misleading, in that many
predicted proteins in public databases are missannotated34, 42-43 or are classified as a “hypothetical
proteins”.44-45 In fact, it has been reported that up to 40% of known proteins are not annotated in
public databases and their define functions are still pending.44-45 Sub-cellular localization has
been successful in giving insight to the chemical environment an enzyme performs its function;
however, it will not confirm the exact in vivo reaction(s) the enzyme will catalyze. Protein
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docking strategies have been immensely successful in defining substrates for uncharacterized
enzymes.46 As the public databases grow with solved crystal structures, defining the chemistry
of these enzymes have become easier and cheaper by using computational methods. However,
this method requires a solved crystal structure for the protein being studied or a structurally
similar protein that can be evaluated by a homology model.47 In 2012, the PDB database
contained > 2,000 non-redundant crystal structures that were annotated with unknown
functions.48 This suggests that even with a solved crystal structure, it can still be extremely
challenging to define the biological function of a protein just from a crystal structure. In all, we
identified a need to develop a high-throughput screening strategy, to define the function for
enzymes that have not been previously characterized.
Very few screening methods have been developed to discover substrates for an
uncharacterized enzyme.

There are examples of published screening methods that utilize

substrate pooling strategies, individual substrate screening methods, or enzyme pooling methods
to define the cellular function of enzymes. The report by von Buhler et al.39 uses a substrate
pooling strategy to measure percent conversion by GC/MS and LC/MS for cytochrome P450s.
Kuznetsova et al.40 used a 96-well plate reader to annotate functions for a broad class of different
enzymes (phosphodiesterases, esterases, proteases, dehydrogenases, and oxidases), using
individual and pooling strategies. Kuhn et al.41 also used a 96-well plate reader to individually
screen possible amine substrates with acetyl-CoA for different GNAT enzymes. Our method is a
hybrid of these methods; where we incorporate a pooling strategy, followed by individual
screening, and finally analyzing the N-acylamide product by LC/QTOF-MS.

Our screening

strategy is similar to that developed for bacterial GNAT enzymes by Kuhn et al.,41 whereas the
differences are that we used an initial amine pooling step and a final LC/QTOF-MS N-acylamide

60

product confirmation step. Also, with recent evidence that long-chain fatty acid amides can be
biosynthesized by GNAT enzymes,2, 27 we decided that our screening method should incorporate
long-chain acyl-CoA substrates, in addition to acetyl-CoA.

In addition, we evaluated the

activity-based screening steps with Cary 300 Bio UV-vis spectrophotometer, whereas Kuhn et
al.41 used a 96-well plate reader to measure free release of CoA-SH at 412 nm using Ellman’s
reagent.12 We believe our pooling method could also be translated to a 96-well plate reader in
the future. One major advantage to our method is the successful use of an initial high-throughput
amine pooling strategy, instead of individually evaluating every amine. Screening different
substrates for an enzyme could be laborious and expensive, especially GNAT enzymes that use
an expensive acyl-CoA substrate [currently acetyl-CoA is ~150-fold > the price of gold (as of
12/23/2014)]. Our method can minimize the cost and time in defining substrates for GNAT
enzymes. For example with one enzyme, if we pool together 5-10 amine substrates into seven
groups, in combination with screening a short-chain (acetyl-CoA) and long-chain acyl-CoA
(oleoyl-CoA) substrate separately, we can initially screen 70-140 combinations in only 14
experiments. This method totals to 5-10 fold less experiments when compared to individually
screening each substrate. Therefore, this method would significantly decrease the overall cost
and time when compared to screening each substrate, separately.
In our study, we report the successful expression and purification of four D.
melanogaster AANATL enzymes (AANATL2, AANATL3, AANATL7, and AANATL8) and
the novel discovery of substrates for each enzyme by our screening strategy. AANATL2 was the
first enzyme to be evaluated, which generated excitement for our method. We identified that it
will catalyze the formation of N-oleoylserotonin (Table 3.3). These data led to the first report of
an enzyme that will catalyze the formation of long-chain N-acylserotonins and N-acyldopamines
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(Appendix B).11

These data also corroborate the original report by Amherd et al.5 that

AANATL2 will catalyze the formation of N-acetylarylalkylamides. The second enzyme studied,
AANATL3, was shown to catalyze the formation of N-acetylserotonin and N-acetyltyramine
(Table 3.4). Following this work, we showed that histamine, arylalkyamines, ethanolamine,
agmatine, putrescine, and cadaverine will serve as substrates for AANATL7, whereas agmatine,
histamine, tyramine, and other polyamines will serve as substrates for AANATL8. Histamine is
known to function as a neurotransmitter for photoreceptors in the D. melanogaster nervous
system,16 whereas agmatine is an unknown metabolite in the fly. However, agmatine is known
to exist in mammals, with the highest concentration found in the stomach and brain, where it
functions as a neurotransmitter.49 These enzymes could function in the inactivation of these
neurotransmitters. Very few reports are published for enzymes that can catalyze the formation of
N-acetylhistamine or N-acetylagmatine, especially with the higher velocities observed for
agmatine (AANATL8) and histamine (AANATL7).30-33 We must express some caution with
these data, in which the high velocities observed for substrates is not completely indicative of
substrate specificity. We would need to determine the second order rate constant (kcat/Km) for all
substrates in order to rank the “best substrate(s)” for that particular enzyme, as shown with
AANATL3 (Table 3.5). Regardless, these are exciting results that need to be followed up with a
more compressive characterization of each enzyme (AANATL2 – Chapter 5 and AANATL7 –
Chapter 4).
In conclusion, we were able to successfully develop and implement a screening method
for the general identification of substrates for GNAT enzymes found in D. melanogaster. Using
the method described herein, we were able to annotate acyl-CoA and amine substrates to each
enzyme evaluated in this study. We were able to discover enzymes which catalyze well known

62

N-acetylamide products, such as N-acetyltyramine17 and N-acetylserotonin.17-18 We also were
able to define enzymes that catalyze the formation of understudied or undiscovered N-acylamide
products, such as or N-acetylhistamine,16 N-oleoylserotonin,11,
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and N-acetylagmatine.29 We

believe this method could be translated to GNAT enzymes in other organisms and to other
classes of enzymes that have an activity-based assay (ex. dehydrogenases, proteases,
phosphodiesterases, etc…).40

The subsequent chapters in this dissertation will discuss the

characterization of AANATL7 and AANATL2, which evolved from the work defined in this
chapter.

3.4 References
1.

Finocchiaro, L., Callebert, J., Launay, J. M., and Jallon, J. M. (1988) Melatonin
biosynthesis in Drosophila: its nature and its effects, J. Neurochem. 50, 382-387.

2.

Waluk, D. P., Battistini, M. R., Dempsey, D. R., Farrell, E. K., Jeffries, K. A., Mitchell,
P., Hernandez, L. W., McBride, J. C., Merkler, D. J., and Hunt, M. C. (2014) Mammalian
fatty acid amides of the brain and CNS.

3.

Hintermann, E., Jeno, P., and Meyer, U. A. (1995) Isolation and characterization of an
arylalkylamine N-acetyltransferase from drosophila-melanogaster FEBS Lett. 375, 148150.

4.

Hintermann, E., Grieder, N. C., Amherd, R., Brodbeck, D., and Meyer, U. A. (1996)
Cloning of an arylalkylamine N-acetyltransferase (aaNAT1) from Drosophila
melanogaster expressed in the nervous system and the gut, Proc. Natl. Acad. Sci. U. S. A.
93, 12315-12320.

63

5.

Amherd, R., Hintermann, E., Walz, D., Affolter, M., and Meyer, U. A. (2000)
Purification, cloning, and characterization of a second arylalkylamine N-acetyltransferase
from drosophila melanogaster, DNA Cell Biol. 19, 697-705.

6.

Dempsey, D. R., Jeffries, K. A., Bond, J. D., Carpenter, A. M., Rodriguez-Ospina, S.,
Breydo, L., Caswell, K. K., and Merkler, D. J. (2014) Mechanistic and Structural
Analysis of Drosophila melanogaster Arylalkylamine N-Acetyltransferases, Biochemistry
53, 7777-7793.

7.

Cheng, K. C., Liao, J. N., and Lyu, P. C. (2012) Crystal structure of the dopamine Nacetyltransferase-acetyl-CoA complex provides insights into the catalytic mechanism,
Biochem. J. 446, 395-404.

8.

Maranda, B., and Hodgetts, R. (1977) Characterization of dopamine acetyltransferase in
drosophila-melanogaster Insect Biochem. 7, 33-43.

9.

Dyda, F., Klein, D. C., and Hickman, A. B. (2000) GCN5-related N-acetyltransferases: a
structural overview, Annu. Rev. Biophys. Biomol. Struct. 29, 81-103.

10.

Vetting, M. W., S. de Carvalho, L. P., Yu, M., Hegde, S. S., Magnet, S., Roderick, S. L.,
and Blanchard, J. S. (2005) Structure and functions of the GNAT superfamily of
acetyltransferases, Arch. Biochem. Biophys. 433, 212-226.

11.

Dempsey, D. R., Jeffries, K. A., Anderson, R. L., Carpenter, A. M., Rodriquez Opsina,
S., and Merkler, D. J. (2014) Identification of an arylalkylamine N-acyltransferase from
Drosophila melanogaster that catalyzes the formation of long-chain N-acylserotonins,
FEBS Lett. 588, 594-599.

12.

Ellman, G. L. (1959) Tissue sulfhydryl groups, Arch. Biochem. Biophys. 82, 70-77.

13.

(1981) Handbook of chemsitry and physics, 61 ed., CRC Press, Boca Raton.

64

14.

Tortoriello, G., Rhodes, B. P., Takacs, S. M., Stuart, J. M., Basnet, A., Raboune, S.,
Widlanski, T. S., Doherty, P., Harkany, T., and Bradshaw, H. B. (2013) Targeted
lipidomics in Drosophila melanogaster identifies novel 2-monoacylglycerols and N-acyl
amides, PLoS One 8, e67865.

15.

Jeffries, K. A., Dempsey, D. R., Behari, A. L., Anderson, R. L., and Merkler, D. J. (2014)
Drosophila melanogaster as a model system to study long-chain fatty acid amide
metabolism, FEBS Lett. 588, 1596-1602.

16.

Sarthy, P. V. (1991) Histamine: a neurotransmitter candidate for Drosophila
photoreceptors, J. Neurochem. 57, 1757-1768.

17.

Powell, P. R., Paxon, T. L., Han, K. A., and Ewing, A. G. (2005) Analysis of biogenic
amine variability among individual fly heads with micellar electrokinetic capillary
chromatography-electrochemical detection, Anal. Chem. 77, 6902-6908.

18.

Paxon, T. L., Powell, P. R., Lee, H. G., Han, K. A., and Ewing, A. G. (2005)
Microcolumn separation of amine metabolites in the fruit fly, Anal Chem 77, 5349-5355.

19.

Dempsey, D. R., Bond, J. D., Carpenter, A. M., Rodriguez Ospina, S., and Merkler, D. J.
(2014) Expression, purification, and characterization of mouse glycine N-acyltransferase
in Escherichia coli, Protein Expr. Purif. 97, 23-28.

20.

Dalton, J. B., and Schmidt, C. L. A. (1933) The solubilities of certain amino acids in
water, the densities of their solutions at twenty-five degrees, and the calculated heats of
solution and partial molal volumes, J. Biol. Chem. 103, 549-578.

65

21.

Dalton, J. B., and Schmidt, C. L. A. (1935) The solubilities of certain amino acids and
related compounds in water, the densities of their solutions at twenty- five degrees, and
the calculated heats of solution and partial molal volumes. II, J. Biol. Chem. 109, 241248.

22.

Nozaki, Y., and Tanford, C. (1971) The solubility of amino acids and two glycine
peptides in aqueous ethanol and dioxane solutions. Establishment of a hydrophobicity
scale, J. Biol. Chem. 246, 2211-2217.

23.

Hegde, S. S., Chandler, J., Vetting, M. W., Yu, M., and Blanchard, J. S. (2007)
Mechanistic and structural analysis of human spermidine/spermine N1-acetyltransferase,
Biochemistry 46, 7187-7195.

24.

Seiler, N., and al-Therib, M. J. (1974) Acetyl-CoA: 1,4-diaminobutane Nacetyltransferase. Occurrence in vertebrate organs and subcellular localization, Biochim.
Biophys. Acta 354, 206-212.

25.

Khalil, E. M., and Cole, P. A. (1998) A potent inhibitor of the melatonin rhythm enzyme,
J. Am. Chem. Soc. 120, 6195-6196.

26.

Ferry, G., Ubeaud, C., Dauly, C., Mozo, J., Guillard, S., Berger, S., Jimenez, S., Scoul,
C., Leclerc, G., Yous, S., Delagrange, P., and Boutin, J. A. (2004) Purification of the
recombinant human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization
of and comparison with AANAT from other species, Protein Expr. Purif. 38, 84-98.

27.

Waluk, D. P., Schultz, N., and Hunt, M. C. (2010) Identification of glycine Nacyltransferase-like 2 (GLYATL2) as a transferase that produces N-acyl glycines in
humans, FASEB J. 24, 2795-2803.

66

28.

Farrell, E. K., and Merkler, D. J. (2008) Biosynthesis, degradation and pharmacological
importance of the fatty acid amides, Drug Discov. Today 13, 558-568.

29.

Wang, H., Li, J., Li, J., Meng, G., Wei, K., and Ruan, J. (2005) Identification of agmatine
and its acetylation metabolites in rat urine by stable isotope labeling coupled ion trap
mass spectrometry, Yaowu Fenxi Zazhi 25, 131-136.

30.

Han, Q., Robinson, H., Ding, H., Christensen, B. M., and Li, J. (2012) Evolution of insect
arylalkylamine N-acetyltransferases: structural evidence from the yellow fever mosquito,
aedes aegypti, Proc. Natl. Acad. Sci. U. S. A. 109, 11669-11674.

31.

Aisien, S. O., and Walter, R. D. (1993) Biogenic-amine acetylation: an additional
function of the N-acetyltransferase from Fasciola hepatica, Biochem. J. 291 ( Pt 3), 733737.

32.

Wittich, R. M., and Walter, R. D. (1990) Putrescine N-acetyltransferase in Onchocerca
volvulus and Ascaris suum, an enzyme which is involved in polyamine degradation and
release of N-acetylputrescine, Mol. Biochem. Parasitol. 38, 13-17.

33.

Forouhar, F., Lee, I. S., Vujcic, J., Vujcic, S., Shen, J., Vorobiev, S. M., Xiao, R., Acton,
T. B., Montelione, G. T., Porter, C. W., and Tong, L. (2005) Structural and functional
evidence for Bacillus subtilis PaiA as a novel N1-spermidine/spermine acetyltransferase,
J. Biol. Chem. 280, 40328-40336.

34.

Schnoes, A. M., Brown, S. D., Dodevski, I., and Babbitt, P. C. (2009) Annotation error in
public databases: misannotation of molecular function in enzyme superfamilies, PLoS
Comput. Biol. 5, e1000605.

67

35.

Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and
Lipman, D. J. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein
database search programs, Nucleic Acids Res. 25, 3389-3402.

36.

Dreger, M. (2003) Proteome analysis at the level of subcellular structures, Eur. J.
Biochem. 270, 589-599.

37.

Xu, T., Zhang, L., Wang, X., Wei, D., and Li, T. (2009) Structure-based substrate
screening for an enzyme, BMC Bioinformatics 10, 257.

38.

Zhao, S., Kumar, R., Sakai, A., Vetting, M. W., Wood, B. M., Brown, S., Bonanno, J. B.,
Hillerich, B. S., Seidel, R. D., Babbitt, P. C., Almo, S. C., Sweedler, J. V., Gerlt, J. A.,
Cronan, J. E., and Jacobson, M. P. (2013) Discovery of new enzymes and metabolic
pathways by using structure and genome context, Nature 502, 698-702.

39.

von Buhler, C., Le-Huu, P., and Urlacher, V. B. (2013) Cluster screening: an effective
approach for probing the substrate space of uncharacterized cytochrome p450s,
Chembiochem. 14, 2189-2198.

40.

Kuznetsova, E., Proudfoot, M., Sanders, S. A., Reinking, J., Savchenko, A., Arrowsmith,
C. H., Edwards, A. M., and Yakunin, A. F. (2005) Enzyme genomics: Application of
general enzymatic screens to discover new enzymes, FEMS Microbiol. Rev. 29, 263-279.

41.

Kuhn, M. L., Majorek, K. A., Minor, W., and Anderson, W. F. (2013) Broad-substrate
screen as a tool to identify substrates for bacterial Gcn5-related N-acetyltransferases with
unknown substrate specificity, Protein Sci. 22, 222-230.

42.

Bork, P., and Bairoch, A. (1996) Go hunting in sequence databases but watch out for the
traps, Trends Genet. 12, 425-427.

68

43.

Karp, P. D. (1998) What we do not know about sequence analysis and sequence
databases, Bioinformatics 14, 753-754.

44.

Jaroszewski, L., Li, Z., Krishna, S. S., Bakolitsa, C., Wooley, J., Deacon, A. M., Wilson,
I. A., and Godzik, A. (2009) Exploration of uncharted regions of the protein universe,
PLoS Biol. 7, e1000205.

45.

Konc, J., Hodoscek, M., Ogrizek, M., Trykowska Konc, J., and Janezic, D. (2013)
Structure-based function prediction of uncharacterized protein using binding sites
comparison, PLoS Comput. Biol. 9, e1003341.

46.

Hermann, J. C., Marti-Arbona, R., Fedorov, A. A., Fedorov, E., Almo, S. C., Shoichet, B.
K., and Raushel, F. M. (2007) Structure-based activity prediction for an enzyme of
unknown function, Nature 448, 775-779.

47.

Pierri, C. L., Parisi, G., and Porcelli, V. (2010) Computational approaches for protein
function prediction: a combined strategy from multiple sequence alignment to molecular
docking-based virtual screening, Biochim. Biophys. Acta 1804, 1695-1712.

48.

Nadzirin, N., and Firdaus-Raih, M. (2012) Proteins of unknown function in the Protein
Data Bank (PDB): an inventory of true uncharacterized proteins and computational tools
for their analysis, Int. J. Mol. Sci. 13, 12761-12772.

49.

Piletz, J. E., Aricioglu, F., Cheng, J. T., Fairbanks, C. A., Gilad, V. H., Haenisch, B.,
Halaris, A., Hong, S., Lee, J. E., Li, J., Liu, P., Molderings, G. J., Rodrigues, A. L.,
Satriano, J., Seong, G. J., Wilcox, G., Wu, N., and Gilad, G. M. (2013) Agmatine:
clinical applications after 100 years in translation, Drug Discov. Today 18, 880-893.

69

50.

Verhoeckx, K. C., Voortman, T., Balvers, M. G., Hendriks, H. F., H, M. W., and
Witkamp, R. F. (2011) Presence, formation and putative biological activities of N-acyl
serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract, Biochim.
Biophys. Acta 1811, 578-586.

70

Chapter Four
Mechanistic and Structural Analysis of a Drosophila melanogaster Enzyme, Arylalkylamine
N-acetyltransferase Like 7, that Catalyzes the Formation of N-acetylarylalkylamides and
N-acetylhistamine

4.1 Introduction
The N-acetylation of biogenic amines is a critical chemical step in the inactivation of
potent neurotransmitters. In Drosophila melanogaster, the biogenic amines are composed of
dopamine, serotonin, tyramine, octopamine, and histamine.1 Biosynthesis of these biogenic
amines and the corresponding N-acetylamide product are derived from their cognate amino acid
precursor. Tyramine, dopamine, and octopamine are products of tyrosine metabolism; serotonin
is generated from tryptophan, whereas histamine is derived from histidine.
biosynthesis

of

the

arylalkylamine

biogenic

amines

and

the

Complete

corresponding

N-acetylarylalkylamide has been discussed immensely;2-6 however, there has been very little
discussion for the N-acetylation of histamine as a degradative pathway in the fly. Histamine has
been predominantly localized to the fly nervous system,7-10 in which the highest amount in the
head was identified in the eye,11 where it functions as a neurotransmitter for photoreceptors.12
Histamine is biosynthesized (Scheme 4.1) by the decarboxylation of histidine by a histidine
decarboxylase.12-14 Degradation of histamine can occur by three different pathways, which
consists of either an oxidation reaction or two conjugation reactions (N-acetylation or β-alanine
conjugation) in D. melanogaster. The oxidation pathway is proposed to deaminate histamine by
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two subsequent steps catalyzed by a diamine oxidase (histaminase)15 and an aldehyde
dehydrogenase16-19 to generate the respective products, imidazole-4-acetaldehyde and
imidazole-4-acetic acid.

These enzymes have not been characterized in D. melanogaster,

however the product imidazole-4-acetic acid has been identified in the fly head.12 Another
pathway for histamine degradation is the conjugation with β-alanine to generate carcinine
(β-alanylhistamine),20-21 which is catalyzed by N-β-alanyl dopamine synthase.22-23 This pathway
has been attributed as the major pathway for recycling histamine in the fly head through which
carcinine can be subsequently hydrolyzed to regenerate histamine, by the enzyme N-β-alanyl
dopamine hydrolase.23-24 Finally, histamine can be inactivated by an N-acetyltransferase enzyme
that catalyzes the formation of N-acetylhistamine.

Evidence for each of these pathways has

been provided in insects, where the final products of N-acetylhistamine,12 imidazole-4-acetic
acid,12 and carcinine23 have been identified in the D. melanogaster head. We report herein, an
enzyme that catalyzes the formation of the N-acetylhistamine and N-acetylarylalkylamide
products, or known as arylalkylamine N-acetyltransferase like 7 (AANATL7).
AANATL7 is a member of the GCN5-related N-acetyltransferase (GNAT) family of
enzymes.25-26

AANATL7

catalyses

the

formation

of

N-acetylarylalkylamides

and

N-acetylhistamine from acetyl-CoA and the corresponding amine substrate. The N-acetylation of
biogenic amines was first identified in D. melanogaster by Dewhurst et al. in 19724 by
measuring N-acetyltransferase activity of crude extracts with the substrates: acetyl-CoA with
serotonin, tyramine, or dopamine. Later N-acetylhistamine was identified in the fly head12 as a
product of histamine metabolism. Herein, we report an N-acetyltransferase enzyme that can
catalyzed the formation of N-acetylarylalkylamides and N-acetylhistamine in D. melanogaster.
Further studies solved the kinetic mechanism by dead-end inhibition, followed by pH-activity
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profiling and site-directed mutagenesis experiments to delineate a proposed chemical mechanism
for this enzyme.

Finally, we discuss some structure-function relationships identified for

AANATL7 with respect to different substrates and amino acid residues involved in substrate
binding and regulation of catalysis.

Scheme 4.1. Proposed biosynthetic and degradative pathways for histamine metabolism.
Reaction 1, Histidine decarboxylase (HDC). Reaction 2, Diamine oxidase (DAO). Reaction 3,
Aldehyde dehydrogenase (AlDH). Reaction 4, N-β-alanyl dopamine synthase (NBAD synthase).
Reaction 5, N-β-alanyl dopamine hydrolase (NBAD hydrolase). Reaction 6, Histamine
N-acetyltransferase (HNAT) and arylalkylamine N-acetyltransferase (AANAT).

4.2 Materials and methods:
4.2.1 Materials
ProBond™ nickel-chelating resin was purchased from Invitrogen. PCR primers were
purchased from Eurofins MWG Operon.
purchased from Agilent.

PfuUltra High-Fidelity DNA polymerase was

BL21 (DE3) E. coli cells, E. coli XL10 competent cells, and

pET-28a(+) vector were purchased from Novagen. NdeI, XhoI, Antarctic Phosphatase, and T4
DNA ligase were purchased from New England Biolabs. Kanamycin monosulfate and IPTG
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were purchased from Gold Biotechnology.

Acetyl-CoA, butyryl-CoA, hexanoyl-CoA,

octanoyl-CoA, oleoyl-CoA, coenzyme A, and Nω-acetylhistamine were purchased from
Sigma-Aldrich.

All other reagents were of the highest quality available from either

Sigma-Aldrich or Fisher Scientific.

4.2.2 AANATL7 transcript localization
We used the D. melanogaster cDNA library generated for the head and thorax-abdomen
that was discussed in Dempsey et al.27 Amplification of AANATL7 and glyceraldehyde
3-phosphate dehdrogenase (GAPDH) transcripts were completed by polymerase chain reaction
(PCR) under the following conditions: initial denaturing step of 95°C for 2 min, then 45 cycles
of 95°C for 30 s; varying annealing temperatures (45°C, 50°C, 55°C, and 60°C) for 30 s; 72°C
for 1 min; then a final extension step of 72°C for 10 min. The primers used to amplify the 268
bp

(AANATL7)

and

449

bp

(GAPDH)

products

were

(AANATL7:

forward

-

TTTCCGCAAGATTTTCGACT, reverse TGTAGGGTTGCTCCGAGAAG; GAPDH: forward ATCGTCGAGGGTCTGATGAC, reverse - ACCGAACTCGTTGTCGTACC) were synthesized
by Eurofins MWG Operon. The amplified products were analyzed by a 1.3% agarose gel and
the band was visualized by 0.5 µg/mL ethidium bromide under ultraviolet light. Each positive
band was cut out of the agarose gel, purified by the Promega Wizard® SV Gel and PCR Clean-up
system, and sequence by Eurofins MWG Operon.

4.2.3 Production of site-directed mutants
The site-directed AANATL7 mutants were generated using the overlap extension
method.28 The AANATL7 mutants were amplified using PfuUltra High-Fidelity DNA polymerase
with the following set of PCR conditions: initial denaturing step of 95°C for 2 min, then 30
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cycles (95°C for 30 s; 60°C for 30 s; 72°C for 1 min), then a final extension step of 72°C for 10
min. Primers were designed by using Agilent QuickChange Primer Design tool (Table 4.1) and
synthesized by Eurofins MWG Operon. Using NdeI and XhoI restriction enzymes, the resulting
AANATL7 mutant PCR products were then inserted into a pet28a(+) vector. The AANATL7
mutant proteins were expressed and purified using the same protocol as the wild-type enzyme.

Table 4.1. AANATL7 site-directed mutagenesis primers
Mutant
E26A
P27A
R138A
T167A
S171A
T167A/S171A
H206A

Forward or
Reverse Primer
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

Primer Sequence
CTT CTT CGC CGA CGC GCC GCT AAA CAA GG
CCT TGT TTA GCG GCG CGT CGG CGA AGA AG
CTT CGC CGA CGA GGC GCT AAA CAA GGC
GCC TTG TTT AGC GCC TCG TCG GCG AAG
TGG ACT CGT GCT ACG CTG GCC AGG GGA TTG
CAA TCC CCT GGC CAG CGT AGC ACG AGT CCA
GAA GGC CGA TGC CGC CGG CAT CTT CTC
GAG AAG ATG CCG GCG GCA TCG GCC TTC
GAA AGA TCT TCT GCG CGA AGA TGC CGG TG
CAC CGG CAT CTT CGC GCA GAA GAT CTT TC
GAA GGC CGA TGC CGC CGG CAT CTT CGC
GCG AAG ATG CCG GCG GCA TCG GCC TTC
CCG TGG AGG CGC CCG CCA TCA AAT TGC AGC A
TGC TGC AAT TTG ATG GCG GGC GCC TCC ACG G

4.2.4 Enzyme assay
Ellman’s reagent29 was used to assay the AANATL7 activity by measuring the release of
coenzyme A at 412 nm with a molar extinction coefficient of 13,600 M-1 cm-1. Initial velocities
were measured by a Cary 300 Bio UV-Visible spectrophotometer at 22°C in 300 mM Tris pH
8.0, 150 µM DTNB. The apparent kinetic constants were generated for each amine substrate by
holding acetyl-CoA at a fixed saturating concentration. Apparent kinetic constants for each
acyl-CoA substrate were determined by holding histamine at a fixed saturating concentration.
The resulting data were fit to equation 4.1 using Sigma Plot 12.0 to generate the steady-state
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kinetic constants, where vo is the initial velocity, Vmax,app is the apparent maximal velocity, Km,app
is the apparent Michaelis constant, and [S] is the substrate concentration. Each assay was
performed in triplicate. Uncertainty calculations for kcat,app, (kcat/Km)app, and relative (kcat/Km)app
were calculated using equation 4.2, where σ is the standard error.30

Equation 4.1

Equation 4.2

4.2.5 Kinetic mechanism
Initial velocity patterns for acetyl-CoA and histamine were assessed by varying the
concentration of one substrate while holding the concentration of the other substrate at a fixed
concentration. The resulting data was then fitted to equation 4.3 for an ordered Bi-Bi mechanism
and plotted as a double reciprocal plot using IGOR Pro 6.34A., where Kia (Michaelis constant) is
the dissociation constants, Kb (Michaelis constant) is the Km of substrate B (histamine), and Ka is
the Km of substrate A (acetyl-CoA). The two plots were generated by holding the histamine
concentration constant (250 µM, 500 µM, 750 µM, and 2500 µM) and varying the concentration
of acetyl-CoA. The second plot held the concentration of acetyl-CoA constant (10 µM, 25 µM,
50 µM, and 100 µM) and varied the concentration of histamine.

76

Equation 4.3

In combination with the initial velocity analysis, we used dead-end inhibition to solve the
kinetic mechanism.

Oleoyl-CoA and tyrosol were evaluated as dead-end inhibitors for

AANATL7. The initial velocities were generated by holding one substrate (acetyl-CoA or
histamine) at a fixed concentration, varying the concentration of the other substrate, with each
data set evaluated at different fixed concentrations of the inhibitor. Using SigmaPlot 12.0, the
resulting data were fit to equation 4.4 – 4.6 for competitive, noncompetitive, and uncompetitive
inhibition respectively; where vo is the initial velocity, Vmax,app is the apparent maximal velocity,
Km,app is the apparent Michaelis constant, [S] is the substrate concentration, [I] is the inhibitor
concentration, and Ki is the inhibition constant. Each assay was performed in triplicate.

Equation 4.4

Equation 4.5

Equation 4.6
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4.2.6 Rate versus pH dependence
The pH dependence on the apparent kinetic constants was determined for both
acetyl-CoA and histamine. The kinetic constants for each substrate were evaluated at intervals
of 0.5 pH units ranging from pH 6.0 – 9.5. The following buffers were used for the pH
dependence experiments: MES (pH 6.0 – 7.0), Tris (pH 7.0 – 9.0), and AMeP (pH 9.0 – 9.5).
Using Igor Pro 6.34A, the resulting data were fit to equation 4.7 (log kcat/Km – acetyl-CoAand log
kcat/Km – histamine) and equation 4.8 (log kcat), where c is the pH-independent plateau, to determine
the apparent pKa of measured ionizable groups. The wild-type enzyme is reported from triplicate
experiments, whereas the E47A mutant profile was performed in duplicate.

Equation 4.7

Equation 4.8

4.2.7 Intrinsic fluorescence measurements for the determination of the coenzyme A
dissociation constant
A JASCO FP-8300 spectrofluorometer was used to generate fluorescent spectra for the
AANATL7 wild-type and R138A mutant enzymes. Fluorescent emission spectra (excitation 280
nm, emission 290 – 300 nm) were generated for both the AANATL7 wild-type and R138A
mutant in a 0.4 cm pathlength cell containing 400 µL of 300 mM Tris pH 8.0, a fixed enzyme
concentration of 0.1 mg/mL of either protein, and varying concentrations of coenzyme A at
22°C. Emission spectra were collected with a 50 nm/min scan speed, excitation bandwith – 5
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nm, and emission bandwith – 2.5 nm in triplicate. The coenzyme A dissociation constant for
AANATL7 wild-type and R138A mutant were determined by fitting the data to equation 4.9
using SigmaPlot 12.0, where ΔFmax is the maximum change of fluorescence at infinite ligand
concentration, ΔF is the change in intrinsic fluorescence, L is the ligand concentration, and Kd is
the ligand dissociation constant.

Equation 4.9

4.3 Results and discussion
4.3.1 Transcript localization of AANATL7
The localization of the D. melanogaster AANATL7 transcript was evaluated using reverse
transcription polymerase chain reaction (RT-PCR). The agarose gel for the amplification of the
AANATL7 transcript (Figure 4.1) showed a similar trend in both the fly head and
thorax-abdomen when compared to the GAPDH control. These data suggest that the AANATL7
transcript is found at similar levels in both anatomical regions, indicating this enzyme will
catalyze the acyl-CoA dependent N-acylation of biogenic amines in both the head and
thorax-abdomen of the fly. Further evaluation of the respective substrates and final products of
the AANATL7-catalyzed reaction will be discussed in subsequent sections.
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Figure 4.1. AANATL7 RT-PCR. (A) AANATL7 – 268 bp product. Lane 1 – 4 RT-PCR product
from D. melanogaster cDNA library generated from the heads with different PCR annealing
temperatures. Lane 1. 45°C, Lane 2. 50°C, Lane 3. 55°C, Lane 4. 60°C. Lane 5. New England
Biolabs Quick-Load® 100 bp DNA Ladder. Lane 6 – 9 RT-PCR product from D. melanogaster
cDNA library generated from the thorax-abdomen with different PCR annealing temperatures.
Lane 6. 45°C, Lane 7. 50°C, Lane 8. 55°C, Lane 9. 60°C. (B) GAPDH control
(NM_001038847.1) – 449 bp product. Lane 1 – 4 RT-PCR product from D. melanogaster cDNA
library generated from the heads with different PCR annealing temperatures. Lane 1. 45°C, Lane
2. 50°C, Lane 3. 55°C, Lane 4. 60°C. Lane 5. New England Biolabs Quick-Load® 100 bp DNA
Ladder. Lane 6 – 9 RT-PCR product from D. melanogaster cDNA library generated from the
thorax-abdomen with different PCR annealing temperatures. Lane 6. 45°C, Lane 7. 50°C, Lane
8. 55°C, Lane 9. 60°C.

4.3.2 Steady-state kinetic characterization of AANATL7 acyl-CoA substrates
Activity was assayed using Ellmans reagent29 by monitoring the rate of coenzyme A
release at 412 nm.

Different acyl-CoA substrates with increasing acyl chain length were

evaluated with AANATL7 to determine their respective substrate specificity at saturating
concentrations of histamine. The relative (kcat/Km)app for the acyl-CoA substrates decreased as
the acyl chain length was increased (Table 4.2). Butyryl-CoA and hexanoyl-CoA was only
found to have 10% and 0.082% the activity of acetyl-CoA, respectively.

The significant

decrease in the (kcat/Km)app resulted mainly from the kcat,app value, while the Km,app value was
similar for each acyl-CoA substrate. Octanoyl-CoA and oleoyl-CoA were also evaluated as
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substrates with histamine as the corresponding amine substrate and activity was not observed at
500 µM of each substrate. These data suggest that AANATL7 will predominantly catalyze the
N-acetylation of histamine. Another enzyme recently characterized in D. melongaster was
arylalkylamine N-acetyltransferase variant A (AANATA),6 which was shown to catalyze the
formation of N-acetylarylalkylamides, similar to AANATL7.

The AANATL7 data are in

significant contrast to D. melanogaster AANATA, where AANATA was shown to have more
promiscuity for acyl-CoA substrates.6 At saturating concentration of tyramine, the AANATA
(kcat/Km)app value for butyryl-CoA and hexanoyl-CoA did not observed as dramatic of a decrease
as observed with these same substrates for AANATL7 at saturating concentrations of histamine.
The first question that arose from these data was if these differences between AANATA and
AANATL7 observed for the (kcat/Km)app

- acetyl-CoA/(kcat/Km)app – butyryl-CoA or hexanoyl-CoA

is (a) a

function of the amine substrate used in the evaluation of the acyl-CoA steady-state kinetic
constants or (b) is it related to general structural differences in the enzyme active site yielding
AANATL7 less accommodating for longer chain (> C6) acyl-CoA substrates. To assess if the
significant decrease in the (kcat/Km)app - acetyl-CoA/(kcat/Km)app – acyl-CoA observed for AANATL7 is
derived from the amine substrate, we reevaluated the kinetic constants for acetyl-CoA and
butyryl-CoA at saturating concentrations of tyramine. A similar trend was observed for the
acyl-CoA kinetic constants when tyramine (Table 4.2) and histamine were used as the
corresponding saturating amine substrate, where the (kcat/Km)app for acetyl-CoA and butyryl-CoA
is (1.1 ± 0.1) × 106 and (2.9 ± 0.2) × 105, respectively (kcat,app – acetyl-CoA = 21 ± 1 s-1, Km,app –
acetyl-CoA

= 20 ± 1; kcat,app – butyryl-CoA = 1.87 ± 0.04 s-1, Km,app – butyryl-CoA = 7 ± 1). A structural

rational for these data when compared to D. melanogaster AANATA is difficult without a
crystal structure; however, AANATA was found to have a deep funnel leading to its active site. 6
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This suggests that as the acyl chain length is increased for the acyl-CoA substrate, it can perturb
the amine substrate binding by occupying its respective binding site. This could result in a
decrease rate of catalysis, which we observed for both AANATA and AANATL7. Our data
suggest that the AANATL7 binding pocket does not have the available space to accommodate a
larger than C-6 acyl-CoA substrate (hexanoyl-CoA), independent of the amine substrate.

Table 4.2. AANATL7 steady-state kinetic constants for different acyl-CoAsa,b
Km, app
kcat, app
(kcat/Km)app
Relative
-1
-1 -1
(µM)
(s )
(M s )
(kcat/Km)appc
Acetyl-CoA
29 ± 2
32 ± 1
(1.1 ± 0.1) × 106
1200 ± 400
Butyryl-CoA
6±1
0.66 ± 0.02
(1.1 ± 0.2) × 105
130 ± 50
2
Hexanoyl-CoA
64 ± 21
0.06 ± 0.01
(9 ± 3) × 10
1.0 ± 0.5
a
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 7.5 mM histamine, and varying
concentration of acyl-CoA.
b
Kinetic constants are reported as ± standard error (n=3).
c
The relative (kcatt/Km)app – acyl-CoA is indexed with hexanoyl-CoA.
Substrate

4.3.3 Steady-state kinetic characterization of AANATL7 amine substrates
Different amine substrates were characterized to determine the substrate specificity for
AANATL7. A panel of various arylalkylamines, polyamines, histamine, and ethanolamine were
evaluated for their respective steady-state kinetic constants (Table 4.3) at saturating
concentrations of acetyl-CoA.

Herein, we define structure-activity relationships for amine

substrates that posses different “structural features” and evaluated their respective effect on
binding and/or catalysis. These structural features are divided into five general classes consisting
of (a) indole ring and phenyl ring modifications, (b) length of the spacer group dividing the
phenyl ring and the nucleophilic primary amine, (c) modification of the α-position of the
ethylamine spacer group, (d) modification of the β-position of the ethylamine spacer group, and
finally (e) evaluation of other non-arylalkylamine substrates.
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The first arylalkylamines to be evaluated were a set of substrates with different functional
groups (-H, -OH, -OMe, and –OCH2C6H5) substituted at the 5-position of the indole ring, which
yielded (kcat/Km)app values that decreased in the following order: 5-benzyloxytryptamine
(-OCH2C6H5) > tryptamine (-H) > 5-methoxytryptamine (-OMe) > serotonin (-OH).

The

(kcat/Km)app order predominantly resulted from the measured Km,app value, suggesting that amine
substrate binding is important for its specificity. Serotonin is hydroxylated at the 5-position of
the indole ring, which produced the highest Km,app value (160 ± 20 µM). 5-Benzyloxytryptamine
is generated by the modification of tryptamine with a benzyloxy group at the 5-position of the
indole ring, which yielded the lowest Km,app value (9 ± 1 µM). These data suggest that amine
substrate binding affinity is driven by the hydrophobicity of the modified group at the 5-position
of the indole ring, where the more hydrophobic the substitution, the lower Km,app value. There
was not a significant difference in the observed kcat,app values for each substrate evaluated that
possessed an indole ring, except for 5-benzyloxytryptamine, which yielded a 2.3 – 3.0-fold lower
turnover number compared to tryptamine, serotonin, and 5-methoxytryptamine. These data
coincides with the observation that 5-benzyloxytryptamine had the lowest observed Km,app value,
which suggest that the large hydrophobic modification at the 5’ position of the indole ring could
have an effect on a rate-limiting step, possibly product release by decreasing the koff rate for the
enzyme-catalyzed products. These data also suggest that AANATL7 can catalyze the direct
formation of melatonin from acetyl-CoA and 5-methoxytryptamine. Melatonin is biosynthesized
from the cognate amino acid, L-tryptophan, in four sequential reactions: initial hydroxylyation
of L-tryptophan to generate 5-hydroxytryptophan, then decarboxylation to serotonin, followed by
acetylation to N-acetylserotonin, and finally methylation to generate melatonin.31-32 Our data
shows that 5-methoxytryptamine has a 2.8-fold increase in the (kcat/Km)app value when compared
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to serotonin, which is consistent with what was found in D. melanogaster AANATA,6 yeast
AANAT,33 human AANAT,33 ovine AANAT,33 and other vertebrate and nonvertebrate AANAT
enzymes.34 These data suggest that AANATL7 could catalyze the direct formation of melatonin
in D. melanogaster; however, further work is necessary to evaluate if this is physiologically
relevant.

Table 4.3. AANATL7 steady-state kinetic constants for different amine substratesa,b
Km, app
(µM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)

5-Benzyloxytryptamine

9±1

5.7 ± 0.1

(6.3 ± 0.4) × 105

Tryptamine

26 ± 2

15.8 ± 0.3

(6.0 ± 0.4) × 105

Tyramine

42 ± 2

22.8 ± 0.4

(5.5 ± 0.3) × 105

3-Methoxyphenethylamine

61 ± 4

26 ± 1

(4.3 ± 0.3) × 105

5-Methoxytyrptamine

42 ± 2

13.1 ± 0.2

(3.1 ± 0.2) × 105

3(Trifluoromethyl)phenethylamine

180 ± 10

40 ± 1

(2.2 ± 0.1) × 105

Phenethylamine

320 ± 40

42 ± 2

(1.3 ± 0.2) × 105

Octopamine

120 ± 10

15.6 ± 0.3

(1.3 ± 0.1) × 105

Dopamine

170 ± 20

21 ± 1

(1.2 ± 0.1) × 105

β-Methylphenethylamine

260 ± 30

29 ± 1

(1.1 ± 0.1) × 105

Serotonin

160 ± 20

17 ± 1

(1.1 ± 0.1) × 105

4-Methoxyphenethylamine

190 ± 20

15.2 ± 0.4

(8.0 ± 0.7) × 104

Substrate

Structure
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Table 4.3. (Continued)
3,4Methylenedioxyphenethylamine

320 ± 30

23 ± 1

(7.4 ± 0.7) × 104

Histamine

520 ± 50

30 ± 1

(5.8 ± 0.6) × 104

Norepinephrine

230 ± 50

13 ± 1

(6 ± 1) × 104

4-Phenylbutylamine

610 ± 30

8.5 ± 0.2

(1.4 ± 0.1) × 104

Putrescine

81 ± 11

0.25 ± 0.01

(3.0 ± 0.4) × 103

Benzylamine

890 ± 80

0.87 ± 0.02

980 ± 100

Agmatine

790 ± 100

0.68 ± 0.03

850 ± 110

(1.00 ±
2.3 ± 0.1
23 ± 1.0
0.01) × 105
a
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 500 µM acetyl-CoA, and varying
concentration of the amine substrate.
b
Kinetic constants are reported as ± standard error (n=3).
Ethanolamine

Next, we evaluated different arylalkylamine substrates that possess a phenyl ring that are
analogs of phenylalanine or tyrosine.

These data showed that tyramine has the highest

(kcat/Km)app value and norephinephrine the lowest (kcat/Km)app value for all the substrates
possessing a two methylene spacer group. Each arylalkylamine substrate in this category ranged
from a 1.3 – 9.2-fold difference (3-methoxyphenethylamine → norepinephrine) in the (kcat/Km)app
value when compared to tyramine. The comparison of the phenyl ring analogs yielded substrates
with minimal differences in specificity; however, within these data the largest differences
resulted from the modification of the phenyl ring when compared to substrates that are
unmodified (phenethylamine and β-methylphenethylamine). Within this respective data set, the
(kcat/Km)app values differ predominantly from the Km,app with small differences resulting from the
kcat,app. For the phenyl ring analogs, the Km,app values ranged from 42 ± 2 µM → 320 ± 40 µM
(tyramine → phenethylamine) yielding a 7.6-fold difference while the kcat,app values ranged from
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42 ± 2 → 13 ± 1 (phenethylamine → norepinephrine) constituting a 3.2-fold difference. A
general trend observed in the data is that an increased kcat,app value, albeit a small difference, was
observed for substrates without a modified phenyl ring. One exception to this general trend is
(trifluoromethyl)phenethylamine, which is modified at the 3-position on the ring with a small
trifluoromethyl- group produced a similar kcat,app value (40 ± 1 s-1) as phenethylamine (42 ± 2 s-1).
An opposite trend was generally observed for the Km,app values where an increase was observed
for substrates without a modified phenyl ring, except for 3,4-methylenedioxyphenethylamine.
This trend presumably results from a partial rate limiting step of product release, where the
products of weakly bound substrates (unmodified phenyl ring) can dissociate faster yielding a
higher turnover rate.
Another structural feature that has an effect on enzyme activity is the length of spacer
group between the amino group and the phenyl ring. Increasing the spacer length from two
methylene groups to four methylene groups (4-phenylbutylamine) has a 9-fold decrease in the
(kcat/Km)app value when compared to phenethylamine. The decrease in the (kcat/Km)app resulted
from an 2-fold increase in the Km,app and a 5-fold decrease in the kcat,app values. Decreasing the
spacer length by one methylene group is benzylamine, which observed a 133-fold decrease in the
(kcat/Km)app value when compared to phenethylamine. The decrease in the (kcat/Km)app resulted
from an 3-fold increase in the Km,app and a 48-fold decrease in the kcat,app values.

These

differences observed for benzylamine and 4-phenylbutylamine can be explained by the optimal
length necessary for the primary amine to bind and function in catalysis. These data suggest that
the positioning of the primary amine in an optimal region for nucleophilic attack is critical;
therefore, changes to the length will impact substrate binding and enzyme catalysis. Our data
indicates the optimal length of the spacer would be two methylene groups (phenethylamine).
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We next evaluated other non-arylalkyamine substrates consisting of histamine,
ethanolamine, putrescine, agmatine, histidine, Nω-acetylhistamine, and isoniazid. The decreasing
order for the observed (kcat/Km)app values for these non-arylalkylamine substrates is histamine >
putrescine > agmatine >> ethanolamine. AANATL7 utilizing non-arylalkylamines substrates
highlights a greater promiscuity for amine substrates than that observed for D. melanogaster
AANATA. From the non-arylalkylamine substrates evaluated in this study, histamine was the
“best” substrate, with a (kcat/Km)app that is 9% of the “best” arylalkylamine substrate,
5-benzyloxytryptamine. The difference in second order rate constant between histamine and
5-benzyloxytryptamine results from the 58-fold difference in the Km,app value. The kcat,app value
for histamine is 5.3-fold greater than 5-benzyloxytryptamine, in addition to possessing the third
highest kcat,app value for all the amine substrates evaluated in this study. Only phenethylamine
and 3-(trifluoromethyl)phenethylamine observed a greater kcat,app than histamine. The in vivo
role of AANATL7 in catalyzing the formation of N-acetylhistamine is unknown; however, there
is a preponderance of evidence suggesting in could function in this chemistry. First, the total
amount of histamine found in D. melanogaster head10-11 is 1.98 ± 0.15 ng, contributing to a total
concentration of 540 µM and 574 µM in the heads and eyes, respectively.11 This is consistent
with the detection of N-acetylhistamine12 and our identification of the AANATL7 transcript
colocalized in the fly head. Additionally, the Km,app value determined for histamine (520 ± 50
µM) correlates well with the published concentrations of histamine in the fly head and eyes. 11
All these data combined indicates a likely in vivo role for AANATL7 in the N-acetylation of
histamine. There are some reports in the literature of N-acetyltransferase enzymes that catalyze
the formation of N-acetylhistamine,35-37 whereas two reports, (a) of a polyamine Nacetyltransferase identified in the parasitic flatworm Fasciola hepatica35
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and (b) two

arylalkylamine N-acetyltransferase (aaNAT2 and aaNAT5b) in Aedes aegypti37 have a similar
apparent Km (760 µM, 740 µM, and 660 µM, respectively) as AANATL7. This suggests that
N-acetylation of histamine, albeit understudied, could occur in a broad range of different species.
Putrescine, agmatine, and ethanolamine were shown to be poor substrates for AANATL7, where
the (kcat/Km)app value is 0.48%, 0.13%, and 0.0037% of the (kcat/Km)app value for
5-benzyloxytryptamine, respectively. This is the second report to our knowledge of an enzyme
that will catalyze the formation of N-acetylagmatine,38 albeit with low specificity when
compared to the other arylalkylamine substrates. We then evaluated Nω-acetylhistamine to help
delineated if the acetylation occurs with the primary amine or the imidazole amine. Activity was
not observed at 1 mM Nω-acetylhistamine, which suggests, along with all the other data
generated in this study that the acetylation occurs at the primary amine on the spacer group.
Then we showed that isoniazid, which is a first line drug in the treatment of tuberculosis,39-41 will
not serve as a substrate for AANATL7.
Finally, we evaluated the cognate amino acids as substrates for AANATL7. A rate of
coenzyme A release was not observed at 1 mM of each amino acid, which suggests that this
enzyme will not catalyze the formation of N-acetyl amino acids. The amino acids evaluated in
this study were tyrosine, tryptophan, phenylalanine, and histidine, which differ from tyramine,
tryptamine, phenethylamine, and histamine by modification of the spacer group α-position with a
carboxylate. Our data suggest that inserting a carboxylate at the α-position of the spacer group
will prevent the corresponding amino acid from serving as a substrate because of either an
electrostatic effect or a steric effect that perturbs substrate binding to the AANATL7 active site.
To evaluate these possibilities, we used tyrosine methyl ester, which would remove the possible
electrostatic effect induced by the negatively charged carboxylate. We determined that tyrosine
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methyl ester was not a substrate at a concentration of 1 mM, which suggests that modification of
the α-position induces a steric effect that interferes with binding to the active site of AANATL7.
Further evidence to support this theory was generated by assaying each amino acid and tyrosine
methyl ester as inhibitors to the AANATL7-catalyzed formation of N-acetylhistamine. Each
amino acid (tyrosine, tryptophan, phenylalanine, and histidine) and tyrosine methyl ester was
evaluated at a concentration of 1 mM, while holding acetyl-CoA and histamine at a constant
concentration equal to their respective Km,app value. We did not observed any inhibition at 1 mM
of each inhibitor evaluated, suggesting that tyrosine, tryptophan, phenylalanine, histidine, and
tyrosine methyl ester will either not bind to AANATL7 or bind with low affinity (Kd > 10 mM).
These data suggest that the modification with a α-carboxylate or α-carboxylate ester will
decrease the binding affinity to AANATL7 because of steric effect that perturbs binding in the
active site. Interesting, these data are in direct contrast to what was observed for modification of
the β-position of the spacer group (β-methylphenethylamine, octopamine, and norepinephrine),
where we did not observed a significant difference in the kinetic constants when compared to
unmodified amine substrates (phenethylamine, tyramine, and dopamine; respectively).
A summary of the structure-activity relationships of amine substrates from Table 4.3 are
as follows: (a) arylalkylamine substrates exhibited differences in binding dependent on the
hydrophopicity of the group at the 5-position of the indole ring, whereas the kcat,app value is
relatively unchanged except for 5-benzyloxtryptamine; (b) the length of the spacer group effects
both binding and catalysis, with the optimal length being two methylene groups; (c) the Km,app
value for phenyl ring substituted analogs were generally lower than phenethylamine; (d)
substitution at the α-position of the spacer group induces steric interference for binding to the
active site of AANATL7, while substitution at the β-position had minimal impact on the kinetic
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constants; (e) and AANATL7 catalyzes the formation of some non-arylalkylamine substrates
consisting of histamine, putrescine, agmatine, and ethanolamine showing greater promiscuity for
amine substrates when compared to D. melanogaster AANATA.

4.3.4 Kinetic mechanism
Initial velocities for AANATL7 were measured for acetyl-CoA and histamine, while
holding the other substrate at a fixed concentration. The resulting double reciprocal plots (Figure
4.2) show a pattern of intersecting lines for both acetyl-CoA and histamine. The intersecting
lines indicate that AANATL7 catalyzes the formation of N-acetylhistamine by a sequential
mechanism, in which both substrates must be bound to generate the ternary complex before
catalysis can occur. The next question is whether the kinetic mechanism is an ordered or random
sequential mechanism.
Dead-end inhibition studies were used to distinguish between these respective sequential
mechanisms, using oleoyl-CoA and tyrosol as the inhibitors in this study. Oleoyl-CoA is an
analog of acetyl-CoA that did not show a rate of reaction above the baseline rate of hydrolysis.
Tyrosol was used as a structural analog of the amine substrate, in which the primary amine is
replaced with a hydroxyl group. Tyrosol did not show a rate of coenzyme A release above the
background rate of hydrolysis at a concentration of 25 mM, which also suggests that AANATL7
will not catalyze the O-acetylation of at least this substrate.

These two inhibitors were

previously used as dead-end inhibitors for the determination of the kinetic mechanism for D.
melanogaster AANATA6 while oleoyl-CoA was also shown to be an inhibitor of mammalian
serotonin N-acetyltransferase.42-43

Oleoyl-CoA was found to be a competitive inhibitor versus

acetyl-CoA and a pure noncompetitive inhibitor versus histamine with inhibition constants of
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200 ± 10 nM and 410 ± 10 nM, respectively (Figure 4.3).

Tyrosol was found to be an

uncompetitive inhibitor versus acetyl-CoA and a competitive inhibitor versus histamine, with
inhibition constants of 620 ± 20 µM and 430 ± 20 µM, respectively. These inhibition patterns
demonstrate that AANATL7 will catalyze the formation of N-acetylhistamine as an ordered
sequential mechanism, with acetyl-CoA binding first followed by histamine to generate a ternary
complex of AANATL7•acetyl-CoA•histamine before catalysis occurs.

This type of kinetic

mechanism is consistent with what was found for both D. melanogaster AANATA6 and sheep
serotonin N-acetyltransferase.44

Figure 4.2. Double reciprocal plots of initial velocities for acetyl-CoA and histamine. (A)
Velocities measured at a fixed concentration of histamine: 2.5 mM (●), 750 µM (o), 500 µM
(▼), 250 µM (Δ). (B) Velocities measured at a fixed concentration of acetyl-CoA: 100 µM (●),
50 µM (o), 25 µM (▼), 10 µM (Δ).
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Figure 4.3. Dead-end inhibtion analysis of AANATL7. (A) Velocities measured at a fixed
concentration of histamine (520 µM), varying the concentration of acetyl-CoA, and varying the
concentration of the inhibitor, oleoyl-CoA: 0 nM (●), 200 nM (o), 600 nM (▼); Ki = 200 ± 10
nM. (B) Velocities measured at a fixed concentration of acetyl-CoA (29 µM), varying the
concentration of histamine, and varying the concentration of the inhibitor, oleoyl-CoA: 0 nM (●),
200 nM (o), 600 nM (▼);Ki = 410 ± 10 nM. (C) Velocities measured at a fixed concentration of
histamine (520 µM), varying the concentration of acetyl-CoA, and varying the concentration of
the inhibitor, tyrosol: 0 µM (●), 650 µM (o), 1.3 mM (▼); Ki = 620 ± 20 µM. (D) Velocities
measured at a fixed concentration of acetyl-CoA (29 µM), varying the concentration of
histamine, and varying the concentration of the inhibitor, tyrosol: 0 µM (●), 650 µM (o), 1.3 mM
(▼); Ki = 430 ± 20 µM.
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4.3.5 Evaluation of the pH dependence on the kinetic constants and the use of site-directed
mutagenesis to define catalytic amino acids
We used a combination of pH activity studies and site-directed mutagenesis to aid in the
identification of the AANATL7 catalytic residues and subsequently use these data to propose a
chemical mechanism for AANATL7. In the absence of a crystal structure, we indexed all the
data generated herein, to D. melanogaster AANATA,6, 45 sheep serotonin N-acetyltransferase,4651

and other GNAT enzymes to define a function for the amino acid residues evaluated in this

study. The first method to help delineate the residues involved in catalysis was to generate a pH
rate profile to ascertain the apparent pKa of the catalytic amino acid residues.

A rising

(kcat/Km)app pH rate profile was observed for both acetyl-CoA (Figure 4.4C) and histamine
(Figure 4.4D), with pKa,app values of 6.8 ± 0.1 and 7.6 ± 0.1, respectively. The (kcat/Km)app pH
rate profile represents the ionizable groups important for binding and catalysis for the free
enzyme and substrate, up until the first irreversible step (E + S ⇋ ES) in catalysis; therefore, it is
likely that these two apparent pKa values both represent the general base in catalysis. The kcat,app
pH profile for both acetyl-CoA and histamine observed a bell-shaped profile (Figures 4.4A and
4.4B) with two pKa,app values (pKa,app – acetyl-CoA = 7.1 ± 0.1 and 9.5 ± 0.1; pKa,app – histamine = 7.2 ±
0.1 and 9.6 ± 0.1). The apparent pKa value of 7.2 (7.1) is attributed to the general base identified
in both (kcat/Km)app profiles, while the apparent pKa value of 9.5 (9.6) can represent either a
general acid in catalysis or the thiol group of coenzyme A. A pKa,app value of 9.5 (9.6) was not
observed in either (kcat/Km)app pH rate profiles, suggesting this ionizable group contributes to
catalysis after the first irreversible step (ES → E + P). A lack of a pK a,app value ≥ 9.5 in the
(kcat/Km)app profiles can also result from inability to evaluate AANATL7 at higher pH values,
because the instability of Ellman’s reagent and hydrolysis of the acetyl-CoA substrate. We must
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note that the pKa,app value identified in the kcat,app profiles is 9.5 (9.6), which is ≥ to the highest
pH evaluated in this study, and this apparent value is a product of the best fit from our data to
equation 4.8. Therefore, the lack of pKa,app value ≥ 9.5 in the (kcat/Km)app profiles may just be a
result from our inability to evaluated AANATL7 at pH(s) > 9.5. The observed difference from
the (kcat/Km)app and kcat,app pH rate profiles for the general base likely results from the kinetic
stickiness of the substrates evaluated in this study.

Figure 4.4. AANATL7 pH rate profiles. (A) kcat for acetyl-CoA. pKa1 - slope = 1, pKa2 - slope = -0.6.
(B) kcat for histamine. pKa1 - slope = 0.9, pKa2 - slope = -0.5. (C) kcat/Km for acetyl-CoA. pKa1 - slope =
0.8. (D) kcat/Km for histamine. pKa1 - slope = 0.9.
The pH-activity profiles do not provide definitive information on the specific residues
involved in catalysis. Therefore, we further evaluated amino acid residues that can function as
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either a general base or acid by site-directed mutagenesis. With the lack of a crystal structure,
we utilized a primary sequence alignment of AANATL7 with D. melanogaster AANATA6 to
identify possible amino acid residues that can function in substrate binding and/or catalysis.
AANATA has been previously characterized with the function of specific residues clearly
defined, including a general base in catalysis and other residues critical in substrate binding
and/or regulation of catalysis.6 From the primary sequence alignment, the proposed general base
of AANATA (Glu-47)6 is conserved, corresponding to Glu-26 in AANATL7. Two serines in D.
melanogaster (Ser-182 and Ser-186)45 have been proposed to function in catalysis, which
corresponds to Thr-167 and Ser-171 in AANATL7.6 Other amino acid residues with defined
functions from AANATA (Pro-48, Arg-153, and His-220) that are also conserved in
AANATL7,6 consists of Pro-27, Arg-138, and His-206. We mutated each one of these residues
to an alanine to define their respective function in AANATL7. The resulting data was indexed to
the data from corresponding residue in AANATA6, 45 to finally propose its respective function in
AANATL7.
Glu-26 is the AANATL7 residue that could function as a general base in catalysis. The
mutation to an alanine resulted in 22- to 32-fold decrease in the kcat,app relative to the wild-type
(Table 4.4). The (kcat/Km)app – acetyl-CoA (kcat/Km)app – histamine was only 7.0% and 0.15% of the
wild-type, respectively. In addition, the E26A mutant has a similar Km,app

– acetyl-CoA

when

compared to the wild-type; however, the Km,app – histamine was increased 31-fold. E26A was the
most catalytically deficient residue evaluated in our study (Table 4.4) and most likely represents
the pKa,app value of ~ 7.2 observed in the pH rate profiles (Figure 4.4).
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Table 4.4. Steady-state kinetic constants for AANATL7 site-directed mutantsa
Acetyl-CoA
Mutant b

Km, app
(µM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)
6

Wild-type
E26A
R138A
T167A
S171A
T167A/S171A
H206A

29 ± 2
13 ± 1
550 ± 60
140 ± 4
19 ± 1
29 ± 2
210 ± 5

32 ± 1
1.01 ± 0.02
88 ± 3
1.84 ± 0.02
8.6 ± 0.1
1.61 ± 0.03
9.6 ± 0.1

(1.1 ± 0.1) × 10
(7.7 ± 0.5) × 104
(1.6 ± 0.2) × 105
(1.36 ± 0.05) × 104
(4.6 ± 0.1) × 105
(5.6 ± 0.3) × 104
(4.6 ± 0.1) × 104
Histamine

Mutant c

Km, app
(mM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)

%
100
7.0
15
1.2
42
5.1
4.2

%
0.52 ±
Wild-type
30 ± 1
(5.8 ± 0.6) × 104
100
0.05
E26A
16 ± 1
1.39 ± 0.04
86 ± 32
0.15
R138A
4.9 ± 0.4
71 ± 2
(1.5 ± 0.1) × 104
26
T167A
6.7 ± 0.7
1.9 ± 0.1
280 ± 30
0.48
S171A
3.4 ± 0.2
10.4 ± 0.2
(3.0 ± 0.2) × 103
5.2
T167A/S171A
13 ± 1
2.2 ± 0.1
160 ± 20
0.28
H206A
2.3 ± 0.1
7.7 ± 0.1
(3.3 ± 0.2) × 103
5.7
a
Kinetic constants are reported as ± standard error (n=3).
b
The kinetic constants were measured at a fixed saturating concentration of histamine while varying the
concentration of acetyl-CoA.
c
The kinetic constants were measured at a fixed saturating concentration of acetyl-CoA while varying the
concentration of histamine.

To further evaluate if Glu-26 functions as the general base in catalysis, we generated a
pH rate profile for the E26A mutant. The kcat,app – acetyl-CoA and (kcat/Km)app – acetyl-CoA pH rate
profiles for the E26A mutant resulted in a linear increase as the pH was increased from 7.5 – 9.5,
with a slope of 0.6 and 0.2, respectively (Figure 4.5). We were not able to resolve a velocity for
E26A above the background hydrolysis rate at pH = 7.0, suggesting the mutant enzyme is close
to being catalytically dead at pH conditions < 7.5. The linear pH rate profile likely results from
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hydroxide chemically rescuing the function of Glu-26 in deprotonation of the positively charged
primary amino group of histamine. These data for the E26A mutant are consistent with what has
been published for D. melanogaster AANATA.6 Furthermore, the proposal of a Glu residue to
function as a general base has been reported for other GNAT enzymes, including human
spermidine/spermine

N1-acetyltransferase52-53

and

the

Gcn5/PCAF

family of

histone

N-acetyltransferases.54-55

Figure 4.5. AANATL7 E26A pH rate profiles. (A) kcat. (B) kcat/Km for acetyl-CoA.

Next, we evaluated the role Thr-167 and Ser-171 has in binding and/or catalysis. The
corresponding residues in AANATA (Ser-182 and Ser-186, respectively) were previously
proposed to function in catalysis.45 Therefore, we mutated Thr-167 and Ser-171 each to an
alanine to define a specific function in AANATL7 catalysis. The T167A mutant produced a
kcat,app decrease of 16- to 17-fold relative to the wild-type enzyme. The (kcat/Km)app – acetyl-CoA and
(kcat/Km)app – histamine for T167A was only 1.2% and 0.49% of the wild-type enzyme, respectively.
In addition, the T167A mutant yielded a Km,app – acetyl-CoA that increases 5-fold when compared to
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wild-type and a Km,app – histamine that was increased 13-fold. The S171A mutant produced a kcat,app
decrease of 3- to 4-fold relative to the wild-type enzyme.

The (kcat/Km)app

– acetyl-CoA

and

(kcat/Km)app – histamine for S171A was 42% and 5.2% of the wild-type enzyme, respectively. In
addition, the S171A mutant has a similar Km,app – acetyl-CoA when compared to wild-type; however,
the Km,app – histamine was increased 7-fold. These data suggest that Thr-167 and Ser-171 could
function in catalysis and/or substrate binding; however, a direct role as a general acid is unlikely.
Since threonine and serine are chemically similar (both possess a hydroxyl group), we evaluated
a T167A/S171A double mutant to delineate if these residues function in a redundant role. The
T167A/S171A double mutant produced a kcat,app decrease of 14- to 20-fold relative to the
wild-type enzyme, similar to what was observed for the T167A mutant. The (kcat/Km)app
acetyl-CoA

and (kcat/Km)app

– histamine

–

for T167A/S171A was 5.1% and 0.28% of the wild-type

enzyme, respectively. In addition, the T167A/S171A mutant has the same Km,app – acetyl-CoA as the
wild-type; however, the Km,app

– histamine

was increased 25-fold. These data, as well as data

generated for the corresponding residues from D. melaongaster AANATA,6,

45

allows us to

define a function for both of these residues. The corresponding residue for Ser-171 from
AANATA was proposed to function as the general acid in catalysis.45 Specifically, AANATA
Ser-186 was proposed to protonate the thiolate of CoA-S- in the breakdown of the tetrahedral
intermediate.45 If the corresponding residue in AANATL7, Ser-171, has a similar function, then
the pKa = 9.5 would represent this amino acid residue. We do not favor a serine or threonine to
function as a general acid in catalysis. This would require a significant depression in the pK a
(3-5 pH units), as well as it is thermodynamically unfavorable for a serine to protonate a thiolate.
A redundant role in catalysis for these residues is unlikely since the T167A/S171A double
mutant was not anymore catalytically impaired than the T167A mutant. Instead, we propose that
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Thr-167 and Ser-171 is functioning to change the active site architecture, most likely through a
network of hydrogen bonds, similar to what was observed for the corresponding amino acids in
AANATA.6
This proposal still does not obviate the need to define the ionizable group responsible for
the pKa,app of 9.5 (9.6) identified in the kcat,app pH rate profiles. We propose that the thiol group
from the CoA-SH product is responsible for this pKa,app, which has been reported to range from
9.6-10.4,56-57 similar to the pKa,app value observed in our study. Protonation of CoA-SH is a
chemical step that occurs during the collapse of the tetrahedral intermediate and is likely
necessary for catalysis. The decrease in the kcat,app at pH ≥ 9.0, results from the deprotonation of
CoA-SH to yield CoA-S-, inhibiting its release from the active site. This proposal alleviates the
need for an amino acid residue to function as a general acid in catalysis.

4.3.6 Use of site-directed mutagenesis to define the function of AANATL7 amino acids in
binding and/or regulation of catalysis
From the primary sequence alignment, AANATL7 Pro-27, Arg-138, and His-206 was
found to be conserved with AANATA (Pro-48, Arg-153, and His-220);6 therefore, we mutated
each of these residues to an alanine and evaluated the kinetic constants (Tables 4.4 and 4.5) in an
effort to define their function. The P27A mutant produced a 38- to 42-fold decrease in the kcat,app
value when histamine was used as the amine substrate. Additionally, the Km,app – acetyl-CoA and
Km,app – histamine increased 3-fold for both substrates, yielding (kcat/Km)app – acetyl-CoA and (kcat/Km)app
– histamine

values that were only 0.67% and 0.76% relative to the wild-type enzyme.

The

significant decrease in the kcat,app and an increase in the Km,app for the P27A mutant, suggest that
Pro-27 functions to organize the active site and regulate catalysis. The corresponding residues
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from sheep serotonin N-acetyltransferase (Pro-64)47,

58-59

and D. melanogaster AANATA

(Pro-48)6 were located on a flexible loop that undergoes a major conformational change resulting
in the formation the amine binding pocket. This conformational change converts the substrate
binding pocket from a low affinity state to a high affinity state.59

For sheep serotonin

N-acetyltransferase, there are two crystal structures solved, one showing the apo enzyme (PDB
1B6B)58

code:

and

the

other

was

co-crystallized

with

the

bisubstate

inhibitor,

tryptamine-acetyl-CoA (PDB code: 1CJW).47 These crystal structures identify that Pro-68 is
located in the acetyl-CoA binding pocket in the low affinity state (apo form), whereas the
conformational change yields a high affinity state where the proline residue migrates ~8 Å to
form a direct base-stacking interaction with the tryptamine moiety of the bisubstrate inhibitor.6,
47, 59

The promiscuity of AANTL7 for amine substrates allows us to test the possibility of direct

binding interactions from Pro-27. We further evaluated the AANATL7 P27A mutant with
agmatine as the amine substrate at saturating concentrations of acetyl-CoA as shown in Table
4.5. If Pro-27 has a direct binding interaction with histamine, then we would expect a smaller
Km,app-P27A/Km,app-wildtype ratio for agmatine, when the amine substrate is modified from an neutral
imidazole group to a positively charged guanidinium group. If Pro-27 is only important for the
formation of the amine binding site and does not have a direct binding interaction with
histamine, then we would expect the Km,app-P27A/Km,app-wildtype ratio for agmatine to be the same as
histamine. The Pro-27 mutant produced a kcat,app - agmatine that decreased 57-fold and Km,app –
agmatine

that increased only 1.6-fold relative to the wild-type enzyme.

histamine

and

wild-type)agmatine

agmatine

yielded

a

The P27A data for

(Km,app-P27A/Km,app-wild-type)histamine/(Km,app–P27A/Km,app–

ratio of 2.2, suggesting that Pro-27 functions in both the general organization of the

active site and in a direct interaction with the amine substrate, possibly by a base-stacking
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interaction. These data suggest that a disruption of a direct binding interaction between the
amine substrate and Pro-27 occurs when the amine substrate is modified from an imidazole
group to a positively charged guanidinium group.

Table 4.5. Steady-state kinetic constants for Pro-27 site-directed mutanta

Mutanta

Wildtypeb
P27Ab
Wildtypec
P27Ac
Wildtypec

Varied
Substrate

Km, app
(µM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)

32 ± 1
(1.1 ± 0.1) × 106
Acetyl-CoA
0.77 ± 0.02 (7.4 ± 0.3) × 103
30 ± 1
(5.8 ± 0.6) × 104
Histamine
0.80 ± 0.02
440 ± 30
0.68 ± 0.03
850 ± 110
Agmatine
0.012 ±
P27Ac
1300 ± 100
9.7 ± 0.7
0.001
a
Kinetic constants are reported as ± standard error (n=3).
b
The kinetic constants were measured at a fixed saturating concentration of histamine.
c
The kinetic constants were measured at a fixed saturating concentration of acetyl-CoA.
29 ± 2
105 ± 4
520 ± 50
1800 ± 100
790 ± 100

%
100
0.67
100
0.76
100
1.1

Next, we mutated Arg-138 to an alanine to delineate its respective function. The R138A
mutant resulted in increases for the kcat,app (2.4- to 2.8-fold) and both Km,app – acetyl-CoA (19-fold)
and Km,app – acetyl-CoA values (9-fold). The increases in the kcat,app value for R138A is counteracted
by the increase in the Km,app values to yield a mutant enzyme with (kcat/Km)app – acetyl-CoA and
values (kcat/Km)app – histamine that is only 15% and 26% of the wild-type, respectively (Table 3).
These data suggest that Arg-138 functions to regulate catalysis and in substrate binding.
Arg-138 likely does not have a direct role in catalysis as a general acid or base; however, the
increase in the kcat,app data is more consistent with regulating a conformational change that
induces domain mobility yielding product release partially rate-limiting. The corresponding
residue in D. melanogaster AANATA (Arg-153)6 produced a similar increase in the kcat,app value,
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which is attributed to the elimination of a salt bridge that is critical for a conformation change
that regulates the rate of CoA-SH release. The AANATL7 R138A mutant likely eliminates a salt
bridge, which increase the rate of CoA-SH release, similar to what was observed for AANATA.
We would expect that if the R138A mutant is increasing the koff rate for the CoA-SH product,
then its dissociation constant should increase since the Kd = the ration of koff – CoA-SH/kon – CoA-SH.
We determined the Kd for CoA-SH binding for the wild-type enzyme and R138A mutant by
measuring its quenching of intrinsic AANATL7 fluorescence as the [CoA-SH] is increased. This
resulted in a Kd – wild-type = 530 ± 110 µM and Kd – R138A = 1.1 ± 0.2 mM (Figure 4.6), showing a
2.1-fold decrease in the binding affinity for the R153A mutant relative to the wild-type enzyme.
The ratio of Kd –R153/Kd –wild-type (2.1-fold) is in reasonable agreement with the kcat –R153A/kcat –
wild-type

(2.4- to 2.8-fold) ratio (Table 4.4). These data suggest that a salt bridge consisting of

Arg-138 is important to regulate the protein dynamics of AANATL7, contributing to a partial
rate-limiting release of CoA-SH. These data are consistent with what is observed with D.
melanogaster AANATA6 and other GNAT enzymes that have product release as a partial
rate-limiting step.26, 46, 60-61
Similar to Pro-27 and Arg-138, His-206 is conserved with D. melanogaster AANATA
(His-220).6 The H206A mutant produced a 3- to 4-fold decrease in the kcat,app value (Table 4.4)
and an increase in the Km,app for both acetyl-CoA (7-fold) and histamine (4-fold). This suggests
that His-206 functions to organize the binding pocket for both substrates, similar to what is
proposed for the corresponding residue in AANATA (His-220).6
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Figure 4.6. Determination of the coenzyme A dissociation constant by measuring the intrinsic
fluorescence quenching of AANATL7 for the wild-type enzyme and R138A mutant. (A)
Wild-type. (B) R153A.

4.3.7 Proposed chemical mechanism for AANATL7
A chemical mechanism consistent with our data is shown in Scheme 4.2. The mechanism
details (a) ordered substrate binding, with acetyl-CoA binding first followed by histamine to
generate a AANATL7•acetyl-CoA•histamine ternary complex prior to catalysis, (b) followed by
Glu-26 serving as the general base in catalysis by deprotonating of the positively charged
primary amino group of histamine through ordered water molecules, similar to AANATA, (c)
nucleophilic attack of histamine to the carbonyl of the acetyl-CoA thioester to generate the
zwitterionic tetrahedral intermediate, (d) collapse of the zwitterionic tetrahedral intermediate
followed by the protonation the coenzyme A thiolate, (e) and finally, ordered product release,
with N-acetylhistamine leaving first, followed by CoA-SH.

Evidence supporting ordered

product release results for the ability to measure the direct binding affinity for CoA-SH in the
absence of the N-acetylated product, which is also consistent with a synergistic effect from
ordered substrate binding. This chemical mechanism is consistent with the data generated
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herein, with the mechanism proposed for D. melanogaster AANATA,6 and for other GNAT
enzymes.62-63

Scheme 4.2. Proposed chemical mechanism for D. melanogaster AANATL7. The dashed arrow
represents the possible positions of the irreversible step based on data generated herein and for
other D. melanogaster AANATL enzymes.6, 45

4.3.8 Conclusions
We showed that AANATL7 will catalyze the formation of N-acylamides from the
corresponding acyl-CoA and amine substrates. AANATL7 is relatively discriminative for the
acyl-CoA substrates, showing that the (kcat/Km)app for acetyl-CoA is ≥ 10-fold higher than any
other acyl-CoA substrate analyzed in this study. The amine substrates have more promiscuous
selectively, where arylalkylamines, histamine, putrescine, agmatine, and ethanolamine will all
serve

as

AANATL7

substrates.

We

proposed

a

chemical

mechanism

for

AANATL7-catalyzed formation of N-acetylhistamine as illustrated in Scheme 4.2.

the
First,

substrate binding is ordered sequential with acetyl-CoA binding first, followed by histamine to
generate the ternary complex (AANATL7•acetyl-CoA•histamine) prior to catalysis. Next, we
invoked Glu-26 as the general base in catalysis with a pKa,app of ~7.2, that will deprotonate the
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positively charged primary amino group of histamine through ordered water molecules that make
up an active site “proton wire”. Finally, we suggest that protein dynamics has a significant
regulatory effect on AANATL7 catalysis, where non-catalytic amino acid residues (Arg-138 and
Pro-27) have a significant impact on the rate of catalysis.
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Chapter Five
Probing the Chemical Mechanism and Critical Regulatory Amino Acid Residues of Drosophila
melanogaster Arylalkylamine N-acyltransferase Like 2

5.1. Introduction
The N-acylation of biogenic amines are important for neurotransmitter inactivation,
cuticle sclerotization, melatonin biosynthesis, and biosynthesis of potent cell signaling lipids.
The biogenic amines identified in Drosophila melanogaster consist of serotonin, dopamine,
octopamine, tyramine, and histamine.1

Biosynthesis of these amines and the subsequent

N-acylamide products are all derived from their cognate amino acid precursors. Tyramine,
octopamine, and dopamine are all derived from tyrosine metabolism, whereas serotonin is
generated from tryptophan.

Histamine and N-acetylhistamine is a product of histidine

metabolism. The biosynthesis of tyramine (Scheme 5.1) initially occurs from decarboxylation of
tyrosine by tyrosine decarboxylase2-3 and then is either acylated by an arylalkylamine
N-acetyltransferese (AANAT)4-6 to generate N-acyltyramine or is hydroxylated to form
octopamine, which is catalyzed by tyramine β-hydroxylase.7-9 Subsequently, octopamine can be
acetylated by AANAT to generate N-acetyloctopamine.6,

10-12

In addition, tyrosine can be

hydroxylated by tyrosine hydroxylase2, 13-15 to generate L-dopa followed by decarboxylation by
an aromatic amino acid decarboxylase (AADC) to generate dopamine.16-18 Dopamine can then
be N-acylated by an AANAT to generate the N-acyldopamine product.4 Serotonin biosynthesis
occurs initially by the hydroxylation of tryptophan by tryptophan hydroxylase19 to generate
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5-hydroxyl-L-tryptophan followed by decarboxylation by AADC.18-19 In addition to tyramine,
octopamine, dopamine; serotonin is also N-acylated by an AANAT4,
N-acylserotonin product.

6

to generate the

Herein, we report the characterization of arylalylamine

N-acyltransferase like 2 (AANATL2), which is responsible for the chemical formation of
N-acetylarylalkylamides, long-chain N-acylserotonins, and long-chain N-acyldopamines.

Scheme 5.1. Biosynthetic pathway for biologically relevant arylalkylamine biogenic amines and
their N-acylated products in D. melanogaster. (A) Tyrosine biosynthesis. Rxn 1,tyrosine
decarboxylase (TDC); 2, tyrosine hydroxylase (TYH); 3, aromatic amino acid decarboxylase
(AADC); 4, tyramine β-hydroxylase (TβH); 5, arylalkylamine N-acetyltransferase (AANAT).
(B) Tryptophan biosynthesis. Rxn 6, tryptophan decarboxlyase (TPH); 7, aromatic amino acid
decarboxylase (AADC); arylalkylamine N-acetyltransferase (AANAT).
AANATL2 is a member of the GCN5-related N-acetyltransferase (GNAT) family20-21 of
enzymes and has been identified to catalyze the formation of N-acylarylalkylamides11, 22 from the
corresponding acyl-CoA and arylalkylamine. The N-acetylation of biogenic amines were first
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identified in D. melanogaster by measuring N-acetyltransferase activity in fly crude extracts, by
Dewhurst et al. in 1972.4 We previously showed that this enzyme is likely involved in the
biosynthesis of long-chain N-acyldopamines and N-acylserotonins (Appendix B), while also
showing that this enzyme will catalyze the formation of N-acetylserotonin, N-acetyldopamine,
N-acetyltyramine, and N-acetyloctopamine.11 Endogenous levels of N-acetylated products of
these biogenic amines have been identified in D. melanogaster,23 along with long-chain
N-acylserotonins11 and N-acyldopamines.24 Therefore, it is likely that this enzyme or another
AANATL enzyme could function the biosynthesis of these biologically revelvant
N-acylarylalkyamides.
Herein, we define the substrate specificity of different amine substrates for the
AANATL2-catalyzed formation of N-acetylamides.

Subsequently, we solved the kinetic

mechanism by using double reciprocal analysis and dead-end inhibition, followed by using
pH-rate profiles and site-directed mutagenesis in order to generate data that led to a proposed
chemical mechanism for AANATL2. Finally, we discuss some structure-activity relationships
for different amine substrates and define functions of AANATL2 amino acid residues involved
in binding and regulation of catalysis.

5.2. Material and methods
5.2.1 Materials
PCR primers were purchased from Eurofins MWG Operon. PfuUltra High-Fidelity DNA
polymerase was purchased from Agilent. pET-28a(+) vector, XL10 E.coli cells, and BL21
(DE3) E.coli cells were purchased from Novagen. NdeI, XhoI, Antarctic Phosphatase and T4
DNA ligase were purchased from New England Biolabs. Kanamycin monosulfate and IPTG
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were purchased from Gold Biotechnology. ProBond™ nickel-chelating resin was purchased
from Invitrogen. Acetyl-CoA and oleoyl-CoA were purchased from Sigma-Aldrich. Wild-type
AANATL2 was expressed and purified with the same procedures as published by Dempsey et al
or also found in Appendix B.11 All other reagents were of the highest quality available from
either Sigma-Aldrich or Fisher Scientific.

5.2.2 Cloning, expression, and purification of AANATL2 site-directed mutants
All the AANATL2 mutants were generated by using the overlap extension method.25
PCR primers (Table 5.1) were generated for each mutant by using the Agilent QuickChange
Primer Design tool. The following PCR conditions were used with PfuUltra High-Fidelity DNA
polymerase: initial denaturing step of 95°C for 2 min, then 30 cycles of (95°C for 30 s; 60oC for
30 s; 72°C for 1 min), then a final extension step of 72°C for 10 min. The AANATL2 mutant
PCR product was then inserted into a pET-28a(+) vector using NdeI and XhoI restriction sites.
The AANATL2-mutant-pET-28a product was then transformed into E. coli XL10 competent
cells, plated on Luria Broth (LB) agar plates supplemented with 40 µg/mL kanamycin, and
incubated overnight at 37°C. The following day, a single colony from the LB agar plate
containing E. coli XL10 cells with the AANATL2-mutant-pET-28a vector was used to inoculate
an overnight culture in LB media, supplemented with 40 µg/mL kanamycin at 37°C. The next
day, the AANATL2-mutant-pET-28a plasmid was purified using Promega Wizard® Plus SV
Minipreps DNA purification kit and sequenced by Eurofins MWG operon.

Following

confirmation of the AANATL2 mutant sequence, the AANATL2-mutant-pET-28a plasmid was
then transformed into BL21 (DE3) E.coli cells. Each AANATL2 mutant protein was expressed
and purified using the same procedures that were defined for the wild-type enzyme (Appendix
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B).11 After the purification of each enzyme, the AANATL2 mutants and wild-type enzyme were
dialyzed out of the elution buffer and into 20 mM Tris pH 7.4, 200 mM NaCl for 16 hr at 4°C.

Table 5.1. Site-directed mutagenesis primers
Mutant
E29A
P30A
R138A
S167A
S171A
H206A

Primer
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

Primer Sequence
CCA TTT CTT TAA GCA GGC ACC GCT GAT GCT GAT TC
GAA TCA GCA TCA GCG GTG CCT GCT TAA AGA AAT GG
TCA GCA TCA GCG CTT CCT GCT TAA AGA AAT GGA CTG
CAG TCC ATT TCT TTA AGC AGG AAG CGC TGA TGC TGA
CGT CGA TGT GTC CAT TGC TCG CCA ACG T
ACG TTG GCG AGC AAT GGA CAC ATC GAC G
CGT TTA CTA TTT TGG TTC GCG CAC GTT GAG GTC ACG AC
GTC GTG ACC TCA ACG TGC GCG AAC CAA AAT AGT AAA CG
GTC ATC AGG CGT TTA GCA TTT TGG TTC GAG CAC GTT GAG G
CCT CAA CGT GCT CGA ACC AAA ATG CTA AAC GCC TGA TGA C
GTG CCT CAG AAC CGG CCA CGA GTG CAT CCG
CGG ATG CAC TCG TGG CCG GTT CTG AGG C

5.2.3 Enzyme assay
Ellman’s reagent (DTNB) was used to determine the kinetic constants for different amino
donor substrates and acetyl-CoA with AANATL2 by measuring the rate of coenzyme A release
at 412 nm (molar extinction coefficient = 13,600 M-1 cm-1). The assay consisted of: 300 mM
Tris pH 8.0, 150 µM DTNB, varying concentration of one substrate, and holding the other
substrate at a fixed saturating concentration at 22°C and measuring the initial velocities with a
Cary 300 Bio UV-Visible spectrophotometer. The resulting data was fit to equation 5.1, in
which vo is the initial velocity, Vmax is the maximal velocity, [S] is the substrate concentration,
and Km is the Michaelis constant. Each assay was performed in triplicate and the uncertainty for
the kcat,app and (kcat/Km)app values were calculated by using equation 5.2,26 which σ is the standard
error.

117

Equation 5.1

Equation 5.2

5.2.4 Kinetic mechanism
Initial velocity patterns for acetyl-CoA and tyramine were used to delinate between a
sequential or ping-pong kinetic mechanism. The initial velocities were measured for acetyl-CoA
by holding the tyramine concentration constant (1 µM, 2 µM, 10 µM, and 25 µM) and varying
the concentration of acetyl-CoA. The initial velocities for tyramine were measured by holding
the acetyl-CoA concentration constant (1 µM, 2 µM, 10 µM, and 25 µM) and varying the
concentration of tyramine. The resulting data were fit to equation 5.3 for a Bi Bi sequential
kinetic mechanism and plotted as a double reciprocal plot using IGOR Pro 6.34A. In equation
5.3, Kia is the dissociation constant for substrate A (acetyl-CoA), Ka is the Km (Michaelis
constant) for substrate A (acetyl-CoA), and Kb is the Km (Michaelis constant) for substrate B
(tyramine).

Equation 5.3

118

Following the double reciprocal analysis, dead-end inhibitor analysis was used to
differentiate between an ordered or random sequential kinetic mechanism. Oleoyl-CoA and
tyrosol were used as dead-end inhibitors that are analogs for acetyl-CoA and tyramine,
respectively. Initial velocities for the inhibition experiments were measured for acetyl-CoA and
tyramine by varying the concentration of one substrate, holding the other substrate at a fixed
concentration equal to the respective Km,app (acetyl-CoA = 7.2 µM; tyramine = 3.9 µM),11 at
different concentrations of the inhibitor. Inhibition patterns were determined by fitting the
resulting data, using SigmaPlot 12.0, to equations 5.4 – 5.6; for competitive, noncompetitive, and
uncompetitive inhibition, respectively. The terms in equations 5.4 – 5.6 represent the following:
vo is the initial velocity, Vmax is the maximal velocity, [S] is the substrate concentration, Km is the
Michaelis constant, [I] is the inhibitor concentration, and Ki is the inhibition constant. Each
assay was performed in triplicate.

Equation 5.4

Equation 5.5

Equation 5.6
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5.2.5 Rate versus pH dependence
The pH dependence on the kinetic constants for the wild-type and E29A mutant enzymes
were determined for acetyl-CoA. The kinetic constants were determined at pH values ranging
from 6.5 – 9.5 at intervals of every 0.5 pH units. The following buffers were used for the pH
dependence study: MES (pH 6.5 – 7.0), Tris (pH 7.0 – 9.0), and AMeP (pH 9.0 – 9.5). The
kinetic constants from the pH dependence experiments were fit using IGOR Pro 6.34A, to
equation 5.6 [log (kcat/Km – tyramine)] and equation 5.7 [log (kcat)], where c is the pH-independent
plateau. Each assay was performed in duplicate.

Equation 5.6

Equation 5.7

5. 3. Results and discussion
5.3.1 Structure-activity relationship of AANATL7 substrates
Previously, we showed that short- and long-chain acyl-CoAs will serve as substrates for
AANATL2.11 This same study also determined that only serotonin or dopamine are utilized as
the corresponding biogenic arylalkylamine substrate when a long-chain acyl-CoA (oleoyl-CoA)
is the other substrate in the conjugation reaction.11 However, when acetyl-CoA is used as the
corresponding acyl-CoA substrate, then all the D. melanogaster biogenic arylalkylamines will
serve as amino donor substrates to generate N-acetylarylalkylamides.11

Herein, we further

evaluate the structure-activity relationships for other amino donor substrates with acetyl-CoA
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serving as the corresponding acyl-CoA substrate (Table 5.2). This study focused on five major
structure features of potential amino donor substrates consisting of: (a) modification of the 5’
position of substrates containing an indole ring, (b) modification of the phenyl ring for substrates
containing a two methyl spacer group that links the phenyl ring and primary amine, (c) the length
of the spacer group that links the phenyl ring and primary amine, (d) modification of the a two
methyl spacer group, and (e) other non-arylalkylamine amino donors.
The first set of substrates that were evaluated is decarboxylated analogs of tryptophan, in
which each substrate contained an indole ring.

The (kcat/Km)app value for these panel of

substrates are found in decreasing order: 5-benzyloxytryptamine ≥ serotonin ≥ tryptamine >
5-methoxytryptamine. The only indole ring substrate evaluated in this study that was outside the
standard error range for the other substrates was 5-methoxytryptamine, resulting mainly from a
1.8 - 3.5-fold (tryptamine – serotonin) increase in the Km,app value. The kcat,app value was
generally the same for each indole ring substrate evaluated, except for a ~2-fold higher value for
tryptamine. In all, the kinetic constants for this panel of substrates had minimal difference when
compared to the other substrates that contain an indole ring.

Table 5.2. Steady-state kinetic constants for different amino donorsa,b
Km, app
(µM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)

3-(Trifluoromethyl)phenethylamine

10 ± 2

4.5 ± 0.2

(4.4 ± 0.7) × 105

4-Methoxyphenethylamine

10 ± 2

3.7 ± 0.1

(3.7 ± 0.6) × 105

3-Methoxyphenethylamine

13 ± 2

4.4 ± 0.2

(3.5 ± 0.6) × 105

5-Benzyloxytryptamine

8±1

2.8 ± 0.1

(3.3 ± 0.4) × 105

Substrate

Structure
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Table 5.2. (Continued)
β-Methylphenethylamine

9±1

2.9 ± 0.1

(3.2 ± 0.4) × 105

Tryptamine

14 ± 3

4.3 ± 0.3

(3.1 ± 0.6) × 105

Tyramine

5±1

1.47 ± 0.03

(2.9 ± 0.3) × 105

3,4-Methylenedioxyphenethylamine

27 ± 5

6.3 ± 0.4

(2.3 ± 0.4) × 105

Phenethylamine

35 ± 10

7.3 ± 1

(2.1 ± 0.7) × 105

Norepinephrine

27 ± 3

5.6 ± 0.3

(2.1 ± 0.3) × 105

4-Phenylbutylamine

9.5 ± 0.4

1.03 ± 0.02

(1.09 ± 0.05) ×
105

5-Methoxytyrptamine

25 ± 2

2.6 ± 0.1

(1.0 ± 0.1) × 105

Benzylamine

210 ± 4

0.092 ±
0.002

430 ± 10

0.90 ± 0.02

260 ± 5

0.82 ± 0.03

7±1

3500 ±
200
(1.1 ± 0.1)
× 105

Histamine
Ethanolamine

Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 50 µM acetyl-CoA, and varying
concentration of amine substrate.
b
Kinetic constants are reported as ± standard error (n=3).
a

The second set of substrates evaluated were arylalkylamines that contained a phenyl ring
+ two methyl spacer group + primary amine.

3-(Trifluoromethyl)phenethylamine,

4-methoxyphenethylamine, and 3-methoxylphenethylamine were shown to be the amino donor
substrates that had the highest (kcat/Km)app value for this group of substrates. We could not
distinguish between these amino donor substrates which had the largest (kcat/Km)app value,
because each one is within the uncertainty of 3-(trifluoromethyl)phenethylamine. The other
amino

donor

substrates

in

3-(trifluoromethyl)phenethylamine

this

group
are

that

are

outside

the

β-methylphenethylamine,
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uncertainty

of

tyramine,

3,4-methylenedioxyphenethylamine,

phenethylamine,

norepinephrine,

dopamine,

and

octopamine. The largest difference in the (kcat/Km)app value results from octopamine, which is
7% of that reported for 3-(trifluoromethyl)phenethylamine, resulting mainly from the 8-fold
increase in the Km,app value. All the other amino donors in this group are found to have a
(kcat/Km)app that is ≥ 35% (dopamine) of that reported for 3-(trifluoromethyl)phenethylamine.
The Km,app values for this group of amino donors ranged from 5 – 78 µM (tyramine –
octopamine), whereas the kcat,app values ranged from 1.47 – 6.5 s-1 (tyramine – dopamine).
Overall, very little difference was observed for the kinetic constants in this group of amino donor
substrates, pointing to an enzyme with significant substrate promiscuity.
The third set of substrates evaluated were those that have a different length of the spacer
group that links the phenyl group to the primary amine. The (kcat/Km)app value in this group of
amino donor substrates ranks from highest to lowest as: phenethylamine > 4-phenylbutylamine
>> benzylamine.

The (kcat/Km)app value for phenethylamine was only 2-fold higher than

4-phenylbutlyamine; however, phenethylamine was ~500-fold > benzylamine.

These data

suggest that a two methyl spacer group is optimal for substrate specificity; however, AANATL2
will use substrates with a spacer group of four methyl groups (4-phenylbutylamine) with similar
specificity.

Decreasing the spacer group by one CH2 group to generate benzylamine;

significantly increases the Km,app and decreases the kcat,app, resulting in a large decrease in the
(kcat/Km)app value.
The fourth set of substrates we evaluated were amino donors that contain a phenyl group
+ two methyl spacer + primary amine, where the two methyl linker group is modified at either
the α- or β-position. We first evaluated the modification of the α-position with a carboxylate,
resulting in the amino acids: tyrosine, phenylalanine, tryptophan, and histamine. Activity was
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not observed for these amino acids above the baseline hydrolysis rate at a concentration of 1
mM, suggesting that the modification of the α-position on the spacer group induces either a steric
or electrostatic effect.

To evaluate these possibilities, we used tyrosine methyl ester at a

concentration of 1 mM, in which we did not observe a rate above the baseline rate suggesting
that the arylalkylamines with a modification at the α-position of the spacer group will not serve
as substrates prominently due to a steric effect. We further evaluated tyrosine, phenylalanine,
tryptophan, histamine, and tyrosine methyl ester as inhibitors for the AANATL2-catalyzed
formation of N-acetyltyramine. No inhibition was observed at a concentration of 1 mM of each
inhibitor, confirming that these α-position modified arylalkylamines do not bind or binds weakly
(Kd ≥ 10 mM) to AANATL2, predominantly due to steric interference in the active site. Next,
we evaluated how modifications at the β-position will affect the kinetic constants. These data
resulted in minimal difference in the (kcat/Km)app value except for octopmaine, in which we rank
these amino donor substrates in decreasing order: β-methylphenethylamine ≥ phenethylamine ≥
norephinephrine > octopamine. The (kcat/Km)app value for octopamine was 10% of that reported
for phenethylamine, due to both an increase in the Km,app (1.4-fold) and decrease in the kcat,app
(3.2-fold).
Next, we evaluated if other non-arylalkylamines will serve as substrates for AANATL2.
We identified that AANATL2 will catalyzed the N-acetylation of histamine and ethanolamine,
albeit with low specificity when compared to arylalkylamine substrates. Both histamine and
ethanolamine have a large increase in the Km,app (350- and 1.1 × 104-fold, respectively) and
decrease in the kcat,app values (5-fold for both substrates) when compared to the “best” substrate,
3-(trifluoromethyl)phenethylamine. These data resulted in histamine and ethanolamine having
(kcat/Km)app values that are only 0.06% and 0.002% of 3-(trifluoromethyl)phenethylamine,
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respectively.

We also determined that AANATL2 does not catalyze the N-acetylation of

isoniazid, which is a first line drug for the treatment of tuberculosis.27-29 These data suggest that
AANATL2 predominantly catalyzes the N-acylation of biologically relevant arylalkyamines.
Previous data suggests that the promiscuity of AANATL2 for certain arylalkylamines is
decreased as the acyl-chain length is increased from acetyl-CoA (C2) to oleoyl-CoA (C18).11
These data resulted in tyramine and octopamine serving as substrates for AANATL2 when
acetyl-CoA is the corresponding acyl-CoA substrate; however, tyramine and octopmaine does
not function in the conjugation chemistry with oleoyl-CoA. There are two possible explanations
to these data: (a) longer chain acyl-CoAs will serve as substrates in a different enzyme form (or
different active site) which is only specific for serotonin or dopamine, or (b) the acyl group of the
long-chain acyl-CoAs will occupy the amine binding pocket, resulting in the perturbed binding
of amino donor substrates.

The Km,app value increased > 25-fold for both serotonin and

dopamine when a longer chain acyl-CoA (C16 – C20) is used instead of acetyl-CoA. Coupling
these data to the dead-end inhibition data (section 3.2), it is more likely that the longer acyl
group is perturbing amino donor binding, resulting in only certain amino donors (serotonin and
dopamine) that will function as substrates.11
Overall, a preponderance of the data from the structure-activity studies and other data
published for AANATL2 identifies that this enzyme has significant substrate promiscuity for
both acyl-CoA11 and amino donor substrates. The three major structural features that affected
binding and/or catalysis for AANATL2 substrates were amino donors that were modified at the
α-position, the length of the acyl group for the acyl-CoA substrate, and the length of the spacer
group linking the phenyl and primary amino groups of the amine substrates. Amino donors that
were modified at the α-position will not bind to AANATL2 because of steric inference within the
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active site, resulting in the inability to function in catalysis. The length of the spacer group for
the amine substrate linking the phenyl group and primary amine was shown to be critical, where
decreasing the length by one CH2 group resulted in a significant decrease in the kcat,app and
increase in the Km,app values. This is likely a result from the primary amino group needing to be
properaly positioned for nucleophilic attack of acetyl-CoA. Shortening the length of the spacer
group likely results in improper positioning of the amine group, whereas the active site of
AANATL2 is more accommodating for an increase in the length of the spacer group as observed
for 4-phenylbutlamine.

Earlier work highlighted that AANATL2 functions to catalyze the

formation of long-chain N-acylserotonins and N-acyldopamines; however, will not utilize
octopamine and tyramine as substrates when a long-chain acyl-CoA (oleoyl-CoA) serves as the
other substrate.11 Selectively for the amino donor seems to increase when long-chain acyl-CoAs
are used in the conjugation reaction by AANATL2, whereas when acetyl-CoA is used as the
corresponding acyl-CoA substrate, then the enzyme has significant promiscuity for amino donor
substrates. Further work, consisting of solving the kinetic mechanism (discussed section 5.3.2)
and crystal structure could give additional insight into the structural makeup of the AANATL2
active site and how it affects amino donor selectivity that is dependent on the length of the
acyl-CoA substrate.

5.3.2 Kinetic mechanism
Solving the kinetic mechanism for AANATL2 could give insight on the reason for broad
acyl-CoA substrate specificity. In addition, understanding ordered substrate binding can assist in
the understanding for the promiscuity differences with the amino donor substrates when
acetyl-CoA or oleoyl-CoA is the corresponding acyl-CoA substrate.
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We used a double

reciprocal analysis for acetyl-CoA and tyramine to delineate between a ping-pong or sequential
mechanism. The intersecting double reciprocal plots (Figure 5.1) for both substrates strongly
suggest that this enzyme will catalyze the formation of N-acylarylalkylamides by a sequential
mechanism. This suggests that AANATL2 generates a ternary complex prior to catalysis.

Figure 5.1. Double reciprocal plots of initial velocities for acetyl-CoA and tyramine. (A)
Velocities measured at a fixed concentration of tyramine: 25 µM (●), 10 µM (o), 2 µM (▼), 1
µM (Δ). (B) Velocities measured at a fixed concentration of acetyl-CoA: 25 µM (●), 10 µM (o),
2 µM (▼), 1 µM (Δ).

Following these data, we sought to delineate between random or ordered substrate
binding for acetyl-CoA and tyramine. To accomplish this, we used dead-end inhibition with
structural analogs for each substrate that serves as inhibitors.

Previous data showed that

oleoyl-CoA will not serve as a substrate for AANATL2 when tyramine is the corresponding
amino donor substrate;11 therefore, we decided to use it as a dead-end inhibitor that is an analog
for acetyl-CoA. Long-chain acyl-CoAs have been previously used as inhibitors30-32 for GNAT
enzymes and as dead-end inhibitors to evaluate the kinetic mechanism for other D. melanogaster
AANATL enzymes.6 We employed tyrosol as the other dead-end inhibitor in determining the
kinetic mechanism for AANATL2. Tyrosol is a structural analog of tyramine, in which the
amino group of tyramine is replaced with a hydroxyl group. Tyrosol has been used to study the
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kinetic mechanism of other GNAT enzymes. We evaluated the possibility that AANATL2 will
catalyze the formation of the O-acetylation of tyrosol by measuring the rate of reaction at a
concentration of 10 mM. We did not observed any rate above the baseline hydrolysis rate,
suggesting that AANATL2 will not catalyzed the formation of O-acetyltyrosol; therefore, we
could use tyrosol as a dead-end inhibitor in solving the kinetic mechanism. Following these
analyses, we evaluated the inhibition profile for oleoyl-CoA and tyrosol (Figure 5.2).
Oleoyl-CoA is a competitive inhibitor with respect to acetyl-CoA (Ki = 180 ± 30 nM) and
noncompetitive for tyramine (Ki = 540 ± 40 nM). Tyrosol is an uncompetitive inhibitor with
respect to acetyl-CoA (Ki = 104 ± 6 µM) and a competitive inhibitor for tyramine (Ki = 52 ± 9
µM). In addition to the double reciprocal analysis, these dead-end inhibition data identifies that
AANATL2 will catalyze the formation of N-acetyltyramine with an ordered sequential
mechanism, in which acetyl-CoA binds first followed by tyramine to generate the
AANATL2*acetyl-CoA*tyramine ternary complex prior to any product formation. These data
also provide more insight into the amino donor substrate promiscuity differences observed
between the use of acetyl-CoA or oleoyl-CoA as the correspdoning acyl-CoA substrate. The
promiscuity differences likely result from active site tolerance of the acyl group versus the ability
to position the amino donor substrate properly for nucleophilic attack.

Since an

AANATL2•acetyl-CoA complex is required prior to tyramine binding, it is likely that the
AANATL2 enzyme becomes more discriminatory to amino donors as the length of the acyl-CoA
substrate is increased, because the acyl group begins to occupy the amino donor binding site,
perturbing the ability for certain amines to bind and function in catalysis. An ordered sequential
mechanism identified for AANATL2 is consistent with other D. melanogaster AANATL
enzymes and with the mammalian ortholog, sheep serotonin N-acetyltransferase.33
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Figure 5.2. Dead-end inhibtion analysis of AANATL2. (A) Velocities measured at a fixed
concentration of tyramine (3.9 µM), varying the concentration of acetyl-CoA, and varying the
concentration of the inhibitor, oleoyl-CoA: 0 nM (●), 125 nM (o), 250 nM (▼); Ki = 180 ± 30
nM. (B) Velocities measured at a fixed concentration of acetyl-CoA (7.2 µM), varying the
concentration of tyramine, and varying the concentration of the inhibitor, oleoyl-CoA: 0 nM (●),
125 nM (o), 250 nM (▼); Ki = 540 ± 40 nM. (C) Velocities measured at a fixed concentration of
tyramine (3.9 µM), varying the concentration of acetyl-CoA, and varying the concentration of
the inhibitor, tyrosol: 0 µM (●), 50 µM (o), 100 µM (▼); Ki = 104 ± 6 µM. (D) Velocities
measured at a fixed concentration of acetyl-CoA (7.2 µM), varying the concentration of
tyramine, and varying the concentration of the inhibitor, tyrosol: 0 µM (●), 50 µM (o), 100 µM
(▼); Ki = 52 ± 9 µM.
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5.3.3 Evaluation of the AANATL2 acid/base chemistry and the corresponding catalytic
residue(s)
We used a series of pH-rate profiles, primary sequence alignment with other D.
melanogaster AANATL enzymes, and site-directed mutagenesis to generate data that can be
used to propose a chemical mechanism for AANATL2. First, we determined the pH-dependence
on the acetyl-CoA kinetic constants (Figure 5.3). Both, the kcat,app – acetyl-CoA and (kcat/Km)app –
acetyl-CoA

profiles produced a bell-shaped curve with two apparent pKa values. The pKa,app values

for the kcat,app – acetyl-CoA profile were 7.4 ± 0.2 and 8.9 ± 0.2, whereas the pKa,app values for the
(kcat/Km)app – acetyl-CoA profile were 6.8 ± 0.2 and 9.0 ± 0.1. The pKa,app values of 7.4 and 6.8 from
both profiles, likely represents the same ionizable group, the general base in catalysis. The
differences in these two pKa,app values most likely results from either the kinetic stickiness of
acetyl-CoA or from the difficulty in measuring the acetyl-CoA kinetic constants with varying
concentrations that range at the low end of the linear response for the DTNB assay. The second
pKa,app values of 8.9 and 9.0 represents the same ionizable group, either a general acid in
catalysis or the thiol group of coenzyme A. The pKa for the thiol group of coenzyme A has been
reported to range from 9.6 to 10.4.34-35
Studying the pH-dependence for kinetic constants of the AANATL2 wild-type
enzyme can only give information on the general acid/base chemistry that this enzyme catalyzes,
but cannot delineate the respective amino acid residues (or substrate/product) responsible for
these ionizable groups. Therefore, we used a combination of primary sequence alignment with
other D. melanogaster AANATL enzymes6 and site-directed mutagenesis of conserved residues
to identify the respective amino acids that function in catalysis. A primary sequence alignment
of the eight D. melanogaster AANATL enzymes generated five conserved amino acid residues
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that may have important functions in catalysis and/or substrate binding: Glu-29, Pro-30,
Arg-138, Ser-171, and His-206.11

For each of these amino acids in AANATL2, the

corresponding residues in D. melanogaster AANATA6 and AANATL7 were evaluated and have
a defined function. Therefore, we can index the data from the site-directed alanine mutants
(Table 5.3) to the corresponding residues from the previously studied D. melanogaster AANATL
enzymes, in order to delineate a respective function in AANATL2.6

Figure 5.3. AANATL2 pH rate profiles. (A) kcat,app for acetyl-CoA. pKa1 - slope = 0.8, pKa2 - slope =
-0.6. (B) (kcat/Km)app for acetyl-CoA. pKa1 - slope = 0.6, pKa2 - slope = -0.7.
In both AANATA and AANATL7, a glutamate has been proposed to be the general base
in catalysis. The corresponding glutamate found in AANATL2 is Glu-29; therefore, based of the
primary sequence alignment, this amino acid residue likely has a similar function as the general
base in catalysis. The kcat,app value of the E29A mutant was 23% - 25% of the wild-type enzyme,
whereas the (kcat/Km)app for acetyl-CoA and tyramine decreased 4.3- and 66-fold, respectively.
The E29A mutant did not produced a change in the Km,app value for acetyl-CoA when compared
to the wild-type enzyme, indicating that this residue does not function in acetyl-CoA binding.
Interestingly, the small decrease in the kcat,app value suggests that Glu-29 is not the general base
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in catalysis; however, the large increase in the tyramine Km,app (17-fold) indicates that this
residue is important to amino donor binding. Since the corresponding glutamates found in D.
melanogaster AANATA (Glu-47)6 and AANATL7 (Glu-26), were identified as the general base
in catalysis, we wanted to confirm that Glu-29 in AANATL2 does not have the same function in
catalysis. This was accomplished by evaluating the pH-dependence on the acetyl-CoA kinetic
constants for the E29A mutant (Figure 5.4). Both, the kcat,app – acetyl-CoA and (kcat/Km)app – acetyl-CoA
profiles for E29A produced a bell-shaped curve with two apparent pKa values, similar to the
wild-type. The pKa,app values for this mutant were: kcat,app – acetyl-CoA = 7.0 ± 0.1 and 8.8 ± 0.1,
whereas the pKa,app values for the (kcat/Km)app – acetyl-CoA profile = 7.1 ± 0.2 and 9.1 ± 0.2. The
pKa,app value of ~7.0 for the E29A mutant corresponds to the general base in catalysis, whereas
the pKa,app value of ~9.0 is either the general acid in catalysis or the thiol group of the coenzyme
A product. Since the pKa,app value of ~7.0 was not abolished in the E29A pH-rate profile when
compared to the wild-type enzyme, it suggests that Glu-29 is not the general base in catalysis.
This is a striking difference from the two other D. melanogaster AANATL enzymes, where the
corresponding glutamate functions as the general base.6 When the glutamate is mutated to an
alanine in these enzymes, the pH-rate profile for the alanine mutant has a linear profile (instead
of a bell-shaped profile), where the general base pKa,app disappears, confirming that the
corresponding glutamates function as catalytic amino acids in D. melanogaster AANATA and
AANATL7.6, 36 This is likely not observed for AANATL2, because either Glu-29 is not the
general base or it functions in a redundant role with another amino acid residue that is not
identified to date. There is literature precedent for two residues functioning in a redundant role
as the general base in catalysis, as observed for sheep serotonin N-acetyltransferase (His-120 and
His-122).37-42
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Table 5.3. Steady-state kinetic constants for AANATL2 site-directed mutantsa
Acetyl-CoA
Mutant b

Km, app
(µM)

kcat, app
(s-1)

Wild-type
E29A
P30A
R138A
S167A
S171A
H206A

5±1
5.1 ± 0.2
3.3 ± 0.4
1.6 ± 0.1
40 ± 2
ndc
ndc

1.6 ± 0.1
0.37 ± 0.01
0.032 ± 0.001
0.313 ± 0.004
0.75 ± 0.01
ndc
ndc

Mutant d

Km, app
(µM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)
5

(3.1 ± 0.4) × 10
(7.2 ± 0.3) × 104
(10 ± 1) × 103
(1.9 ± 0.1) × 105
(1.9 ± 0.1) × 104
ndc
ndc
Tyramine

%
100
23
3.2
61
6.1
ndc
ndc

(kcat/Km)app
(M-1s-1)

%
Wild-type
5±1
1.47 ± 0.03
(2.9 ± 0.3) × 105
100
E29A
85 ± 5
0.37 ± 0.01
(4.4 ± 0.3) × 103
1.5
P30A
52 ± 7
0.043 ± 0.001
820 ± 110
0.28
R138A
6±1
0.26 ± 0.01
(4.5 ± 0.7) × 104
16
S167A
19 ± 2
1.03 ± 0.04
(5.3 ± 0.7) × 104
18
c
c
c
S171A
nd
nd
nd
ndc
H206A
ndc
ndc
ndc
ndc
a
Kinetic constants are reported as ± standard error (n=3).
b
The reaction rate was measured at a fixed saturating concentration of tyramine while varying the
concentration of acetyl-CoA.
c
The notation of “nd” is used for a mutant that did not display a rate of coenzyme A release at 412 nm.
d
The reaction rate was measured at a fixed saturating concentration of acetyl-CoA while varying the
concentration of tyramine.

The second pKa,app observed in the wild-type pH-rate profiles (pKa,app ~9.0) is either the
general base in catalysis or the thiol group of the CoA-SH product. The decrease in the kinetic
constants likely results from CoA-S- having greater affinity to AANATL2 than the CoA-SH
form (Kd, CoA-SH > CoA-S-). Two AANATL2 residues, Ser-167 and Ser-171, could function
as the general acid in catalysis. It has been previously proposed that the corresponding residue
of AANATL2 Ser-171 found in AANATA (Ser-186) is the general acid in catalysis.36
133

Therefore, we mutated both serines to an alanine and determined the kinetic constants in order to
delineate if these residues could function in catalysis. The S167A mutant produced a kcat,app
value that is 47% of the wild-type and a Km,app-acetyl-CoA and Km,app-tyramine that increased 8- and
4-fold, respectively. The minimal decrease in the S167A kcat,app value suggests that this residue
does not function directly in catalysis as the general acid.

However, the increase in both

substrates Km,app values indicates that this residue has an effect in substrate binding, possibly by
functioning in the organization of the active site.

The second serine mutant, S171A, was

completely deficient of catalysis, in which there was not a rate observed above the baseline
hydrolysis rate. This could indicate that Ser-171 is the general acid in catalysis or that this
residue has a critical function in one (or more) of the following: (a) structural component in the
formation of the active site, (b) participates in a “proton wire” by shuttling protons out of the
active site,6, 21, 38, 43 or (c) required for the proper positioning of the catalytic residues.

Since

S171A is catalytically deficient, we could not evaluate the mutant pH-rate profile to determine if
this residue corresponds to the second pKa,app value observed in the wild-type enzyme. It seems
unlikely that Ser-171 functions as a general acid, since it is thermodynamically unfavorable for a
serine residue to transfer a proton to a thiolate anion. The serine residue requires a substantial
depression in the pKa value (3-5 pH units) to function in the protonation of a thiolate. It is more
likely that this residue has a critical structural function, when disrupted, completely abolishes
catalysis.
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Figure 5.4. AANATL2 E29A pH rate profiles. pKa1 - slope = 0.7, pKa2 - slope = -0.8. (A) kcat,app for
acetyl-CoA. (B) (kcat/Km)app for acetyl-CoA. pKa1 - slope = 0.8, pKa2 - slope = -0.7.

5.3.4 Evaluation of AANATL2 amino acid residues that function in substrate binding and
regulation of catalysis
We further evaluated the other conserved residues to understand their respective function
in AANATL2. The amino acid residues, Pro-30, Arg-138, and His-220, were each mutated to an
alanine and their respective kinetic constants evaluated. To further understand the function of
these residues in the absence of a crystal structure, we indexed the data to that generated for the
corresponding residue from D. melanogaster AANATA and AANATL7.6

This will help

delineate a possible function for these conserved residues. The P30A mutant produced a k cat,app
value that is 2% - 3% of the wild-type enzyme, whereas the Km,app for tyramine increased
10-fold. In contrast to the data generated for tyramine, the Km,app for acetyl-CoA was similar to
the wild-type enzyme. These data suggest that Pro-30 has an important function in regulating
catalysis and amino donor substrate binding; however, has minimal impact on acetyl-CoA
binding.

The corresponding residue in D. melanogaster AANATA and AANATL7 was

proposed to function in regulating catalysis by being positioned on a "floppy loop" that occupies
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the binding site of acetyl-CoA.6 After acyl-CoA binding, the proline residue migrates ~ 8 Å to
open up the amine substrate binding pocket, in addition to having a direct stacking interaction
with the arylalkylamine substrate. The dynamics of the “floppy loop” that the proline residue
resides, functions in converting the enzyme from a low to high affinity state.6, 44 The significant
decrease in the kcat,app value and increase in the Km,app – tyramine could be indicative of a similar
function for AANATL2 Pro-30.

A conformation change resulting in the movement of

AANATL2 Pro-30 residue likely functions in converting AANATL2 from a low to high affinity
state. This movement of Pro-30, results in the formation of the amino donor binding pocket,
which gives a structural rational to the ordered sequential mechanism (discussed in section 3.2),
where acetyl-CoA binds first, followed by tyramine. This proposed function for Pro30 as a
catalytic switch and in direct binding of the arylalkylamine substrates is consistent with our data
and for other GNAT enzymes characterized to date.6, 44 It is unclear why there is not a change in
the Km,app – acetyl-CoA for the AANATL2 P30A mutant, as was observed for both corresponding
prolines from D. melanogaster AANATA and AANATL7. It could be from the relative position
of Pro-30 in the low affinity state, which does not have as dramtic effect on acetyl-CoA binding.
What can be delineated from these data is that AANATL2 Pro-30 functions in regulating
catalysis and amine substrate binding.
The next amino acid residue we evaluated was Arg-138. The R138A mutant produced a
kcat,app value that is 18% – 20% of the wild-type enzyme. This mutant also has a Km,app value for
acetyl-CoA and tyramine that was similar to that observed for the wild-type enzyme. Previously,
the corresponding arginine to alanine mutant in D. melanogaster AANATA and AANATL7
generated kinetic constants where the kcat,app and the Km,app for both substrates increased.6 The
arginine residue was proposed to function in the regulation of catalysis and the formation of the
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AANATL2 active site. This amino acid residue regulates catalysis by the formation of an
arginine:aspartate salt bridge, which regulates a conformation change responsible for product
(CoA-SH) release being rate-limiting.6

Based off the kinetic constants generated for the

AANATL2 R138A mutant, this residues does not have the same function as the corresponding
arginines in D. melanogaster AANATA and AANATL7. It is not clear why Arg-138 does not
have a similar function in AANATL2, but some possibilities include: (a) product release might
not be rate-limiting for AANATL2, (b) Arg-138 does not function in the formation of the
acyl-CoA binding pocket or the AANATL2 active site, and/or (c) Arg-138 is not found in a salt
bridge with any residue in AANATL2. It is possible that Arg-138 has more structural flexibility
in AANATL2, assisting in the observed promiscuity for acyl-CoA substrates. Further work to
define a crystal structure for AANATL2 is necessary to define the complete function this residue
contributes to enzyme structure and function.
The final AANATL2 amino acid residue evaluated in our study was His-206. The
H206A mutant did not yield a rate of catalysis above the background acetyl-CoA hydrolysis.
This mutation renders AANATL2 catalytically dead, suggesting an important function. The
corresponding residues in D. melanogaster AANATA and AANATL7 functions in general
active site organization and formation.6 It is possible a similar function can be attributed to
His-206 in AANATL2; however, then this residue must be more critical in the active site
organization. His-206 could function to organize the active site by positioning the catalytic
amino acid residues in their respective position for catalysis. It is also possible that this residue
functions as the general base in catalysis, since Glu-29 was identified to not catalyze this
chemistry. A crystal structure will be necessary to delineate the corresponding function for
His-206 in AANATL2.
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Interestly, all the amino acid residues evaluated for AANATL2 have variable differences
when compared to their corresponding residues in D. melanogaster AANATA and AANATL7,
even though AANATL2 catalyzes similar chemistry with similar substrates.6 So, one major
question is: why do we see these differences? Do these residues have a similar function in
AANATL2 as seen in AANATA and AANATL7; however, will have a different net effect on
binding and/or catalysis or do these residues have a completely different function in this
enzyme.6 One possible explanation for the variable differences is that AANATL2 evolved to
have a greater promiscusity for amine or acyl-CoA substrates, especially functioning in the
formation of long-chain N-acyldopamines and N-acylserotonins.11 We were the first group to
report an enzyme that could catalyze the formation of these fatty acid amides.11 One major
question yet to be solved is: what is the major structural/chemical differences between
AANATL2 and AANATA (or AANATL7) that allows for the conjugation of these long-chain
cell signaling lipids? Further work is nessessary to define these differences in order to fully
understand how these important lipids are biosynthesized.

Scheme 5.2. Proposed chemical mechanisms for D. melanogaster AANATL2. R = different
acyl chain length for acyl-CoA.
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5.3.5 Proposed chemical mechanism for AANATL2
Two possible chemical mechanisms consistent with the data generated herein are
illustrated in Scheme 5.2. Currently, our data does not delineate between these two possible
mechanisms.

The first possible mechanism (Scheme 5.2A) features: (a) ordered substrate

binding to generate the AANATL2•acetyl-CoA•tyramine ternary complex prior to catalysis, (b)
deprotonation of the positively charged amine of tyramine by a catalytic base, possibly through
ordered water molecules (“proton wire”), (c) nucleophilic attack of the carbonyl of the
acetyl-CoA thioester by the deprotonated tyramine to generate the zwitterionic tetrahedral
intermediate, (d) finally the breakdown of the zwitterionic tetrahedral intermediate with the
concomitant protonation of coenzyme A. The pKa,app values of ~7.0 and 9.0 in this possible
mechanism corresponds to a undefined general base and the thiolate of CoA-SH. The second
possible mechanism (Scheme 5.2B) consists of: (a) a sequential ordered mechanism with
acetyl-CoA binding first followed by tyramine to generate the AANATL2•acetyl-CoA•tyramine
ternary complex prior to catalysis, (b) nucleophilic attack of the carbonyl of the acetyl-CoA
thioester by tyramine to generate the zwitterionic tetrahedral intermediate, (c) followed by the
collapse of the zwitterionic tetrahedral intermediate by base catalyzed deprotonation of the
positively charge amine intermediate, in addition to acid catalyzed protonation of coenzyme A.
The pKa,app values of ~7.0 and 9.0 in this possible mechanism corresponds to a undefined general
base and general acid in catalysis. Both mechanisms in Scheme 5.2 have been proposed for
other GNAT enzymes,21, 44, 46-49 where the mechanism found in Scheme 5.2A being proposed for
D. melanogaster AANATA and AANATL7.6 In addition to this chemical mechanism, we
highlight that Pro-30, Ser-171, and His-206 are critical in regulating the AANATL2-catalyzed
reaction. Further work in solving a crystal structure is necessary to completely define the
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function of the amino acid residues evaluated herein, and to ultimately define the chemical
mechanism of AANATL2.
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Abstract
Arylalkylamine N-acetyltransferase (AANAT) catalyzes the penultimate step in the
biosynthesis of melatonin and other N-acetylarylalkylamides from the corresponding
arylalkylamine and acetyl-CoA.

The N-acetylation of arylalkylamines is a critical step in

Drosophila melanogaster for the inactivation of the bioactive amines and the sclerotization of
the cuticle. Two AANAT variants (AANATA and AANATB) have been identified in D.
melanogaster, in which AANATA differs from AANATB by the truncation of 35 amino acids
from the N-terminus. We have expressed and purified both D. melanogaster AANAT variants
(AANATA and AANATB) in Escherichia coli and used the purified enzymes to demonstrate
that this N-terminal truncation does not affect the activity of the enzyme.

Subsequent

characterization of the kinetic and chemical mechanism of AANATA identified an ordered
sequential mechanism, with acetyl-CoA binding first, followed by tyramine.

We used a

combination of pH-activity profiling and site-directed mutagenesis to study perspective residues
believed to function in AANATA catalysis. These data led to an assignment of Glu-47 as the
general base in catalysis with an apparent pKa of 7.0. Using the data generated for the kinetic
mechanism, structure/function relationships, pH rate profiles, and site-directed mutagenesis, we
propose a chemical mechanism for AANATA.
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Biogenic amines are important neuroactive amines found in both vertebrates and
invertebrates functioning as neurotransmitters, neuromodulators, or neurohormones via their
binding to specific receptors. In insects, the biogenic arylalkylamines are dopamine, tyramine,
serotonin, and octopamine, which function primarily as neurotransmitters.1 The pathways for
biosynthesis and degradation have important roles in the function of the arylalkylamines as a
balance between production and clearance is necessary to maintain the appropriate cellular
concentrations of the amines. Dysfunction in either of these opposing pathways would lead to
improper cellular levels of the arylalkylamines, leading to errors in the processes regulated by
them.2
The biogenic arylalkylamines are all derived in vivo from the cognate aromatic amino
acid (tyrosine or tryptophan) precursor. The precursor amino acid is initially hydroxylated by an
aromatic amino acid hydroxylase (tyrosine hydroxylase or tryptophan hydroxylase)3-4 and then
decarboxylated by aromatic L-amino acid decarboxylase (3,4-dihydroxylphenylalanine
decarboxylase)5 to generate either dopamine or serotonin, respectively. Tyramine is derived
from the decarboxylation of tyrosine by tyrosine decarboxylase,6-7 which can then be
β-hydroxylated to generate octopamine, a reaction that is catalyzed by tyramine -hydroxylase.810

One proposed inactivation reaction for the arylalkylamines is N-acetylation as catalyzed by

arylalkylamine

N-acetyltransferase

(AANAT):

acetyl-CoA

+

arylalkylamine

→

N-acetylarylalkylamine + CoA-SH.11-12 In addition to arylalkylamine inactivation, acetyl-CoA
dependent

N-acetylation

is

involved

in

cuticle

sclerotization13-16

and

melatonin

biosynthesis.17-18
AANAT (EC 2.3.1.87), also known as serotonin N-acetyltransferase and dopamine
N-acetyltransferase, has been identified in D. melanogaster11 and is a member of the GCN5-
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related N-acetyltransferase (GNAT) superfamily.19-20 The identification of N-acetyltransferase
activity for arylalkylamines in D. melanogaster was first shown in 1972 by Dewhurst et al.,11
followed by the initial characterization of AANAT in 1977 by Maranda and Hodgetts.21 In 1998,
Brodbeck et al.22 identified two biologically relevant variants, variant A (AANATA) and variant
B (AANATB), which differ by 35 amino acids found only at the N-terminus of the larger
AANATB.

Differential transcription of a single AANAT gene leads to the two different

AANAT variants.22 These variants are expressed in different tissues and at different life stages,
with AANATA being found in the brain, ventral nerve cord, and midgut during late stage
embryogenesis and in adults. AANATB is less abundant and is found in the brain only during
late pupal stages and in adults as well.22 AANAT enzymes have been characterized from many
organisms and are known to catalyze the rate-limiting penultimate step in the formation of
melatonin.20, 23-25 Melatonin is a hormone that is produced in a diurnal cycle24 (higher levels are
found at night) and is suggested to regulate the life-span of D. melanogaster.18
Eight putative AANAT-like enzymes (AANATL) have been identified in D.
melanogaster26 and are proposed to play a role in the biosynthesis of fatty acid amides.27-28
Herein, we report on the cloning, expression, purification, and characterization of D.
melanogaster AANATA and AANATB from recombinant E. coli.

Our data shows that

AANATA and AANATB are catalytically similar with respect to substrate specificities and
measured kinetic constants (Km,app, and kcat,app).

More detailed studies of AANATA were

performed to define the kinetic mechanism and to elaborate a chemical mechanism that is
consistent with both the pH rate profiles and data from a set of site-directed mutant enzymes.
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Experimental Procedures
Materials
Ambion RETROscript® Kit, ProBond™ nickel-chelating resin and MicroPoly(A)
PuristTM were purchased from Invitrogen. NdeI, XhoI, Antarctic Phosphatase, and T4 DNA
ligase were purchased from New England Biolabs. BL 21 (DE3) E. coli cells, XL10 E. coli
cells, and the pET-28a(+) vector were purchased from Novagen. Kanamycin monosulfate and
IPTG were purchased from Gold Biotechnology.

Oligonucleotides were purchased from

Eurofins MWG Operon and PfuUltra High-Fidelity DNA polymerase was purchased from
Agilent.

Benzoyl-CoA,

acetyl-CoA,

butyryl-CoA,

hexanoyl-CoA,

octanoyl-CoA,

decanoyl-CoA, oleoyl-CoA, and N-acetylserotonin were purchased from Sigma-Aldrich. All
other reagents were of the highest quality available from either Sigma-Aldrich or Fisher
Scientific.

Cloning of D. melanogaster AANATA and AANATB
A cDNA library was generated from D. melanogaster heads, using Ambion
RETROscript® Kit and MicroPoly(A) PuristTM kits.

AANATA (NCBI reference sequence

NM_079115.2) and AANATB (NCBI reference sequence NM_206212.1) were amplified from
the D. melanogaster head cDNA library using the following primers: forward 5’ GAC TCA TAT
GAT GGA GGA CGC ATT GAC C 3’ and reverse 5’ ATC CCT CGA GCT ACA GCT TGG
TCT GCG C 3’; forward 5’ GCT ACA TAT GAT GGA AGT GCA GAA GCT and reverse 3’
ATC CCT CGA GCT ACA GCT TGG TCT GCG C respectively. PCR was performed using
PfuUltra High-Fidelity DNA polymerase, using the following set of conditions: initial denaturing
step of 95°C for 2 min, then 30 cycles (95°C for 30 s; 60°C for 30 s; 72°C for 1 min), then a final
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extension step of 72°C for 10 min. The AANATA product or the AANATB PCR product was
inserted into a pET-28a(+) vector using the NdeI and XhoI restriction enzymes, yielding
expression vectors for each enzyme, AANATA pET-28a and AANATB pET-28a. The AANATA
pET-28a or AANATB pET-28a vectors were then transformed into E. coli XL10 competent cells
and cultured in Luria Broth (LB) media supplemented with 40 µg/mL kanamycin at 37°C. The
plasmids were purified using the Promega Wizard® Plus SV Minipreps DNA purification kit and
sequenced by Eurofins MWG operon.

In separate experiments, the AANATA pET-28a or

AANATB pET-28a vector was then transformed into E. coli BL21 (DE3) cells for expression of
AANATA or AANATB.

Expression and purification of AANATA and AANATB
The E. coli BL21(DE3) cells harboring either the AANATA pET-28a or AANATB
pET-28a expression vector was cultured in LB media supplemented with 40 µg/mL kanamycin
at 37°C. The cell cultures were induced at an OD600 of 0.6 with 1 mM isopropyl β-D-1thiogalactopyranoside for 4 h at 37°C. The final cultures were then harvested by centrifugation
at 5,000 g for 10 min at 4°C and the pellet was collected.
The pellet was then resuspended in 20 mM Tris pH 7.9, 500 mM NaCl, and 5 mM
imidazole; the cells were lysed by sonication; and the cellular debris was removed by
centrifugation (10,000 × g for 15 min at 4°C). The supernatant was loaded onto a column
packed with 6 mL of ProBond™ nickel-chelating resin. The column was first washed with 10
column volumes of 20 mM Tris-HCl pH 7.9, 500 mM NaCl, and 5 mM imidazole, then with 10
column volumes of 20 mM Tris-HCl pH 7.9, 500 mM NaCl, 60 mM imidazole, and AANATA
or AANATB eluted in 1 mL fractions of 20 mM Tris-HCl pH 7.9, 500 mM NaCl, and 500 mM
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imidazole.

Purity was assessed by a 10% sodium dodecyl sulfate-polyacrylamide gel

electrophoresis (SDS-PAGE) and visualized using Coomassie stain. Protein concentration was
determined using the Bradford dye binding assay.

Production of site-directed mutants
Each site-directed AANATA mutant was generated by the overlap extension method29
using PfuUltra High-Fidelity DNA polymerase under the following PCR conditions: initial
denaturing step of 95°C for 2 min, then 30 cycles (95°C for 30 s; 60°C for 30 s; 72°C for 1 min),
then a final extension step of 72°C for 10 min. Primers for each mutant (Table S1) were
designed with the Agilent QuickChange Primer Design tool. The AANATA mutant PCR products
were then inserted into a pET-28a(+) vector using the NdeI and XhoI restriction enzymes. The
AANATA mutant pET-28a vectors were transformed into E. coli XL10 competent cells and
cultured in LB media supplemented with 40 µg/mL kanamycin at 37°C. The plasmids were then
purified using the Promega Wizard® Plus SV Minipreps DNA purification kit and sequenced by
Eurofins MWG operon. Individual mutant AANATA proteins were expressed and purified as
described previously for the wild-type enzyme.

Measurement of enzyme assay
AANATA and AANATB activity was analyzed using Ellman’s reagent30 by measuring
the release of coenzyme A at 412 nm in 300 mM Tris-HCl pH 8.0, 150 µM DTNB, and the
desired concentrations of the amino donor substrate and acyl-CoA substrate. Initial velocities of
CoA-SH release were measured using a Cary 300 Bio UV-Visible spectrophotometer and the
resulting initial velocity kinetic data were fit to the desired equation using SigmaPlot 12.0.
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Steady-state kinetic constants were obtained by a fit to equation 1, where vo is the initial velocity,
[S] is the substrate concentration, Vmax is the maximal velocity, and Km is the Michaelis constant.

Equation 1

Apparent kinetic constants for each arylalklyamine substrate were determined by holding
acetyl-CoA at a fixed saturating concentration, whereas those for each acyl-CoA substrate were
determined by holding tyramine at a fixed saturating concentration at 22°C.

Assays were

performed in triplicate and the uncertainty for the (kcat/Km)app and the relative (kcat/Km)app values
were defined by using equation 2, where σ is the standard error.31

Equation 2

Kinetic mechanism and inhibitor analysis
Initial velocity patterns for acetyl-CoA and tyramine were produced by varying the
concentration of one substrate while holding the concentration of the other substrate at a fixed
concentration and fitting the data to equation 3 for an ordered Bi-Bi mechanism using Igor Pro
6.34A, where Kia is the dissociation constant for substrate A (acetyl-CoA), Kb is the Km for
substrate B (tyramine), and Ka is the Km for substrate A (acetyl-CoA). The two experimental
sets were generated by holding the tyramine concentration constant (5 µM, 10 µM, 25 µM, and
50 µM) and varying the concentration of acetyl-CoA, whereas the second set involved holding
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the concentration of acetyl-CoA constant (20 µM, 40 µM, 60 µM, and 100 µM) and varying the
concentration of tyramine.

Equation 3

The IC50 values for long-chain acyl-CoAs and tyrosol were determined at the Km
concentration for the appropriate substrate, tyramine at 12 µM or acetyl-CoA at 39 µM, while
varying the concentration of the respective inhibitor. The IC50 value was determined by a fit of
the resulting data to equation 4 using SigmaPlot 12.0, where vo is the initial velocity without
inhibitor, vi is the initial velocity at different concentration of inhibitor, and [I] is the inhibitor
concentration. The assays were performed in triplicate.

Equation 4

Dead-end inhibitor analysis was determined for both oleoyl-CoA and tyrosol.

The

inhibition patterns were determined by holding one substrate (acetyl-CoA or tyramine) at a fixed
concentration and varying the concentration of the other substrate, with each set carried out at a
different fixed concentration of the inhibitor.

The initial velocities from these inhibitor

experiments were fit to equations 5 – 7 for competitive, noncompetitive, and uncompetitive
inhibition, respectively, where vo is the initial velocity, Vmax is the maximal velocity, [S] is the
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substrate concentration, Km is the Michaelis constant, [I] is the inhibitor concentration, and Ki is
the inhibition constant. The assays were performed in triplicate.

Equation 5

Equation 6

Equation 7

Rate versus pH dependence
The pH dependence of the steady-state kinetic constants was determined for both
acetyl-CoA and tyramine as varied substrates while holding the other substrate at a fixed
concentration. Kinetic constants were determined at 0.5 pH intervals from pH 6.0 – 9.5, using
the

following

buffers:

MES

(pH

6.0

–

7.0),

Tris

(pH

7.0

–

9.0),

and

2-amino-2-methyl-1-propanol (AMeP) (pH 9.0 – 9.5). The resulting data were fit to equation 8
[log (kcat/Km

– acetyl-CoA)

or log (kcat/Km

– tyramine)]

pH-independent plateau using Igor Pro 6.34A.
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and equation 9 (log kcat), where c is the

Equation 8

Equation 9

Intrinsic fluorescence measurements for the determination of the coenzyme A dissociation
constant
Fluorescent spectra were generated with a JASCO FP-8300 spectrofluorometer equipped
with a circulating water bath maintained at 22°C. Emission spectra (excitation 280 nm, emission
290 – 300 nm) were measured in a 0.4 cm path length cell containing 400 µL of 300 mM TrisHCl, pH 8.0, varying concentrations of coenzyme A, and a fixed AANATA enzyme
concentration (wild-type – 0.08 mg/mL, R153A – 0.1 mg/mL). Fluorescent emission spectra
were acquired in triplicate, with a 50 nm/min scan speed, excitation bandwith – 5 nm, and
emission bandwith – 2.5 nm. The Kd for coenzyme A was determined by fitting the data to
equation 10 with SigmaPlot 12.0, where ΔF is the change in intrinsic fluorescence, ΔFmax is the
maximum change of fluorescence at infinite ligand concentration, Kd is the ligand dissociation
constant, and L is the ligand concentration.

Equation 10
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Product characterization
Product characterization was performed using a Phenomenex Kinetex™ 2.6 µm C 18 100
Å
(50

×

2.1

mm)

reverse

phase

column

coupled

with

an

Agilent

6540

liquid

chromatography/quadrupole time-of-flight mass spectrometer (LC/QTOF-MS) in positive ion
mode. An enzyme reaction comprised of 300 mM Tris-HCl pH 8.0, 500 µM acetyl-CoA, 1 mM
serotonin, and 5 µg AANATA to a final volume of 750 µL was incubated for 30 min at room
temperature. Then AANATA was removed from the reaction by centrifugation using a Millipore
10 kDa filter. The resulting sample was injected on the LC/QTOF-MS and the retention time
and

high

resolution

mass

commercial standard of N-acetylserotonin.

were

compared

with

a

Conditions for the LC/QTOF-MS analysis are

described in Dempsey et al.27

Results

Overexpression and purification of AANATA and AANATB
AANATA and AANATB were cloned from a cDNA library generated from the D.
melanogaster head (Figure S1). Both genes were inserted into a pET28a(+) vector that encodes
for a N-terminal His6-tag. Both AANATA and AANATB were purified using ProBond™
nickel-chelating resin to homogeneity, yielding 21 mg of AANATA or 3 mg of AANATB per
liter culture. Purity was assayed by SDS-PAGE (Figure S2) and determined to be >95% pure.
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Characterization of the amino acceptor substrates
Amino acceptors are defined herein as any acyl-CoA or aryl-CoA substrate. Our data for
AANATA and AANATB (Table 1) show that the amino acceptor specificities are approximately
the same for both enzymes. Both catalyze the formation of N-acyltyramines, utilizing a set of
straight-chain saturated acyl-CoAs with little variation in the Km,app values from acetyl-CoA to
hexanoyl-CoA for the two enzymes. A two-carbon increase in the acyl chain length to decanoylCoA has a dramatic and negative effect on catalysis. The Km,app is ~10-fold higher and the kcat,app
is ~10-fold lower than the values for octanoyl-CoA, such that the (kcat/Km)app,decanoyl-CoA is ~1% of
the (kcat/Km)app,octanoyl-CoA and only ~0.04% of the(kcat/Km)app,acetyl-CoA (Table 1).

Acyl-CoA

thioesters possessing an acyl-chain of ≥12 carbon atoms were not substrates for AANATA.
Although lauroyl-CoA and the longer-chain acyl-CoA thioesters were not AANATA substrates,
all were inhibitors of the enzyme with IC50 values  1.1 M. We find a slight increase in the
apparent binding affinity as the acyl-chain length increases, with the IC50 values decreasing from
1.1 M for lauroyl-CoA to 0.4 M for oleoyl-CoA (Table 2).
Benzoyl-CoA was also included in our analysis of amino acceptor substrates to facilitate
the comparison of our substrate specificity data with those published for other Nacyltransferases.32, 33 The (Km,app)benzoyl-CoA is similar to the values we measured for short-chain
acyl-CoA thioesters, but the kcat,app is significantly lower, such the (kcat/Km)app,benzoyl-CoA is ~1.5%
of the (kcat/Km)app,acetyl-CoA.

Characterization of the amino donor substrates
Amino donors are defined herein as compounds that contain a free amino moiety. The
substrate specificity of AANATA was evaluated using a set of arylalkylamine amino donors;
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these data show that tyramine is the amino donor with the highest (kcat/Km)app value at saturating
acetyl-CoA (Table 3). The kinetic constants for tyramine, with both AANATA and AANATB,
were very similar at saturating acetyl-CoA (AANATB, (Km,app)tyramine = 20 ± 3 M and
(kcat,app)tyramine = 16 ± 1 s-1 compared with the AANATA data in Table 3).
A group of other arylalkylamines was evaluated as AANATA amino donor substrates to
better understand the general structural features that affect binding and catalysis (Table 3). The
(kcat/Km)app values ranged over 2 – 3 orders of magnitude for the amino donors we included in
our study, with tyramine as the best amino donor with the highest (kcat/Km)app value and 3,4dimethoxyphenethylamine as the worst amino donor substrate with the lowest (kcat/Km)app value.
Tyramine and tryptamine exhibit relatively high (kcat/Km)app values (Table 3); therefore,
modification at the -position was explored to determine if their cognate amino acids could
serve as substrates. No activity was observed above the baseline rate of acetyl-CoA hydrolysis
for tyrosine, tyrosine methyl ester, or tryptophan. Next, we assessed tyrosine, tyrosine methyl
ester, and tryptophan as AANATA inhibitors at a 1.0 mM concentration, with the acetyl-CoA
(39 µM) and tyramine (12 µM) fixed at their respective Km,app values. No inhibition was
observed for these three compounds.
The amino donor substrate specificity for AANATA was further evaluated to determine if
non-arylalkylamines could serve as substrates.

The decarboxylated amino acids, histamine

(histidine) and ethanolamine (serine), were not AANATA substrates. Isoniazid, a first line drug
for the treatment of tuberculosis,34-36 was evaluated for AANATA binding. There was no
observed decrease in the rate of reaction in the presence of 1.0 mM isoniazid.
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Product characterization
The product formed from the AANATA reaction using acetyl-CoA and serotonin as
substrates was analyzed by LC/QTOF-MS in the positive ion mode. Identification of the product
formed from this reaction was compared with the commercial standard, N-acetylserotonin. The
AANATA product, N-acetylserotonin, was successfully identified by comparing by both
retention time on a Kinetex™ 2.6 µm C18 100 Å (50 × 2.1 mm) reverse phase column and the [M
+ H] (m/z) high resolution mass spectroscopy peak with the commercial standard (Table S2).

Kinetic mechanism and inhibitor analysis
Initial velocity plots were generated using tyramine and acetyl-CoA, by varying the
concentration of one substrate while holding the other substrate at a fixed saturated
concentration. The resulting double reciprocal plots (Figure 1) reveal a pattern of intersecting
lines, suggesting a sequential kinetic mechanism in which both substrates must be bound before
catalysis can occur. Inhibition studies were used to differentiate between a random and an
ordered sequential mechanism for AANATA, using oleoyl-CoA and tyrosol as the dead-end
inhibitors. Oleoyl-CoA is an analog of acetyl-CoA, whereas tyrosol is an analog of tyramine,
neither is a substrate for AANATA.

Oleoyl-CoA is competitive inhibitor (Figure 2) vs.

acetyl-CoA and a pure noncompetitive inhibitor vs. tyramine, with inhibition constants of 78 ± 8
nM and 150 ± 9 nM respectively. Tyrosol is uncompetitive vs. acetyl-CoA and competitive vs.
tyramine, with inhibition constants of 260 ± 10 µM and 302 ± 34 µM, respectively.
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pH dependence of the initial rates
We studied the pH dependence on the kcat,app and (kcat/Km)app for both acetyl-CoA and
tyramine. A rising pH profile was observed for both the (kcat/Km)app - acetyl-CoA (Figure 3C) and
(kcat/Km)app

- tyramine

(Figure 3D).

The data for both are best fit using a single pKa,app value,

yielding a pKa,app value of 7.1 ± 0.2 for the (kcat/Km)app - acetyl-CoA and a pKa,app value of 7.0 ± 0.3
for the (kcat/Km)app

- tyramine

profile. The kcat,app profile is bell-shaped (Figures 3A and 3B) for

acetyl-CoA and tyramine, yielding two ionizable groups with the same apparent pKa values,
consisting of an apparent pKaof 7.0 ± 0.1 and an apparent pKa of 9.8 ± 0.2.

Site-direct mutagenesis of amino acids proposed to function in acid-base catalysis

Our pH rate data indicate that AANATA catalysis involves one species with a pKa,app of
7.0 and a second species with a pKa,app of 9.8. The pH rate profile data provide the apparent pKa
values for the entities involved in catalysis but do not provide definitive information concerning
the identity of these chemical species. Identification of these species is critical for a more
complete understanding of the catalytic mechanism. One method we used to pinpoint residues
important for catalysis was the alignment of the primary sequences of known AANAT-like
(AANATL) enzymes from D. melanogaster (Figure S3).26
The general base in the AANATA catalytic cycle is likely Glu-47, Asp-142, or His-178,
based on our pH rate data, sequence alignment, and crystal structure (Figure 5).

We mutated

each of these residues to Ala to further define their respective role in catalysis. Mutation of Glu47 has the greatest effect on catalysis, in that the kcat,app value decreases ~15-fold and the
(kcat/Km)app decreases 10- to 200-fold relative to wild-type (Table 4).
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In addition, the E47A

mutant exhibited the same Km,app – acetyl-CoA value as the wild-type (within experimental error), but
did show a 10- to 15-fold increase in the Km,app – tyramine. The D142A and H178A mutants were
catalytically competent, exhibiting kcat,app values that were 80-170% of the wild-type. The small
decreases observed in the (kcat/Km)app values for the D142A and H178A mutants relative to wildtype resulted largely from increases in the Km,app values for both acetyl-CoA and tyramine (Table
4).
The AANATA crystal structure also point towards Tyr-64, Cys-181, Ser-182, or Ser-186
serving as the general acid (Figure 6) with a pKa,app of 9.8, visible in our pH rate studies. Each
of these residues was mutated to an Ala and the kinetic parameters for each mutant were
determined. The steady-state kinetic parameters for the C181A mutant are similar to the wildtype values.

In contrast with the C181A mutant, the Y64A and S186A mutants were

catalytically deficient, yielding (kcat/Km)app values that were 5-40% of wild-type, the decrease
mostly came from increases in the Km,app values (Table 4). Also, we constructed and evaluated
the S182A/S186A double mutant. The kinetic parameters for the S182A/S186A were similar to
those of the single S186A mutant, with the exception of an even higher Km,app - tyramine, such that
the value increased from 12 M for the wild-type, to 73 M for the S186A mutant, and to 190
M for the S182A/S186A double mutant (Table 4).

Site-direct mutagenesis of other amino acids conserved between AANATA and other AANAT-like
enzymes found in Drosophila

Three residues, Pro-48, Arg-153, and His-220, were conserved amongst AANATA and
the other Drosophila AANATL enzymes (Figure S3) and seem necessary in maintaining the
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AANATA structure.37

Each of these residues was mutated to an Ala in an attempt to

characterize their function (Figures S4 and S5). The results are similar for both the P48A and
H220A mutant enzymes, including (kcat/Km)app values that are 16- to 830-fold lower than wildtype resulting from decreases in the kcat,app values (16- to 870-fold lower) and increases in the
Km,app values for the substrates (4- to 40-fold higher) (Table 4). Notably, the (kcat /Km)app - tyramine
for the P48A mutant is 830-fold lower than that of wild-type. The pattern of results for the
R153A mutant is different as the (kcat/Km)app value is decreased only 2-5-fold relative to wildtype. The outcome for the R153 mutant results from a 5- to 7-fold increase in kcat,app values that
is balanced against 10- to 24-fold increases in the Km,app values for the acetyl-CoA and tyramine
substrates, respectively (Table 4).

Salt dependence of the initial rates
Arg-153 forms a salt bridge with Asp-46 and our evaluation of the R153A mutant
indicates that the Arg-153/Asp-46 is important in substrate binding and catalysis. The salt
dependence of kinetic parameters, if any, could provide additional support for this suggestion.
We found an increase in the kcat,app and Km,app – acetyl-CoA as the concentration of NaCl added to the
reaction buffer increased from 0 to 500 mM (0 mM NaCl – Table 1; 100 mM NaCl –
(kcat,app)acetyl-CoA = 49 ± 1, (Km,app)acetyl-CoA = 89 ± 10; 500 mM NaCl – (kcat,app)acetyl-CoA = 60 ± 1,
(Km,app)acetyl-CoA = 150 ± 10).

Coenzyme A (CoA-SH) binding to wild-type AANATA and the R153A mutant
The increase in kcat,app values for the R153A mutant was unexpected and may be related
to a decrease in the binding affinity of the AANATA for CoA-SH, one product of the reaction.
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The equilibrium constant for the dissociation of CoA from the enzymeCoA complex was
obtained by measuring the quenching of intrinsic protein fluorescence at different CoA-SH
concentrations for both wild-type AANATA and the R153A mutant.

From these studies, we

determined that the Kd, wild-type = 400 ± 50 µM and the Kd, R153A = 950 ± 110 µM (Figure 4).

Discussion

Comparison of AANATA and AANATB
AANATA differs from AANATB by an N-terminal truncation of 35 amino acids. Both
variants are physiologically relevant in D. melanogaster, but differences are known in the
expression patterns for each enzyme with respect to tissue distribution and stages of
development.22 Although the differences in the expression patterns for the two enzymes suggest
that AANATA and AANATB do not serve the same metabolic role in D. melanogaster, it is not
known if truncation of AANATA to AANATB has any effect on the catalytic efficiency of the
enzyme. A comparison of the kinetic constants for AANATA and AANATB show that the two
enzymes are catalytically equivalent, at least for the substrates included in our study. Thus, our
data provide no clear insight regarding the differential expression of two AANAT variants in
Drosophila. Most likely, the presence of AANATA and AANATB is important for differences
in (a) subcellular localization for the two enzymes, (b) substrate specificities between the two
enzymes that were not revealed by our work, (c) the modes regulation for the two enzymes,
and/or (d) the post-translational modification of the two enzymes. Potential differences in posttranslational modification patterns between AANATA and AANATB could be important
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because the activity of sheep serotonin N-acetyltransferase is regulated by the phosphorylation of
Thr/Ser residues located at N-terminal or C-terminal regions of the protein.38-46

Substrate specificity and the potential role of AANATA in fatty acid amide biosynthesis
We have had a longstanding interest in the biosynthesis of the fatty acid amides, a broad
family of cell signaling lipids. One straightforward route to the fatty acid amides would be the
reaction of a biogenic amine with an acyl-CoA, a possibility that has received relatively little
attention.

The identification of N-acyltransferases that catalyze the acyl-CoA-dependent

formation of N-fatty acylglycines,47 N-fatty acylserotonins,27 and N-fatty acyldopamines27 means
that this chemistry should be examined in greater detail. Fatty acid amides are produced in D.
melanogaster,48 but the enzyme(s) responsible for their production in the fly are largely
unknown.

There is a single report of an enzyme, arylalkylamine N-acyltransferase like 2

(AANATL2),

that

catalyzes

the

formation

of

long-chain

N-acylserotonins

and

N-acyldopamines.27 We undertook a detailed investigation of the substrate specificity of
AANATA to address this question.
We first evaluated the substrate specificity for the acyl-CoA thioester substrates. The
Km,app

–acyl-CoA

values were similar for acetyl-CoA through octanoyl-CoA indicating that the

AANATA active site can effectively bind the straight-chain acyl chain with lengths of 8 carbon
atoms. However, the kcat,app decreased ~30-fold as the acyl change length increased from acetylCoA to octanoyl-CoA, with acetyl-CoA being the substrate with the highest (kcat/Km)app value.
Lengthening the acyl chain to >8 carbon atoms resulted in a dramatic effect on the kinetic
parameters. Decanoyl-CoA is a poor substrate relative to the shorter-chain acyl-CoA substrates,
with a Km,app value of 220 M, >10-fold higher than octanoyl-CoA, and a kcat,app value of 0.04 s-1,
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7-fold lower than octanoyl-CoA. Lauroyl-CoA and longer-chain acyl-CoA thioesters are not
AANATA substrates, but are inhibitors of the enzyme, with IC50 values of 0.4 – 1. 0 M. These
data show that acetyl-CoA is best positioned for nucleophilic attack by the amino group of
tyramine within the AANATA active site and that an increase in the length alters the
arrangement of the two substrates into suboptimal positions, resulting in a decrease in the kcat,app.
The AANATA active site must have sufficient flexibility to accommodate the lengthening acyl
chain, up to 8-carbon atoms, and still position the two substrates for chemistry with reasonable
effectiveness as the (kcat/Km)app for octanoyl-CoA is 3% of the acetyl-CoA value. The limit of
active site “tolerance” is an acyl chain of 10 carbon atoms because decanoyl-CoA is a poor
substrate with a (kcat/Km)app value that is 0.04% of the acetyl-CoA value. Acyl-CoA thioesters
with acyl chains longer than 10 carbon atoms bind to AANATA and are not substrates; the longchain acyl-CoA thioesters either prevent tyramine binding in a position that allows chemistry to
occur or actually prevent tyramine from binding. Thus, the long-chain acyl-CoA thioesters are
inhibitors of AANATA.
Amino donors are defined herein as compounds that contain a free amino moiety. The
substrate specificity of AANATA was evaluated using a variety of arylalkylamine amino donors
and these data show that tyramine is the amino donor with the highest (k cat/Km)app value. The
kinetic constants for tyramine, with both AANATA and AANATB, were very similar
(AANATB, Km,app- tyramine = 20 ± 3 M and kcat,app -tyramine = 16 ± 1 s-1 compared to the data for
AANATA in Table 3).
We evaluated a number of biologically important arylalkylamines as AANATA
substrates, including tyramine, octopamine, dopamine, tryptamine, norepinephrine, and
serotonin. These arylalkylamines are found in vivo and potentially could be found as the amine
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partner in the fatty acid amide family. All are respectable AANATA substrates with tyramine
exhibiting the highest (kcat/Km)app value (at saturating acetyl-CoA) and serotonin the worst, with
a ratio of (kcat/Km)app,tyramine/(kcat/Km)app,serotonin = 6 (Table 3). The differences in the kinetic
parameters amongst this set of biologically relevant arylalkylamines is reflected in the Km,app
values, whereas the kcat,app values are similar for these amino donor substrates. Our results for
the substrate specificity of AANATA with respect to both the acyl-CoA and biologically relevant
arylalkylamines provide evidence that the fatty acid amides can be produced by the conjugation
of biogenic amines to an acyl-CoA. However, AANATA is probably not involved in the in vivo
biosynthesis of long-chain fatty acid amides because the long-chain fatty acyl-CoA thioesters are
not substrates. The major function of AANATA in the cell is likely amine acetylation, a reaction
important in neurotransmitter inactivation, melatonin biosynthesis, and cuticle sclerotization.
Our discovery of the AANATA-catalyzed acetylation of 5-methoxytryptamine opens up
an alternative route for melatonin biosynthesis. Melatonin is produced from L-tryptophan in a
series of four steps:
acetylation

to

(melatonin).49-50

hydroxylation to 5-hydroxytryptophan, decarboxylation to serotonin,

N-acetylserotonin,

and

methylation

to

N-acetyl-5-methoxytryptamine

Our data on the AANATA-catalyzed acetylation of serotonin and 5-

methoxytryptamine, (kcat/Km)app,5-methoxytryptamine/(kcat/Km)app,serotonin ~ 2, show that both of these
amines are effective AANATA substrates, similar to that reported by Falcon et al.51 It seems
plausible that melatonin biosynthesis could involve either serotonin acetylation followed by
methylation or serotonin methylation followed by acetylation.

One question is whether

5-methoxytryptamine is biosynthesized in vivo to allow direct acetylation to melatonin.
5-Methoxytryptamine was shown to have a time-dependent increase in hamster skin cells upon
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incubation with serotonin.52

Further studies are required to address this possible route to

melatonin in D. melanogaster.
In addition to the biologically relevant amines, a larger group of arylalkylamine
substrates were analyzed to understand the general structural features of the amino donor
substrates that affect AANATA binding and/or catalysis. These include indole and phenyl ring
modifications, the length of the spacer group between the amino group and the phenyl ring,
modification of the α- and β-position on the ethylamine spacer group, and other
non-arylalkylamines that may function as amine substrates.
The ring-substituted analogs of tyramine included herein are dopamine, phenethylamine,
3-(trifluoromethyl)phenethylamine,

3-methoxyphenethylamine,

4-methoxyphenethylamine,

3,4-methylenedioxyphenethylamine, 3,4-methoxyphenethylamine, and 7-methyltrypamine. All
are respectable AANATA substrates with kcat,app values that are approximately the same as that
for tyramine (19 sec-1) or higher. The tyramine analog with the highest kcat,app value of 71 s-1 is
3-(trifluoromethyl)phenethylamine. However, there is considerable variation in the Km,app values
amongst the tyramine series, ranging from 12 M for tyramine to 3200 M for 3,4dimethoxyphenethylamine (Table 3).

Similar trends were observed in comparing the kinetic

parameters between tryptamine and the ring-substituted tryptamine analog: little variation in the
kcat,app values with greater differences being found for the Km,app values.
Tyramine and tryptamine exhibit relatively high (kcat/Km)app values allowing us to also
examine how changes in the spacer group between the amine moiety and the phenyl or indole
ring affects AANAT catalysis. First, we determined that the cognate amino acids, tyrosine and
tryptophan, were neither substrates nor inhibitors of AANATA, as were the results for tyrosine
methyl ester. These data demonstrate that the presence of an -carboxylate or -carboxylate
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ester dramatically decrease AANATA binding affinity, mainly due to steric interference in the
active site.

In contrast with our data on the effect of -substitution of tyramine, we find that

modification at the β-position has only a small effect on binding and catalysis as octopamine,
norepinephrine, and β-methylphenethylamine are all AANATA substrates with (kcat/Km)app
values that are 20-80% of the value for tyramine. The relatively minimal effect of β-substitution
is on binding affinity as all of the β-substituted tyramines have approximately the same kcat,app
values.

This pattern holds true for the comparison of dopamine to norepinephrine

(β-hydroxyldopamine), which both have approximately the same Km,app, kcat,app, and (kcat/Km)app
values. Also, we interrogated the importance of the spacer length between the amino group and
the phenyl ring using another set of tyramine analogs. Decreasing the spacer length from two
methylene groups to one methylene group yields benzylamine, C6H5-CH2-NH2. Benzylamine is
not a substrate. Increasing the spacer length from two methylene groups to four methylenes
yields 4-phenylbutylamine, C6H5-(CH2)4-NH2.

4-Phenylbutylamine is a poor AANATA

substrate, exhibiting a (kcat/Km)app that is 120-fold decreased relative to tyramine, with the largest
extent of the decrease reflected in a ~20-fold increase in the Km,app (12 M for tyramine vs. 270
M for 4-phenylbutylamine, Table 3).

Our specificity studies on the amino donor substrates

again demonstrate that the AANATA active site is flexible, being able to accommodate a variety
of

structures

particularly

analogs

of

tyramine

or

tryptamine,

with

either

a

β-substitution of the ethylamine moiety or the addition of hydrophobic bulk to the phenyl or
indole rings. AANATA is less tolerant of substitution at the -substitution of the ethylamine
moiety or changing the length of the methylene spacer between the amino group and the ring.
Substitution at the α-position seems to eliminate binding to AANATA while alternation in the
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length of space hinders the optimal positioning of amino donor for nucleophilic attack of acetylCoA.
The availability of recombinant AANATA has afforded us the opportunity to explore the
specificity of this enzyme for both its acyl-CoA and amine substrates. The structure-activity
information obtained from this work will be valuable for the future development of inhibitors
targeted against the N-acyltransferases, particularly those involved in fatty acid amide
biosynthesis. Errors in fatty acid amide metabolism are correlated to human disease53-56 and
considerable effort has been devoted to development of inhibitors for the major enzyme
responsible for fatty acid amide degradation, fatty acid amide hydrolase (FAAH).57

Kinetic mechanism and inhibitor analysis

An intersecting initial velocity double reciprocal plot indicates that a ternary complex is
formed prior to catalysis for AANATA. The dead-end inhibitor patterns for oleoyl-CoA and
tyrosol point towards an ordered sequential mechanism, with acetyl-CoA binding first, followed
by tyramine binding to generate the AANATA•acetyl-CoA•tyramine ternary complex before
catalysis occurs. An ordered sequential mechanism with acetyl-CoA binding first suggests that
acetyl-CoA binding drives a conformational change to convert the amine binding pocket from a
low affinity state to a high affinity state. Oleoyl-CoA is a known inhibitor of human and sheep
serotonin N-acetyltransferase and the inhibition is not a detergent-effect of the C18-tail because
the IC50 for oleic acid is 500-fold higher than that for oleoyl-CoA.58, 59 Tyrosol is an analog of
tyramine, with the amine being replaced with a hydroxyl group. A rate was not observed for
tyrosol acetylation at 100 mM, which shows that AANATA will not catalyze the O-acylation of
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at least this substrate. Tryptophol, a similar analog of tryptamine, is an inhibitor of sheep
serotonin N-acetyltransferase and was useful in studies to define the kinetic mechanism of this
enzyme.60 An ordered sequential mechanism for D. melanogaster AANATA is consistent with
isothermal calorimetry data demonstrating little binding of dopamine to AANATA in the
absence of acetyl-CoA,37 as well as with the kinetic mechanism proposed for sheep serotonin
N-acetyltransferase.60

Site-directed mutagenesis to match catalytic amino acids to the measured pKa,app values

We employed protein sequence alignments, pH rate studies, site-directed mutagenesis of
targeted amino acids, and information from the AANATA crystal structure37 to propose a
chemical mechanism for the AANATA-catalyzed formation of N-acylarylalkylamides. Primary
sequence alignment of AANATA with other D. melanogaster AANATL enzymes identified a
number of conserved residues that might function in catalysis. A primary sequence alignment of
D. melanogaster AANATA with sheep serotonin N-acetyltransferase, identified a low sequence
alignment score (< 12%) and the catalytic core of the mammalian ortholog61-66 is not conserved
in the fly enzyme.

Therefore, AANATA could catalyze the formation of the same

N-acetylarylalkylamide products as the mammalian ortholog with either a completely different
chemical mechanism, or at minimum, different catalytic amino acid residues.
Our pH rate studies implicate two chemical species with pKa,app values of 7.0 and 9.8 in
AANATA catalysis (Figure 3). The pKa,app value of 7.0 was observed in both the kcat,app and the
(kcat/Km)app profiles and, most likely, reflects deprotonation by Glu-47. Evidence consistent with
the proposal that Glu-47 serves as a general base in the AANAT catalytic cycle includes the
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conservation of Glu-47 amongst the D. melanogaster family of AANATL enzymes, the catalytic
deficiency of the E47A mutant, and the disappearance of the pKa,app = 7.0 in the pH rate profile
of the E47A mutant. Cheng et al.36 report that the log(kcat/Km)app vs. pH profile for the E47A
mutant is linear, with a slope of 0.3, probably resulting from hydroxide chemically rescuing Glu47 as the base in AANATA catalysis.

Furthermore, a Glu residue has been proposed as the

general base in other GNAT enzymes such as members of the Gcn5/PCAF family of histone
N-acetyltransferases67-68 and human spermidine/spermine N1-acetyltransferase.69-70
A pKa,app = 9.8 was only observed in the pH rate profiles for kcat,app indicating that this
chemical species only contributes to catalysis after the first irreversible step (Figures 3A and
3B). We must point out that Ellman’s reagent is unstable and the acyl-CoA substrates are
subject to rapid base-catalyzed hydrolysis at pH > 9.5. Since we measure AANAT activity by
assaying for CoA release using Ellman’s reagent, our pH rate studies are confined to pH values 
9.5. Thus, the lack of a pKa,app  9.8 in our (kcat/Km)app profiles may reflect our inability to
conduct measurements at pH > 9.5 and the presence of pKa,app = 9.8 for in the kcat,app profiles is
based on a fit of our data, all generated at pH  9.5, to equation 9. Cheng et al.37 extended their
studies to pH 10 and found a clearly defined pKa,app of 9.0  0.2 in their pH rate profiles for
(kcat/Km)app. Experimental differences between our work and that of Cheng et al.37 render direct
comparisons of the respective data sets difficult, but it seems likely that a chemical species with
a pKa = 9-10 does participate in AANATA catalysis.
With this in mind, we sought to identify the chemical species that would serve as a
general acid in AANATA; possibilities include Tyr-64, Cys-181, Ser-182, Tyr-185, or Ser-186
(Figure 6). Cys-181 and Tyr-185 were eliminated because the corresponding alanine substitution
mutants (C181A and Y185A) showed little to no effect on the kcat,app relative to wild-type (Table
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4 and ref. 36). Tyr-64 is located within a non-polar binding pocket for the amino donor
substrate37 and comparison of the Y64A mutant to wild-type reveals increases in the Km,app
values for both substrates (2-fold for acetyl-CoA and 6-fold for tyramine) and only a ~2-fold
decrease in the kcat,app values (Table 4). Most likely, Tyr-64 is involved in substrate binding and
is not the general acid in AANATA catalysis. Ser-182 and Ser-186 remain as potential general
acids. The mutation of both to Ala decreases kcat,app relative to wild-type, 12-fold for the S182A
mutant and 3- to 5-fold for the S186A mutant (Table 4 and ref. 36). The pH rate profiles for the
S182A and S186A mutants are pH independent37 at pH  7.0, meaning that the pKa,app of 9.0 is
not observed for these two mutant enzymes. Based on these data and the close proximity of both
Ser-182 and Ser-186 to the acetyl-CoA thiol group, 4.0 Å and 4.1 Å respectively (Figure 7), it is
conceivable that either Ser-182 or Ser-186 is the general acid in AANATA catalysis. In fact,
Cheng et al.37 argue that Ser-186 is the general acid, functioning to protonate the departing
thiolate anion of CoA to complete the catalytic cycle. An argument could be made that Ser-182
and Ser-186 serve redundant roles in catalysis where one of these serines is the general acid,
whereas the other serine serves to depress the pKa of the catalytic serine. In the absence of the
catalytic serine, the other serine could chemically “rescue” the function of the other serine.
We do not favor either Ser-182 or Ser-186 as the general acid in AANATA catalysis.
This would require a significant depression of 3-5 pH units in the pKa for Ser-182 or Ser-186
plus we would expect the S182A/S186A double mutant to be dramatically impaired as a catalyst
relative to either the S182A or S186A single mutant.

Instead, we find that the S182A/S186A

double mutant exhibits a kcat,app similar to the S186A mutant; the largest difference in the
S182A/S186A is an increased Km,app for tyramine. A tyrosine serves as the general acid for other
GNAT enzymes, but the mutation studies eliminate the two active tyrosine residues, Tyr-64 and

176

Tyr-185, as possibilities. There are no other obvious candidate amino acids to serve as a general
acid within the acetyl-CoA binding pocket.37
We propose that the pKa,app of 9.8 in our pH rate profiles (and the pKa,app of 9.0 from
Cheng et al.37) represents the pKa of the thiol group of CoA, which has been reported to range
from 9.6-10.4.71-72 Formation of the protonated CoA-SH product results from the collapse of the
tetrahedral intermediate (Scheme 1), as proposed for other N-acyltransferases.73-75

The

deprotonation of CoA-SH to CoA-S-, in the AANATA active site, inhibits product release,
accounting for the decrease of kcat,app at pH > 9. This was likely not observed in the (kcat/Km)app
profiles because of either the difficulty in measuring the kinetic constants at high pH (instability
of DTNB and/or the rapid hydrolysis of acetyl-CoA) or the protonation of CoA-S- occurs after
the first irreversible step in catalysis. Our suggestion obviates the need for an active site residue
that serves as the general acid and is consistent with the data available for AANATA.

Site-directed mutagenesis of amino acids important in substrate binding and AANAT structure
As detailed previously, we mutated a number of amino acids in AANATA in an attempt
to match an active site amino acid to the pKa,app values identified in the pH rate profiles. The set
of AANATA mutants that we produced also provide information regarding the amino acids
involved in substrate binding and, point towards structural changes in the protein.

In silico

docking of dopamine into the AANATA structure with acetyl-CoA bound suggests that the
amino donor substrate binds into a hydrophobic binding pocket containing Phe-43, Leu-61, Tyr64, Ile-116, and Ile-145.37 Our results are consistent with the docking results as the Km,app
tyramine

–

values for the E47A, P48A, and Y64A mutants are >6-fold higher than the wild-type

(Table 4).

The Km,app

– tyramine

values for H220A and S186A single mutants also are 6-fold
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higher than wild-type, indicating that these amino acids contribute to the binding of the amino
donor substrate. Of the mutants with a 6-fold increase in the Km,app – tyramine value relative to the
wild-type value, only the E47A and S186A mutants shown no difference in the Km,app – acetyl-CoA,
indicating that Glu-47 and Ser-186 contribute little to acetyl-CoA binding. The Km,app

– tyramine

value for the S182A/S186A double mutant is significantly higher than wild-type (190 M vs. 12
M), suggesting that Ser-182 and Ser-186 function synergistically in maintaining the proper
active site architecture for optimal binding to the amino donor substrate. The binding pocket for
acetyl-CoA is more extensive than the pocket for the amino donor substrate and includes the
amino acids involved in catalysis.
There are amino acids uniquely involved in acetyl-CoA binding, which there is a change
of only the value for the Km,app

– acetyl-CoA

upon mutation. This was observed for the D142A and

H178A mutants: Km,app – tyramine values that are approximately the same as wild-type and Km,app –
acetyl-CoA

values that are 2- to 3-fold higher than wild-type. Both the Km,app

acetyl-CoA

values for the P48A, Y64A, R153A, and H220A mutants are all different from and

– tyramine

and Km,app

–

greater than the wild-type values (Table 4). These amino acids are either involved in domains
within AANATA that overlap between the acetyl-CoA and amino donor binding pockets or are
key to maintaining the AANATA structure in a conformation that is optimal for substrate
binding. Overlap between the binding sites for the two substrates is expected because the
binding pocket for acetyl-CoA is more extensive than the pocket for the amino donor substrate36
and should include the amino acids that are required to position the amino group of the amino
donor for nucleophilic attack at the carbonyl of the acetyl-CoA thioester moiety. In addition, the
synergistic effect of acetyl-CoA binding to convert the amine binding pocket from a low affinity
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state to a high affinity state means that specific amino acids important for acetyl-CoA binding
can also have a dramatic effect on amine binding.
In comparing the kinetic constants of our mutants to wild-type AANATA (Table 4), we
find that three of our mutants stand out: E47A, P48A, and R153A. We argue that Glu-47 is the
catalytic base and find, as anticipated, that E47A is catalytically deficient with relatively low
kcat,app values. The AANATA structure containing bound acetyl-CoA37 reveals a set of ordered
water molecules between the carboxylate of Glu-47 and the carbonyl of the acetyl-CoA thioester.
The distance from the carboxyl of Glu-47 to the carbonyl of the acetyl-CoA thioester is 6.8 Å.
We suggest that Glu-47 functions as a general base to enable the water-assisted deprotonation of
the positively charged amino group of the donor substrate (a “proton wire”) and to properly
position the neutral amine for attack at the carbonyl of the acetyl-CoA thioester (Scheme 1).
Elimination of the anionic carboxylate of Glu-47 by mutation to Ala would alter the positions of
the ordered water molecules (perhaps, even resulting in their loss) and would decrease the
affinity for only the amino donor substrate, as found for the E47A mutant.
Pro-48 is found at the beginning of a flexible loop and is positioned within the predicted
binding pocket for the amine donor substrate (Figure S6).

We superimposed the AANATA

crystal structure (PDB code: 3TE4)37 with sheep serotonin N-acetyltransferase (PDB code:
1CJW)61 using Protein Binding Site Tools (ProBiS Tools) and found that Pro-48 from D.
melanogaster AANATA is equivalent to Pro-64 from sheep serotonin N-acetyltransferase. In
sheep serotonin N-acetyltransferase, Pro-64 is also positioned on a flexible loop that undergoes a
major structural change to alter the amino donor substrate binding pocket from a low to high
affinity state.76-77 In the low affinity state, Pro-64 occupies the acetyl-CoA binding pocket,
whereas in the high affinity state, Pro-64 moves ~8 Å to form a base-staking interaction with the
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tryptamine moiety of the tryptamine-acetyl-CoA bisubstrate inhibitor co-crystallized with the
sheep enzyme.
acetyl-CoA

Our data for the P48A mutant, low kcat,app and high Km,app – tyramine and Km,app –

values, suggest that Pro-48 in AANATA functions similarly to Pro-64 in sheep serotonin

N-acetyltransferase and further hints that protein dynamics could regulate catalysis for
AANATA.

His-220 is in van der Waals contact with Pro-48 in AANATA (Figure 8).

Replacement of His-220 with Ala will alter this interaction and, similar to the data for the P48A
mutant, would lead to the observed increases in the Km,app – tyramine and Km,app – acetyl-CoA values for
the H220A mutant.
The R153A mutant is intriguing, with higher values than wild-type values for kcat,app,
Km,app – tyramine, and Km,app – acetyl-CoA. The ~6-fold increase in kcat,app is balanced against 10- to 20fold increases in the Km,app values, such that the (kcat/Km)app value for the R153A mutant is lower
than wild-type by 40-80%. As revealed from the AANATA structure with acetyl-CoA bound,37
Arg-153 participates in a water-mediated hydrogen bond with the carbonyl amide of the
pantothenate moiety (Atom: O9P) of acetyl-CoA and in a salt-bridge to Asp-46 (Figure 9). The
increase in the Km,app values for both substrates suggests that Arg-153 is not only critical in
acetyl-CoA binding pocket, but also in forming the binding pocket for the amine substrate. The
increase in the kcat,app value suggest that Arg-153 contributes to a rate-determining step in
catalysis, related to the salt-bridge between Arg-153 and Asp-46. We suspect that the Arg153/Asp-46 salt bridge is critical to an AANATA conformation that decreases the rate of CoASH release, such that product release is, at least, partially rate limiting. Partially rate-determining
CoA-SH release has been identified in many other N-acetyltransferases.20, 66, 78-79 Elimination of
the Arg-153/Asp-46 salt bridge in the R153A increases the rate of CoA-SH release, reflected in
the increase in kcat,app, but decreases the affinity of AANATA for both substrates, reflected in the
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increases in the Km,app values. Another approach to decrease the influence of the Arg-153/Asp46 salt bridge on the rate of CoA-SH release would be to increase the salt concentration in the
reaction buffer. Our prediction being that that a greater salt concentration would mimic the
pattern of results we obtained for the R153A mutant, which is exactly what we found. The
values for the kcat,app and Km,app - acetyl-CoA increased as the concentration of added NaCl increased
from 0 to 500 mM. Similar data were obtained for sheep serotonin N-acetyltransferase,25 which
was argued to increase the rate of CoA-SH release by shielding charge-charge interactions of the
enzyme with the anionic phosphates of acetyl-CoA. Also, we determined the Kd for CoA-SH
binding to both wild-type AANATA and the R153A mutant by measuring the quenching of
intrinsic protein fluorescence as a function of [CoA-SH], the Kd, wild-type = 400 ± 50 µM and Kd,
R153A

= 950 ± 110 µM (Figure 4). The 2.4-fold decrease in affinity for the binding of CoA-SH to

the R153A mutant is in reasonable agreement with the (kcat,app)wild-type/(kcat,app)R153A ratio of 5-6
(Table 4). The salt dependent increase in both the kcat,app and Km,app – acetyl-CoA and the increase in
Kd for CoA-SH for the R153A mutant provide evidence that the salt bridge between Arg153/Asp-46 is important in decreasing the rate of CoA-SH release from wild-type AANATA.
Similar to our data for the P48A mutant, our data for the R153A mutant point towards protein
dynamics regulating catalysis for AANATA.

Chemical mechanism for AANATA catalysis
A chemical mechanism for the catalytic cycle for AANATA, consistent with our new
data and previously published data,21, 37 is illustrated in Scheme 1. The mechanism features (a)
chemistry occurring after the formation of the AANATA•acetyl-CoA•tyramine complex, (b)
Glu-47 serving as a general base to facilitate water-assisted deprotonation of tyramine, (c)
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nucleophilic attack of deprotonated tyramine at the carbonyl of the acetyl-CoA thioester to form
a zwitterionic tetrahedral intermediate, (d) collapse of the tetrahedral intermediate with the
concomitant protonation of CoA, and (e) ordered product release with CoA-SH departing last to
regenerate AANATA for the next round of catalysis.

Our only evidence for the ordered product

release is the data showing that CoA-SH binds to AANATA in the absence of N-acetyltyramine
(Figure 7) and is consistent with the ordered binding of substrates, acetyl-CoA binding first. The
release of CoA-SH is partially-rate determining resulting from AANATA conformation that has
relatively high affinity for CoA-SH. The Arg-153/Asp-46 salt bridge is critical to maintaining
AANATA

in

this

conformation

and

the

affinity for

CoA-SH

increases

as

the

CoA-S- thiolate forms at higher pH.
One issue remaining with this mechanism is the roles played by Ser-182 and Ser-186 in
catalysis, given that Ser-186 was proposed to serve as the general acid in AANATA catalysis.37
A preponderance of the data for the S182A, S186A, and S182A/S186A mutants seem to rule out
a direct catalytic role for both Ser-182 and Ser-186, plus proton transfer from a serine hydroxyl
to a thiol is thermodynamically unfavorable. Instead, we suggest that Ser-182 and Ser-186 are
involved in an elaborate network of hydrogen bonds that function in both substrate binding and
catalysis (Figure 5). Mutation of Ser-182 and/or Ser-186 to alanine alters the hydrogen-bonding
network, changing the active site architecture. This alteration of the active site is reflected in the
changes observed in the kcat,app and Km,app values for the S182A, S186A, and S182A/S186A
mutants.
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Conclusions
We identified that D. melanogaster AANATA will catalyze the formation of
N-acylarylalkylamides from a broad array of corresponding acyl-CoA and arylalkylamine
substrates. These data validate the potential role of N-acyltransferases in fatty acid amide
biosynthesis and provide structure-activity data for the future development of inhibitors to this
class of enzymes. A chemical mechanism for AANATA, consistent with all the data available
for this enzyme,21,

37

is illustrated in Scheme 1. Substrate binding is sequential ordered with

acetyl-CoA binding first, meaning that that catalysis only occurs after the formation of a
AANAT•acetyl-CoA•arylalkylamine ternary complex. We identified Glu-47 as the general base
involved in the water-assisted deprotonation of the positively charged amino group of the donor
substrate via an active site “proton wire”. The deprotonation of a species with a pKa,app of 9.8
was attributed to the formation of the tightly bound CoA thiolate.

Finally, our mutagenesis data

suggest that protein dynamics regulate substrate binding and catalysis in AANATA. The active
site amino acids, Asp-46, Pro-48, Arg-153, and His-220, seem critical to the regulatory dynamics
of the enzyme.
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Supporting Information
The supporting information section contains three tables and six figures. The three tables consist
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cloning and purification data, mutant SDS-PAGE gels, D. melanogaster AANATL primary
sequence alignment, and a figure of the AANATA active site depicting the location of Pro-48
with respect to bound acetyl-CoA. This material is available free of charge via the Internet at
http://pubs.acs.org.
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Table 1.
Steady-state kinetic constants for AANATA and AANATB with different acyl-CoAs.
AANATAa,b
kcat, app
(kcat/Km)app
Relative (kcat/Km)app
(s-1)
(M-1s-1)
3
Benzoyl-CoA
0.37 ± 0.03
(5.7 ± 1.2) × 10
1.0 ± 0.3
Acetyl-CoA
16 ± 1
(4.1 ± 1.3) × 105
72 ± 27
Butyryl-CoA
9.9 ± 0.4
(2.8 ± 0.2) × 105
49 ± 11
Hexanoyl-CoA
1.6 ± 0.1
(6.8 ± 0.9) × 104
12 ± 3
4
Octanoyl-CoA
0.26 ± 0.01
(1.4 ± 0.2) × 10
2.5 ± 0.6
Decanoyl-CoA
0.04 ± 0.01
(1.7 ± 0.5) × 102
0.04 ± 0.01
AANATBd
Benzoyl-CoA
80 ± 6
0.12 ± 0.04
(1.6 ± 0.5) × 103
1.0 ± 0.4
Acetyl-CoA
64 ± 9
8.3 ± 0.4
(1.3 ± 0.2) × 105
81 ± 31
Butyryl-CoA
19 ± 3
4.4 ± 0.2
(2.3 ± 0.3) × 105
150 ± 55
Hexanoyl-CoA
23 ± 6
0.88 ± 0.04
(3.8 ± 1.0) × 104
25 ± 10
a
Relative (kcat/Km)app values for AANATA amino acceptor substrates were indexed to benzoyl-CoA.
b
Kinetic constants are reported as ± standard error (n = 3).
c
Reaction condition – 300 mM Tris-HCl pH 8.0, 150 µM DTNB, 1.0 mM tyramine, and varying
concentration of acyl-CoA.
d
Relative (kcat/Km)app value for AANATB amino acceptor substrates were indexed to benzoyl-CoA.
Substratec

Km, app
(µM)
65 ± 13
39 ± 12
36 ± 2
23 ± 3
18 ± 3
220 ± 60
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Table 2.
AANATA IC50 values for long-chain acyl-CoAs
IC50
(nM)
Oleoyl-CoA
380 ± 5
18:1 (9)
9
Palmitoleoyl-CoA
430 ± 40
16:1 ( )
Myristoyl-CoA
14:0
580 ± 70
Lauroyl-CoA
12:0
1100 ± 130
a
Reaction was fixed at the Km,app values for both acetyl-CoA (39 µM) and tyramine (12 µM) while varying
the concentration of the long-chain acyl-CoA inhibitor.
b
Kinetic constants are reported as ± standard error (n = 3).
Inhibitora,b

Carbon Skeleton
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Table 3.
AANATA steady-state kinetic constants for different arylalkylamines
Km, app
(µM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)

Tyramine

12 ± 1

19 ± 1

(1.6 ± 0.2) × 106

5-Benzyloxytryptamine

18 ± 3

27 ± 2

(1.5 ± 0.3) × 106

Octopamine

10 ± 2

13 ± 1

(1.3 ± 0.3) × 106

Dopamine

25 ± 2

17.6 ± 0.4

(7.0 ± 0.4) × 105

Tryptamine

33 ± 3

22 ± 1

(6.5 ± 0.7) × 105

3-(Trifluoromethyl)phenethylamine

110 ± 10

71 ± 3

(6.5 ± 0.8) × 105

5-Methoxytyrptamine

54 ± 6

35 ± 1

(6.4 ± 0.7) × 105

Norepinephrine

32 ± 6

20 ± 1

(6 ± 1) × 105

Phenethylamine

56 ± 13

30 ± 3

(5 ± 1) × 105

-Methylphenethylamine

47 ± 11

15 ± 1

(3.2 ± 0.8) × 105

3-Methoxyphenethylamine

120 ± 30

38 ± 4

(3.2 ± 0.9) × 105

Serotonin

110 ± 8

29.7 ± 0.7

(2.7 ± 0.2) × 105

7-Methyltryptamine

130 ± 9

21.2 ± 0.4

(1.6 ± 0.1) × 105

3,4-Methylenedioxyphenethylamine

340 + 10

26 + 1

(7.8 ± 0.4) × 104

4-Methoxyphenethylamine

780 ± 60

41 ± 1

(5.2 ± 0.4) × 104

4-Phenylbutylamine

270 ± 20

3.7 + 0.1

(1.4 ± 0.1) × 104

3,4-Dimethoxyphenethylamine

3200 ± 300

30 ± 1

(10 ± 1) × 103

Substratea,b

Structure

197

Reaction condition – 300 mM Tris-HCl pH 8.0, 150 µM DTNB, 500 µM acetyl-CoA, and varying
concentration of arylalkylamine.
b
Kinetic constants are reported as ± standard error (n = 3).
a
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Table 4.
Steady-state kinetic constants for AANATA site-directed mutants.
Acetyl-CoA
Mutanta,b

Km, app
(µM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)
5

Wild-type
E47A
P48A
Y64A
D142A
R153A
H178A
C181A
S186A
S182A/S186A
H220A

39 ± 12
32 ± 3
190 ± 10
81 ± 5
80 ± 6
430 ± 60
120 ± 7
26 ± 1
29 ± 5
43 ± 4
160 ± 20

16 ± 1
1.26 ± 0.04
1.4 ± 0.1
8.6 ± 0.2
27.5 ± 0.6
106 ± 6
17.9 ± 0.4
19.1 ± 0.2
5.0 ± 0.3
8.9 ± 0.3
4.2 ± 0.2

(4.1 ± 1.3) × 10
(3.9 ± 0.6) × 104
(7.3 ± 0.5) × 103
(1.1 ± 0.1) × 105
(3.4 ± 0.3) × 105
(2.5 ± 0.4) × 105
(1.5 ± 0.1) × 105
(7.3 ± 0.3) × 105
(1.7 ± 0.3) × 105
(2.1 ± 0.2) × 105
(2.6 ± 0.3) × 104
Tyramine

Mutanta,c

Km, app
(µM)

kcat, app
(s-1)

(kcat/Km)app
(M-1s-1)

%
100
9.5
1.8
27
83
61
37
178
41
51
6.3

%
Wild-type
12 ± 1
19 ± 1
(1.6 ± 0.2) × 106
100
E47A
160 ± 50
1.0 ± 0.1
(6 ± 2) × 103
0.38
3
P48A
470 ± 50
0.86 ± 0.04
(1.84 ± 0.2) x 10
0.12
Y64A
87 ± 17
8.8 ± 0.4
(1.0 ± 0.2) × 105
6.3
D142A
17 ± 1
25 ± 1
(1.5 ± 0.1) × 106
94
R153A
290 ± 20
98 ± 2
(3.4 ± 0.3) × 105
21
5
H178A
25 ± 3
14.7 ± 0.5
(5.9 ± 0.8) × 10
37
C181A
17 ± 2
22 ± 1
(1.3 ± 0.1) × 106
81
S186A
73 ± 12
5.0 ± 0.1
(6.9 ± 0.6) × 104
4.3
S182A/S186A
190 ± 20
8.3 ± 0.2
(4.3 ± 0.3) x 104
2.7
H220A
82 ± 9
4.1 ± 0.2
(4.9 ± 0.6) × 104
3.1
a
Kinetic constants are reported as ± standard error (n = 3).
b
The reaction rate was measured at a fixed saturating concentration of tyramine while varying the
concentration of acetyl-CoA.
c
The reaction rate was measured at a fixed saturating concentration of acetyl-CoA while varying the
concentration of tyramine.
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Figure Legends

Figure 1. Double reciprocal plot of initial velocities for acetyl-CoA and tyramine.

(A) Velocities

measured at a fixed concentration of tyramine: 50 µM (●), 25 µM (o), 10 µM (▼), 5 µM (Δ).
(B) Velocities measured at a fixed concentration of acetyl-CoA: 100 µM (●), 60 µM (o), 40 µM (▼),
20 µM (Δ).

Figure 2. Dead-end inhibition analysis of AANATA. (A) Velocities measured at a fixed concentration of
tyramine (12 µM), varying the concentration of acetyl-CoA, and varying the concentration of the
inhibitor, oleoyl-CoA: 0 nM (●), 200 nM (o), 375 nM (▼); Ki = 78 ± 8 nM. (B) Velocities measured at a
fixed concentration of acetyl-CoA (39 µM), varying the concentration of tyramine, and varying the
concentration of the inhibitor, oleoyl-CoA: 0 nM (●), 200 nM (o), 375 nM (▼); Ki = 150 ± 7 nM. (C)
Velocities measured at a fixed concentration of tyramine (12 µM), varying the concentration of
acetyl-CoA, and varying the concentration of the inhibitor, tyrosol: 0 µM (●), 100 µM (o), 580 µM (▼);
Ki = 260 ± 10 µM. (D) Velocities measured at a fixed concentration of acetyl-CoA (39 µM), varying the
concentration of tyramine, and varying the concentration of the inhibitor, tyrosol: 0 µM (●), 100 µM (o),
580 µM (▼); Ki = 302 ± 34 µM.

Figure 3. AANATA pH rate profile. (A) kcat,app-acetyl-CoA. (B) kcat,app-tyramine. (C) (kcat/Km)app-acetyl-CoA. (D)
(kcat/Km)app-tyramine.

Figure 4. (A). Determination of the coenzyme A dissociation constant by fluorescence titration for
wild-type enzyme. (B) Determination of the coenzyme A dissociation constant by fluorescence titration
for R153A mutant.
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Figure 5. Crystal structure of D. melanogaster AANATA with bound acetyl-CoA identifying the possible
general base residues.

Stick model showing the proximity of Glu-47, His-178, and Asp-142 to

acetyl-CoA. Red circles represent water molecules.

Figure 6. Crystal structure of D. melanogaster AANATA with bound acetyl-CoA bound identifying the
possible general acid residues. Stick model showing the proximity of Tyr-64, Cys-181, Ser-182, Ser-183,
and Ser-186 to acetyl-CoA. Red circles represent water molecules.

Figure 7. Crystal structure of D. melanogaster AANATA with bound acetyl-CoA showing a possible
“proton wire” involving the general base, Glu-47.

Figure 8. Crystal structure of D. melanogaster AANATA depicting structural importance of His220.
CPK schematic of His-220 found in AANATA along with secondary structure highlighting van der Waals
interactions between H220:Y185 and H220:P48.

Figure 9. Crystal structure of D. melanogaster AANATA with bound acetyl-CoA depicting the
Asp-46/Arg-153 salt bridge. Stick model showing the proximity of Asp-46 and Arg-153 to acetyl-CoA.
Red circles represent water molecules.

Scheme Legend

Scheme 1. Proposed chemical mechanism for D. melanogaster AANATA. R = different acyl chain
length for acyl-CoA. The dashed arrows represent ambiguities in the position of the irreversible step due
to differences between the pH rate profiles reported herein and those by Cheng et al.37
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Supporting Information
Table S1.
Site-directed Mutagenesis Primers
Mutant
E47A

Forward or
Reverse Primer
Forward
Reverse
Forward

P48A

Reverse
Forward

Y64A

D142A
R153A

H178A

C181A
S186A

Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward

S182A/S186A
H220A

Reverse
Forward
Reverse

Primer Sequence
CTT TTT CTT CAA GGA TGC ACC GCT GAA CAC CTT CC
GGA AGG TGT TCA GCG GTG CAT CCT TGA AGA AAA
AG
AGG TGT TCA GCG CTT CAT CCT TGA AGA AAA AGG
TCT
AGA CCT TTT TCT TCA AGG ATG AAG CGC TGA ACA
CCT
GAA GCG GTT TCA GGG AGG CCT TCT CCA GCT CCT
TGC
GCA AGG AGC TGG AGA AGG CCT CCC TGA AAC CGC
TTC
ACA GGA TCT TGC CGG CCA GGA TGA GCT CC
GGA GCT CAT CCT GGC CGG CAA GAT CCT GT
GTG GAC ACC AAC TAC GCG GGC CTG GGC A
TGC CCA GGC CCG CGT AGT TGG TGT CCA C
GGC TGG AAC AGA GAA CGG CGT ACA CAT TGA TGC
CGT
ACG GCA TCA ATG TGT ACG CCG TTC TCT GTT CCA
GCC
ATG TGT ACC ACG TTC TCG CTT CCA GCC ACT ACT CCG
CGG AGT AGT GGC TGG AAG CGA GAA CGT GGT ACA
CCA GCC ACT ACG CCG CCC GGG TG
CAC CCG GGC GGC GTA GTG GCT GG
TCA ATG TGT ACC ACG TTC TCT GTG CCA GCC ACT
ACG
CGT AGT GGC TGG CAC AGA GAA CGT GGT ACA
CCG GCG GCC CCG GCC GTA GGC ATC CA
TGG ATG CCT ACG GCC GGG GCC GCC GG
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Table S2.
AANATA product characterization.
Retention Time
Mass/Charge
(min)
[M + H] (m/z)
N-acetylserotonin Standard
0.78
219.1132
a
AANAT A Enzyme Assay
0.78
219.1133
a
Reaction condition – 300 mM Tris-HCl pH 8.0, 500 µM acetyl-CoA, 1 mM serotonin, 15 µg AANATA.
Sample
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Table S3.
Conserved D. melanogaster AANATA Arg153 Found in other GNAT Enzymes

Organism

Enzyme

PDB Data Base ID for
Crystal Structure

Conserved Arginine

Drosophila
Sheep
Human
Tuberculosis
Yeast
Human

AANATA
SNAT
SSAT
AgNAT
HAT (Hpa2)
NMT

3TE4
1CJW
2JEV
1M4G
1QSM
3JTK

R153
R131
R101
R91
R100
R255

214

Figure S1. Cloning of AANATA and AANATB from D. melanogaster. (Lane 1) 1 kb DNA ladder (New
England Biolabs), (Lane 2) AANATB; 828 bp band, (Lane 3) AANATA; 723 bp band.
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Figure S2. SDS-PAGE gel for purified AANATA and AANATB. (Lane 1) Precision Plus Protein™
Kaleidoscope™ Standards (Biorad), (Lane 2) AANATA; 27 kDa, (Lane 3) AANATB; 31 kDa.
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Figure S3. Primary sequence alignment of AANATA with putative AANATL enzymes found in D.
melanogaster using clustalW2.
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Figure S4. SDS-PAGE gel of purified AANATA mutants. (Lane 1) PageRuler™ Prestained protein
ladder (Thermo Scientific), (Lane 2) E47A, (Lane 3) R153A, (Lane 4) S186A, (Lane 5) H220A.
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Figure S5. SDS-PAGE gel of purified AANATA mutants. (Lane 1) PageRuler™ Prestained protein
ladder (Thermo Scientific), (Lane 2) P48A, (Lane 3) Y64A, (Lane 4) D142A, (Lane 5) H178A, (Lane 5)
C181A, (Lane 5) S182A/S186A.
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Figure S6. D. melanogaster AANATA Pro-48 (PDB: 3TE4) showing general location with respect to
amine binding pocket and bound actey-CoA.
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Abstract
Arylalkylamine N-acyltransferase-like 22 (AANATL2) from Drosophila melanogaster
was expressed and shown to catalyze the formation of long-chain N-acylserotonins and
N-acydopamines. Subsequent identification of endogenous amounts of N-acylserotonins and
colocalization of these fatty acid amides and AANATL2 transcripts gives supporting evidence that
AANATL2 has a role in the biosynthetic formation of these important cell signalling lipids.

Keywords:

Arylalkylamine

N-acyltransferase;

Arylalkylamine

N-acetyltransferase;

N-acyldopamines; N-acylserotonins; Drosophila melanogaster; thorax-abdomen; steady-state
kinetics

Abbreviations: AANATL2, arylalkylamine N-acyltransferase like 2; FAAH, fatty acid amino
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2

The authors recommend the change of arylalkylamine N-acetyltransferase to arylalkylamine

N-acyltransferase due to the discovery of acyl-CoA substrates longer than C2 (acetyl).
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1. Introduction
Fatty acid amides are an emerging class of cell signalling lipids. This family of bioactive
amides consists of N-acyl amino acids, N-acylarylalkylamines, N-acylethanolamines,
N-monoacylpolyamines, and primary fatty acid amides. The N-acylarylalkylamines can be
subdivided into two groups called the N-acyldopamines and the N-acylserotonins. With the
exception of the N-acylethanolamines, the biosynthetic routes to these long-chain fatty acids
amides in vivo is largely unknown [1-2].
The N-acylserotonins were originally synthesized as inhibitors of fatty acid amino
hydrolase (FAAH), the primary focus being N-arachidonoylserotonin with an IC50 = 12 µM [3].
Following this discovery, N-arachidonoylserotonin was shown to act as a vanilloid TRPV1
receptor antagonist [4], as an inhibitor of soybean lipoxygenase [5], as a regulator for gastric
emptying [6], and also exhibited analgesic, anxiolytic, and anti-allergic activity in various model
systems [4,7-8]. The biological roles for the other known long-chain N-acylserotonins have yet
to be determined. Recently, Verhoeckx et al. [9] identified and quantified the endogenous
amounts of long-chain N-acylserotonins in the different regions of the porcine gastrointestinal
tract, including the ileum.

Like the N-acylserotonins, activities have been ascribed to the

N-acyldopamines, as the N-acyldopamines regulate pain perception, body temperature, and
locomotion in mammals [10-13].

Little is known about the in vivo production of the

N-acylserotonins and N-acyldopamines except for data showing that these could be produced by
the direct conjugation of serotonin or dopamine to a fatty acid [9,14]. One set of biosynthetic
reactions consistent with these data would be the initial formation of the acyl-CoA in a reaction
requiring ATP, followed by a reaction between the resulting acyl-CoA and serotonin or
dopamine to form the long-chain N-acylarylalkylamide (Fig. 1). Acyl-CoA formation is
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catalyzed by an acyl-CoA synthetase, a known enzyme [15], while the enzyme catalyzing the
second reaction is reported here for the first time. This chemistry is consistent with reactions
catalyzed by the arylalkylamine N-acetyltransferases (AANATs) and other enzymes of the
GCN5-related N-acetyltransferase (GNAT) family enzymes [16-18].
AANATs from a number of organisms have been shown to catalyze the production of
different N-acetylarylalkylamines like N-acetyldopamine and N-acetylserotonin [16-18]. Other
than a single report that propionyl-CoA and butyryl-CoA are relatively poor substrates for
human serotonin N-acetyltransferase [19], it has not been determined if the known AANATs will
utilize long-chain acyl-CoA thioesters as substrates to generate the corresponding long chain
N-acylarylalkylamides [19]. Eight putative arylalkylamine N-acetyltransferase-like (AANATL)
enzymes [20] were identified in Drosophila melanogaster and we hypothesized that one of these
enzymes would have a role in the formation of the long-chain N-acylserotonins.
Herein, we provide evidence that AANATL2, an AANATL enzyme from
D. melanogaster (CG9486), will catalyze the formation of long-chain N-acylserotonins. We
further define the expression of AANATL2 transcripts in different anatomical regions of the flies
and find measureable levels of the endogenous N-acylserotonins in regions that overlap with the
expression of the AANATL2 transcripts. While the N-acylserotonins are the major focus of this
report, we also demonstrate that arylalkylamines other than serotonin are AANATL2 substrates,
including dopamine, octopamine, and tyramine. These data suggest that AANATL2 could serve
broadly in the cellular production of numerous different N-acylarylalkylamides.
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2. Materials and Methods
2.1. Materials
Codon optimized AANATL2 was purchased from Genscript.

Oligonucleotides were

purchased from Eurofins MWG Operon. BL21(DE3) Escherichia coli competent cells and
pET-28a(+) vector were purchased from Novagen. Probond™ nickel-chelating resin, Ambion
MicroPoly(A) Purist, and Ambion Retroscript kit were purchased from Invitrogen. NdeI, XhoI,
Antarctic Phosphatase, and T4 DNA ligase were purchased from New England Biolabs.
Ampicillin sodium salt and IPTG were purchased from Gold Biotechnology.

Long-chain

acyl-CoAs were purchased from Sigma-Aldrich. D. melanogaster (Oregon R) and 4-24 Instant
Medium were supplied by Carolina Biological.

Silica was purchased from Suppelco.

Long-chain N-acylserotonins and N-arachidonoylglycine-d8 standards were purchased from
Cayman Chemical.

All other reagents were of the highest quality available from either

Sigma-Aldrich or Fisher Scientific.

2.2. Molecular cloning
AANATL2 (CG9486; Accession No. NM_135161.3) was codon optimized for expression
in E. coli and purchased from Genscript.

The codon optimized gene was inserted into a

pET28a(+) vector using the NdeI and XhoI restriction sites. The AANATL2-pET28a vector was
then transformed into E. coli BL21(DE3) competent cells and plated on a LB agar plate
supplemented with 40 µg/mL kanamycin. A single colony from the transformation was then
used for the expression of AANATL2.
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2.3. Protein expression and purification
The BL21(DE3) E. coli cells containing the D. melanogaster AANATL2-pET28a vector
were cultured in LB media supplemented with 40 µg/mL kanamycin and induced with 1 mM
isopropyl β-D-1-thiogalactopyranoside at an OD600 of 0.6 for 4 hrs at 37°C. The final culture
was then harvested by centrifugation at 5,000 g for 10 min at 4oC and the pellet was collected.
The pellet was then resuspended in 20 mM Tris, 500 mM NaCl, 5 mM imidazole; lysed
by sonication; and then centrifuged at 10,000 g for 15 min at 4°C. The resulting supernatant was
loaded onto 6 mL of Probond™ nickel-chelating resin. The column was first washed with
10 column volumes of 20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole, pH 7.9, then washed
with 10 column volumes of 20 mM Tris-HCl, 500 mM NaCl, 60 mM imidazole, pH 7.9, and
lastly eluted in 1 mL fractions of 20 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, pH 7.9.
The AANATL2 within these fractions were analyzed for purity using a 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, visualized using Coomassie stain,
and pooled together.

The pooled fractions are dialyzed overnight at 4°C in 20 mM Tris, 200

mM NaCl, pH 7.4 and stored at -80°C.

2.4. Activity assay
Steady-state kinetic characterization of AANATL2 was performed in 300 mM Tris-HCl,
pH 8.0, 150 µM 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) [21], and varying concentrations of
substrates. Initial rates were measured continuously at 412 nm. Kinetic constants for long-chain
acyl-CoA substrates were determined by holding the initial serotonin concentration constant at 5
mM. Kinetic constants for the short-chain acyl-CoA substrates, acetyl-CoA and butyryl-CoA,
were determined by holding the initial serotonin concentration constant at 100 M. The steady-
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state kinetic constants for serotonin, dopamine, octopamine, and tyramine were delineated by
holding the initial acyl-CoA concentration at 50 µM.

Steady-state kinetic constants were

obtained by fitting the data to the Michaelis-Menten equation in SigmaPlot 12.0.

2.5. AANATL2 product characterization
The product of the AANATL2-catalyzed reaction was generated by incubating 36 µg of
the enzyme for 1 hour in 300 mM Tris-HCl, pH 8.0, 50 mM serotonin or dopamine, and 500 µM
oleoyl-CoA. The reaction mixture was passed through a 10 kDa ultrafilter (Millipore) to remove
the AANATL2 and resulting protein-free solution injected on an Agilent 6540 liquid
chromatography/quadrupole time-of-flight mass spectrometer (LC/QTOF-MS) in positive ion
mode. A Kinetex™ 2.6 µm C18 100 Å (50 × 2.1 mm) reverse phase column was used for
AANATL2 product separation. Mobile phase A consisted of water with 0.1% formic acid and
mobile phase B consisted of acetonitrile with 0.1% formic acid. A linear gradient of 10% B
increasing to 100% B over the course of 5 min, followed by a hold of 3 min at 100% B was used
for the LC analysis of the reaction product. The reverse phase column was equilibrated with
10% B for 8 minutes after the run to prepare the column for the subsequent injections.
2.6. AANATL2 transcript localization
D. melanogaster were grown on 4-24 Instant Medium from Carolina Biological, flash
frozen for decapitation, and the heads were separated from thorax-abdomens using a wired mesh.
Ambion MicroPoly(A) Purist kit was used to purify the mRNA and Ambion Retroscript kit was
used to generate the cDNA library for subsequent RT-PCR localization of AANATL2 from
D. melanogaster head and thorax-abdomen.

Identification of AANATL2 transcripts was

completed by RT-PCR (45 cycles of 95°C for 30 s; 60°C for 30 s; 72°C for 1 min). The primers
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used to amplify a 247 bp region of AANATL2 (forward – ATGACAATCGGGGATTACGA,
reverse - CCTCCTGGTACTCCCTCTCC) were designed and synthesized by Eurofins MWG
Operon. Amplified product from the RT-PCR reaction was analyzed by a 0.6 % agarose gel and
the band visualized by 0.5 µg/mL ethidium bromide under ultraviolet light. The positive bands
at 247 bp were cut out of the gel, purified by the Promega Wizard® SV Gel and PCR Clean-up
system, and sequenced by Eurofins MWG Operon.

2.7. Endogenous quantification of long-chain N-acylserotonins
Four separate cultures of D. melanogaster were used for the analysis of endogenous
levels of long-chain N-acylserotonins. Lipids were extracted using organic solvents followed by
the solid phase purification of Farrell et al. [22]. The purified extracts were dried under N2,
reconstituted in HPLC grade methanol, and injected on an Agilent 1260 connected to an Agilent
6540 LC/QTOF-MS in positive ion mode. Injected lipid extracts were separated by a Kinetex™
2.6 µm C18 100 Å (50 × 2.1 mm) reverse phase column at 0.6 mL/min. Mobile phase A
consisted of water with 0.1% formic acid and mobile phase B consisted of acetonitrile with 0.1%
formic acid. A linear gradient was used for the separation of the injected lipid extracts by
reverse phase chromatography starting at 10% B and increasing to 100% B over the course of 5
min, followed by a hold of 3 min at 100% B. The reverse phase column was equilibrated with
10% B for 8 minutes after the run to prepare the column for subsequent injections.
N-Arachidonoylglycine-d8, 1 pmole per 10 µL injection, was spiked into each extraction to
measure instrument performance and for data normalization. The four extractions from separate
cultures of D. melanogaster were analyzed in triplicate for a total of 12 runs. Standard curves of
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commercially available N-acylserotonins and N-arachidonoylglycine-d8 were analyzed in
triplicate with a linear range of 100 fmoles to 5 pmoles (r2 values >0.99).

3. Results and Discussion
The codon optimized D. melanogaster AANATL2 gene was prepared commercially by
Genscript and cloned into a pet28a(+) vector that encodes for an N-terminal His6-tag protein.
Recombinant D. melanogaster AANATL2 was expressed in Escherichia coli BL21(DE3) cells
and purified using Probond™ nickel-chelating resin. The purified AANATL2 was then analyzed
by SDS-PAGE (Fig. 2), yielding a single band at 25 kDa.
Potential substrates for AANATL2 were identified using Ellman’s reagent [21] by
measuring the acyl-CoA dependent release of CoA-SH which yields 2-nitro-5-thiobenzoate at
412 nm. Activity was observed with serotonin and oleoyl-CoA from our substrate screening
studies which was evaluated in greater detail with subsequent steady-state kinetic analysis of
AANATL2 with a set of acyl-CoA thioesters and serotonin. We found that acyl-CoA thioesters
from acetyl-CoA to arachidonoyl-CoA are AANATL2 substrates with some variability in the
apparent kinetic constants at saturating serotonin. The (KM,acyl-CoA)app values for all the acyl-CoA
thioesters included in our study were approximately the same, ranging from ~2 M for
butyryl-CoA and arachidonoyl-CoA to ~ 10 M for palmitoyl-CoA. Greater variability was
observed for the (kcat,acyl-CoA)app and (kcat/KM)acyl-CoA,app values with a range of 20-30-fold. Based
on our data, the short-chain acyl-CoA thioesters are, in general, substrates with higher
(kcat/KM,acyl-CoA)app values than the long-chain acyl-CoA thioesters (Table 1). Amherd et al. [20]
expressed D. melanogaster AANATL2 in COS-7 cells and report a (KM,acyl-CoA)app for
acetyl-CoA of 7.2 ± 0.6 M with tryptamine as a co-substrate that is similar to the value we
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measure using serotonin as the co-substrate. A comparison of (kcat,acyl-CoA)app and (kcat/KM)acylCoA,app

values we measure (Table 1) to those reported by Amherd et al. [20] is difficult as these

researchers did not purify recombinant AANATL2 from the COS-7 cells.
We have also evaluated biologically relevant arylalkylamines other than serotonin as
substrates for AANATL2, namely dopamine, octopamine, and tyramine. Ahmerd et al. [20]
have already demonstrated that tryptamine is a substrate for D. melanogaster AANATL2.
Neither tyramine nor octopamine were substrates when the acyl acceptor was oleoyl-CoA as the
observed rate of CoA release from oleoyl-CoA was equivalent to the background rate of
hydrolysis obtained in the absence of the arylalkylamine. However, both were substrates when
the acyl acceptor was acetyl-CoA. The kinetic constants for the AANATL2-catalyzed formation
of N-acetyltyramine and N-acetyloctopamine are similar to those determined for the formation of
N-acetylserotonin except for a relatively high (KM,amine)app for octopamine of 78 ± 3.9 M
(Table S1, supplementary materials).

Dopamine is a substrate for AANATL2 when the co-

substrate is acetyl-, palmitoyl-, or oleoyl-CoA (Table 2). Again, the kinetic constants for the
formation of N-acetyldopamine are similar to those determined for the generation of the other
N-acetylarylalkylamides.
We evaluated the relationship between the (KM,amine)app for serotonin or dopamine as a
function of acyl chain length for the acyl-CoA substrates (Table 2) because both of these were
substrates when acetyl-CoA and the long-chain acyl-CoA were co-substrates. The pattern in the
data was the same for both serotonin and dopamine, the (KM,amine)app increased, the (kcat,amine)app
decreased, and the (kcatKM)amine,app decreased as the acyl chain length increased from acetyl to
arachidonoyl. The ratio of (kcatKM

/(kcatKM

is 3,400 for dopamine and

5,000 for serotonin indicating that acetyl-CoA is substantially preferred by AANATL2.
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Side-by-side comparisons of the acyl-CoA thioesters between serotonin and dopamine show that
AANATL2 exhibits a slight preference for serotonin as the amine donor substrate.
An examination of our kinetic data reveals some patterns: (a) limited variation in the
(KM,acyl-CoA)app values for the acyl-CoA substrates as all are in the range of 2-10 M, (b) limited
variation (kcat,amine)app and (kcat/KM)amine,app values on the amine substrate, (c) an increase in the
(KM,amine)app values for the amine substrates as the length of the acyl chain increases for the
acyl-CoAs, and (d) a decrease in the (kcat,amine)app and (kcat/KM)amine,app values as the length of the
acyl chain increases for the acyl-CoAs. These data suggest that the long-chain acyl group either
interferes with the binding of the arylalkylamine substrates or that the binding of the long-chain
acyl-CoAs results in an AANATL2 conformation that is less optimal for catalysis. An X-ray
structure of AANATL2 with bound acetyl-CoA or oleoyl-CoA could differentiate between these
two possibilities. We also note the relatively low kcat,app values [(kcat,acyl-CoA)app and (kcat,amine)app]
values for the long-chain acyl-CoA substrates; however, low kcat,app values are not surprising
since the long-chain N-acyl- serotonins and dopamines likely serve as potent cell signaling lipids
[9-13].

The cellular function of AANATL2 may be the generation of the long-chain

N-acylarylalkylamides and the measured kcat,app values are sufficient to supply the cellular needs
of these potent lipid amides. Saghatelian and Cravatt [23] have shown in their studies of
FAAH(-/-) that in vitro measurements of kinetic constants may not provide a complete
understanding of the functional role of an enzyme in vivo.
The products from the AANATL2 catalyzed reaction between oleoyl-CoA and serotonin
or dopamine were positively identified as N-oleoylserotonin and N-oleoyldopamine (Table 3).
AANATL2 was incubated with serotonin or dopamine and oleoyl-CoA for one hour, the enzyme
was removed by ultrafiltration using a 10 kDa cutoff filter, followed by product analysis by
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liquid

chromatography/quadrupole

time-of-flight

mass

spectrometry

(LC/QTOF-MS).

AANATL2-generated N-oleoylserotonin or N-oleoyldopamine was compared to a commercial
standard. Positive identification was delineated by a comparable retention time and molecular
ion m/z for the AANATL2 product and the standard (Table 3).
The in vitro data we obtained using purified AANATL2 (substrate specificity and product
characterization) lead to questions such as: (a) are the long-chain N-acylarylalkylamides found in
D. melanogaster, (b) if so, what are the steady-state endogenous levels of these fatty acid
amides, and (c) would we find colocalization of endogenous N-acylarylalkylamides and
AANATL2? To address these intriguing questions, we first identified the localization of the
AANATL2 transcripts by RT-PCR. Primers were designed and synthesized commercially to
generate a 247 bp AANATL2-derived RT-PCR product from the cDNA libraries generated from
D. melanogaster head and thorax-abdomen. The RT-PCR experiments show that AANATL2
transcripts were only found in the thorax-abdomen of D. melanogaster (Fig. 3).
AANATL2 was positively identified by the 247 bp RT-PCR product generated from the
D. melangaster thorax-abdomen cDNA library; however, a similar RT-PCR product was not
observed from the head cDNA library.

The sequence of the 247 bp product from the

thorax-abdomen library was confirmed as AANATL2 by DNA sequencing. These data are in
slight contrast to the report a faint band for AANATL2 from D. melanogaster head by Northern
analysis [20]. Together, our data and that from Amherd et al. [20] indicate that AANATL2
transcripts are found at substantially higher levels in the thorax-abdomen relative to the head in
D. melanogaster.
Our identification of the AANATL2 transcripts in the thorax-abdomen and the relatively
high levels of serotonin in the mammalian gastrointestinal tract [9,24] strongly suggested to us
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that the long-chain N-acylserotonins would exist endogenously in the thorax-abdomen of D.
melanogaster.

Four long-chain N-acylserotonins were identified in the thorax-abdomen by

molecular ion m/z and retention time comparisons to commercially available standards (Table 4)
by LC/QTOF-MS in positive ion mode. Endogenous amounts of N-acylserotonins were not
identified in the heads, consistent with our RT-PCR data in which the AANATL2 transcripts were
not found. Standard curves with a linear range of 100 fmoles to 5 pmoles (r2 values >0.99) were
used to quantify the endogenous amounts of N-acylserotonins in the thorax-abdomen.
N-Stearoylserotonin

was

the

most

abundant

followed

by

N-palmitoylserotonin,

N-arachidonoylserotonin, and N-oleoylserotonin (Table 4). The N-acylserotonin levels that we
found in the thorax-abdomen of D. melanogaster are similar to that reported for these fatty acid
amides in porcine gastrointestinal tract [9]. In contrast to the long-chain N-acylserotonins, the
long-chain N-acyldopamines are found in both the thorax-abdomen and the heads of D.
melanogaster [25]. The dissimilarities in the localization of the long-chain N-acylserotonins
relative to the long-chain N-acyldopamines are likely the result of differences in biosynthesis,
degradation, and/or transport of these different N-acylarylalkylamides.
In summary, AANATL2 from D. melanogaster was shown to catalyze the formation of a
diverse set of N-acylarylalkylamides with the most intriguing products being the long-chain
N-acylserotonins and N-acyldopamines. Colocalization of AANATL2 transcripts and endogenous
long-chain N-acylserotonins to the thorax-abdomen points to an important role for this enzyme in
the biosynthesis of these cell signalling long-chain N-acylarylalkylamides.

Future work to

expand our understanding of biosynthesis and degradation of the N-acylserotonins,
N-acyldopamines, and other long-chain N-acylarylalkylamides involving the inhibition of key
enzymes is ongoing.
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Figure Legends

Figure 1. Proposed reaction for the formation of long-chain N-acylserotonins catalyzed by
AANATL2.

Figure 2. SDS-PAGE analysis of purified D. melanogaster AANATL2. Left lane is
PageRuler™ Prestained Protein Ladder. Right lane is purified AANATL2.

Figure 3. RT-PCR of AANATL2 in D. melanogaster head and thorax-abdomen. Lane 1-4
is data generated from the D. melanogaster head cDNA library at 45°C, 50°C, 55°C, and 60°C
annealing temperatures respectively. Lane 5 is 100 bp DNA ladder from New England Biolabs.
Lane 6-9 is data generated from the D. melanogaster thorax-abdomen cDNA library at 45°C,
50°C, 55°C, and 60°C annealing temperature respectively. Lane 10 is a 1 kb DNA ladder from
New England Biolabs.
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Table 1
Acyl-CoA Specificity for AANATL2

Substratea

(KM,acyl-CoA)app
µM

(kcat,acyl-CoA)app
s-1

(kcat/KM)acyl-CoA,app
M-1s-1

Acetyl-CoA

6.1 ± 0.27

1.3 ± 0.012

(2.2 ± 0.020) × 105

Butyryl-CoA

1.8 ± 0.17

0.53 ± 0.011

(2.9 ± 0.058) × 105

Palmitoyl-CoA

9.9 ± 1.6

0.16 ± 0.0090

(1.6 ± 0.091) × 104

Stearoyl-CoA

6.0 ± 0.75

0.059 ± 0.0023

(9.8 ± 0.39) × 103

Oleoyl-CoA

3.6 ± 0.58

0.075 ± 0.0033

(2.1 ± 0.091) × 104

Arachidonoyl-CoA

1.9 ± 0.25

0.043 ± 0.0013

(2.3 ± 0.068) × 104

a

Background rates of acyl-CoA hydrolysis were obtained at each CoA concentration in the absence of
serotonin and subtracted from the rate obtained in the presence of serotonin. The non-serotonin
background rates were ≤15% of rates obtained in the presence of serotonin, with exception of steroylCoA. For stearoyl-CoA, the background hydrolysis rates were ≤30%.
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Table 2
Apparent Kinetic Constants for Serotonin and Dopamine using Different Acyl-CoA Substrates

Substratea

(KM,amine)app
µM

(kcat,amine)app
s-1

(kcat/KM)amine,app
M-1s-1

Serotonin
Acetyl-CoA

7.2 ± 1.1

2.4 ± 0.097

(3.3 ± 0.13) × 105

Butyryl-CoA

2.9 ± 0.33

0.52 ± 0.011

(1.8 ± 0.040) × 105

Palmitoyl-CoA

870 ± 60

0.15 ± 0.0034

(1.7 ± 0.039) × 102

Stearoyl-CoA

350 ± 35

0.057 ± 0.0014

(1.6 ± 0.040) × 102

Oleoyl-CoA

490 ± 86

0.085 ± 0.0059

(1.7 ± 0.12) × 102

Arachidonoyl-CoA

460 ± 69

0.030 ± 0.0014

66 ± 3.0

(KM,amine)app

(kcat,amine)app

(kcat/KM)amine,app

Substratea

mM

s

-1

M-1s-1

Dopamine
Acetyl-CoA
Palmitoyl-CoA

0.042 ± 0.0097

6.5 ± 0.67

(1.6 ± 0.16) × 105

1.1 ± 0.13

0.14 ± 0.0050

(1.2 ± 0.045) × 102

Oleoyl-CoA
1.2 ± 0.20
0.058 ± 0.0033
47 ± 2.7
Background rates of acyl-CoA hydrolysis were obtained at a saturating CoA concentration in the absence
of the arylalkylamine and subtracted from the rate obtained in the presence of arylalkylamine. The nonarylalkylamine (background rates) were ≤20% of rates obtained in the presence of arylalkylamine.
a
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Table 3
Standards used for identification of endogenous long-chain N-acylserotonins and
the AANATL2 product characterization

N-Acylarylalkylamine Standard
N-Oleoylserotonin
N-Palmitoylserotonin
N-Stearoylserotonin
N-Arachidonoylserotonin
N-Oleoyldopamine

Retention Time
Min

Molecular Ion
[M+H]+ m/z

6.132
6.038
6.368
5.900
5.929

441.3878
415.3344
443.3620
463.3291
418.3326

6.130
441.3464
AANATL2 Producta
b
5.929
418.3325
AANATL2 Product
a
Reaction conditions: 300 mM Tris-HCl, pH 8.0, 50 mM serotonin, and 500 µM oleoyl-CoA was
incubated with 36 µg of AANATL2 for one hour.
b
Reaction conditions: 300 mM Tris-HCl, pH 8.0, 50 mM dopamine, and 500 µM oleoyl-CoA was
incubated with 36 µg of AANATL2 for one hour.
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Table 4
Endogenous amounts of N-acylserotonins found in D. melanogaster head and thorax-abdomen

N-Acylserotonin

Heada
Extracted
amount
pmoles g-1

N-Oleoylserotonin

ndc

N-Palmitoylserotonin

N-Stearoylserotonin

N-Arachidonoylserotonin

ndc

ndc

nd

c

Thorax-abdomenb
Extracted
Retention
Molecular Ion
amount
Time
-1
pmoles g
min
[M+H]+ m/z
6.147
441.2633
6.009
441.2684
0.42 ± 0.55
6.149
441.2666
6.180
441.2622

1.16 ± 0.12

53.5 ± 33.3

0.25 ± 0.15

a

6.036
6.032
6.023
6.040

415.3249
415.3237
415.3203
415.3243

6.367
6.244
6.368
6.262

443.3143
443.2986
443.3167
443.2993

5.907
5.906
5.882
5.940

463.2998
463.3022
463.3478
463.3138

Identification and quantification of endogenous amounts extracted from one gram of
D. melanogaster heads.
b
Identification and quantification of endogenous amounts extracted from one gram of
D. melanogaster thorax-abdomen.
c
nd indicates that these N-acylserotonins were “not detected” in one gram of this anatomical
location of D. melanogaster.
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Supporting Information
Table S1
Amino Donor Specificity for AANATL2

Substratea,b

Km, app
µM

kcat, app
s-1

(kcat/Km) app
M-1s-1

Octopamine

78 ± 3.9

2.3 ± 0.038

(3.0 ± 0.049) × 104

3.9 ± 0.30

0.81 ± 0.013

(2.1 ± 0.033) × 105

Tyramine
a

Reaction conditions: 300 mM Tris-HCl pH 8.0, 150 µM DTNB, 50 µM acetyl-CoA, and varying
concentration of different amino donors.
b
Each amino donor was screen under two reaction conditions to determine if AANATL2 will catalyze the
formation of long-chain N-acyl amino donor. Reaction condition 1: 300 mM Tris-HCl pH 8.0, 150 µM
DTNB, 50 µM oleoyl-CoA, and 5 mM amino donor. Reaction condition 2: 300 mM Tris-HCl pH 8.0,
150 µM DTNB, 500 µM oleoyl-CoA, and 50 mM amino donor. A rate was not observed above the
background rate of oleoyl-CoA hydrolysis for each amino donor.
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Figure S.1.
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Figure S.2. AANATL7 – 500 µM acetyl-CoA and varied tyramine.
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Figure S.3. AANATL7 – 500 µM acetyl-CoA and varied ethanolamine.
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Figure S.4. AANATL7 – 500 µM acetyl-CoA and varied tryptamine.
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Figure S.5. AANATL7 – 500 µM acetyl-CoA and varied serotonin.
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Figure S.6. AANATL7 – 500 µM acetyl-CoA and varied octopamine.
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Figure S.7. AANATL7 – 500 µM acetyl-CoA and varied phenethylamine.
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Figure S.8. AANATL7 – 500 µM acetyl-CoA and varied 3-methoxyphenethylamine.
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Figure S.9. AANATL7 – 500 µM acetyl-CoA and varied 3,4-methylenedioxyphenethylamine.
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Figure S.10. AANATL7 – 500 µM acetyl-CoA and varied 4-phenylbutylamine.
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Figure S.11. AANATL7 – 500 µM acetyl-CoA and varied β-methylphenethylamine.
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Figure S.12. AANATL7 – 500 µM acetyl-CoA and varied dopamine.
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Figure S.13. AANATL7 – 500 µM acetyl-CoA and varied norephinephrine.
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Figure S.14. AANATL7 – 500 µM acetyl-CoA and varied 5-benzyloxytryptamine.
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Figure S.15. AANATL7 – 500 µM acetyl-CoA and varied 3-(trifluoromethyl)phenethylamine.
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Figure S.16. AANATL7 – 500 µM acetyl-CoA and varied 5-methoxytryptamine.
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Figure S.17. AANATL7 – 500 µM acetyl-CoA and varied benzylamine.
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Figure S.18. AANATL7 – 500 µM acetyl-CoA and varied agmatine.
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Figure S.19. AANATL7 – 500 µM acetyl-CoA and varied putrescine.
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Figure S.20. AANATL7 – 500 µM acetyl-CoA and varied 4-methoxyphenethylamine.
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Figure S.21. AANATL7 – 7.5 mM histamine and varied acetyl-CoA.
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Figure S.22. AANATL7 – 7.5 mM histamine and varied butyryl-CoA.
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Figure S.23. AANATL7 – 7.5 mM histamine and varied hexanoyl-CoA.
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Figure S.24. AANATL7 – 750 µM tyramine and varied acetyl-CoA.
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Figure S.25. AANATL7 – 750 µM tyramine and varied butyryl-CoA.
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Figure S.26. AANATL7 E26A – 50 mM histamine and varied acetyl-CoA.
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Figure S.27. AANATL7 E26A - 500 µM acetyl-CoA and varied histamine
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Figure S.28. AANATL7 P27A – 50 mM histamine and varied acetyl-CoA.

267

800
.

1.8

Vo (µmol/min/mg)

1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0

5

10

15

20

25

30

[Histamine (mM)]
Figure S.29. AANATL7 P27A – 1.0 mM acetyl-CoA and varied histamine.
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Figure S.30. AANATL7 P27A – 1.0 mM acetyl-CoA and varied agmatine.
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Figure S.31. AANATL7 R138A - 50 mM histamine and varied acetyl-CoA.
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Figure S.32. AANATL7 R138A – 2.5 mM acetyl-CoA and varied histamine.
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Figure S.33. AANATL7 T167A – 50 mM histamine and varied acetyl-CoA.
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Figure S.34. AANATL7 T167A – 2.0 mM acetyl-CoA and varied histamine.
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Figure S.35. AANATL7 S171A – 50 mM histamine and varied acetyl-CoA.
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Figure S.36. AANATL7 S171A – 500 µM acetyl-CoA and varied histamine.
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Figure S.37. AANATL7 T167A/S171A – 50 mM histamine and varied acetyl-CoA.
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Figure S.38. AANATL7 T167A/S171A – 500 µM acetyl-CoA and varied histamine.
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Figure S.39. AANATL7 H206A – 50 mM histamine and varied acetyl-CoA.
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Figure S.40. AANATL7 H206A – 2.0 mM acetyl-CoA and varied histamine.
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Figure S.41. AANATL2 – 50 µM acetyl-CoA and varied tryptamine.
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Figure S.42. AANATL2 – 50 µM acetyl-CoA and varied norepinephrine.
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Figure S.43. AANATL2 – 50 µM acetyl-CoA and varied phenethylamine.
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Figure S.44. AANATL2 – 50 µM acetyl-CoA and varied 3-(trifluoromethyl)phenethylamine.
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Figure S.45. AANATL2 – 50 µM acetyl-CoA and varied 3,4-methylenedioxyphenethylamine.
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Figure S.46. AANATL2 – 50 µM acetyl-CoA and varied histamine.
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Figure S.47. AANATL2 – 50 µM acetyl-CoA and varied 3-methoxyphenethylamine.
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Figure S.48. AANATL2 – 50 µM acetyl-CoA and varied β-methylphenethylamine.
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Figure S.49. AANATL2 – 50 µM acetyl-CoA and varied 4-methoxyphenethylamine.
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Figure S.50. AANATL2 – 50 µM acetyl-CoA and varied ethanolamine.
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Figure S.51. AANATL2 – 50 µM acetyl-CoA and varied 5-benzyloxytryptamine.
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Figure S.52. AANATL2 – 50 µM acetyl-CoA and varied 4-phenylbutylamine.
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Figure S.53. AANATL2 – 50 µM acetyl-CoA and varied 5-methoxytryptamine.
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Figure S.54. AANATL2 – 50 µM acetyl-CoA and varied benzylamine.
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Figure S.55. AANATL2 – 50 µM acetyl-CoA and varied tyramine.
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Figure S.56. AANATL2 – 100 µM tyramine and varied acetyl-CoA.
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Figure S.57. AANATL2 E29A – 1.0 mM tyramine and varied acetyl-CoA.
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Figure S.58. AANATL2 E29A – 50 µM acetyl-CoA and varied tyramine.
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Figure S.59. AANATL2 P30A – 2.5 mM tyramine and varied acetyl-CoA.
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Figure S.60. AANATL2 P30A – 50 µM acetyl-CoA and varied tyramine.
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Figure S.61. AANATL2 R138A – 500 µM tyramine and varied acetyl-CoA.
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Figure S.62. AANATL2 R138A – 50 µM acetyl-CoA and varied tyramine.
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Figure S.63. AANATL2 S167A – 100 µM tyramine and varied acetyl-CoA.
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Figure S.64. AANATL2 S167A – 500 µM acetyl-CoA and varied tyramine.
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Figure S.65. AANATL3 – 10 mM tyramine and varied acetyl-CoA.
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Figure S.66. AANATL3 – 1.0 mM acetyl-CoA and varied tyramine.
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Figure S.67. AANATL3 – 1.0 mM acetyl-CoA and varied serotonin.
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Figure S.68. AANATL3 – 1.0 mM acetyl-CoA and varied octopamine.
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Figure S.69. Cloning and Purification of AANATL7 from D. melanogaster. (A) Lane 1 - 1 kb
DNA ladder (New England Biolabs), Lane 2 - AANATL7; 687 bp band. (B) Lane 1 PageRuler™ Prestained protein ladder (Thermo Scientific), Lane 2 – Purified AANATL7; 26
kDA.
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Figure S.70. SDS-PAGE gel of purified AANATL7 mutants. Lane 1 - PageRuler™ Prestained
protein ladder (Thermo Scientific), Lane 2 – Wildtype AANATL7, Lane 3 – E26A, Lane 4 –
P27A, Lane 5 - R138A, Lane 6 – T167A, Lane 7 - S171A, Lane 8 – H206A.
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Figure S.71. SDS-PAGE gel of purified AANATL7 mutants. Lane 1 - PageRuler™ Prestained
protein ladder (Thermo Scientific), Lane 2 – Wildtype AANATL7, Lane 3 – T167A/S171A.
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Figure S.72. SDS-PAGE gel of purified AANATL2 site-directed mutants. Lane 1 - PageRuler™
Prestained protein ladder (Thermo Scientific), Lane 2 – Wildtype AANATL2, Lane 3 – E29A,
Lane 4 – P30A, Lane 5 - R138A, Lane 6 – S167A, Lane 7 - S171A, Lane 8 - H206A.
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